

BMJ Open

Bee venom acupuncture for rheumatoid arthritis: a systematic review of randomised clinical trials

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006140
Article Type:	Research
Date Submitted by the Author:	18-Jul-2014
Complete List of Authors:	Lee, Ju Ah; Korea Institute of Oriental Medicine, Son, Mi-Ju; Korea Institute of Oriental Medicine, Literature & Informatics Research Division Choi, Jiae; Korea Institute of Oriental Medicine, Medical research division Jun, Ji Hee; Korea Institute of Oriental Medicine, Kim, Jong-In; Kyung Hee University, Department of Acupuncture and Moxibustion, College of Korean Medicine Lee, Myeong Soo; Korea Institute of Oriental Medicine,
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Complementary medicine
Keywords:	Rheumatology < INTERNAL MEDICINE, COMPLEMENTARY MEDICINE, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY

SCHOLARONE™
Manuscripts

1
2
3
4 **Bee venom acupuncture for rheumatoid arthritis:**
5
6
7 **a systematic review of randomised clinical trials**
8
9

10
11 Ju Ah Lee,^{1,†} Mi Ju Son,^{2,†} Jiae Choi,¹ Ji Hee Jun,¹ Jong-In Kim,³ Myeong Soo Lee^{1,*}
12
13

14
15
16 ¹*Medical Research Division, Korea Institute of Oriental Medicine, Daejeon, South Korea,*
17

18 ²*Medical Culture & Informatics Research Division, Korea Institute of Oriental Medicine,*
19
20
21 *Daejeon, South Korea*
22

23 ³*Division of Acupuncture & Moxibustion medicine, Kyung Hee Korean Medicine Hospital,*
24
25 *Kyung Hee University, Seoul, Korea*
26
27

28
29
30 † Contributed equally
31

32
33 ***Correspondence to:**

34 Myeong Soo Lee, PhD
35 Medical Research Division,
36 Korea Institute of Oriental Medicine,
37 Daejeon, 305-811, South Korea
38 Tel: 82-(0)42-868-9266
39 Fax: 82-(0)42-868-9299
40 E-mail: drmslee@gmail.com
41
42
43
44
45
46
47

48 Lee JA: motoong@kiom.re.kr

49 Son MJ: mj714@kiom.re.kr

50 Choi J: ksjiae@kiom.re.kr

51 Jun JH: zhixi04@kiom.re.kr

52 JIK: hann8400@hanmail.net
53
54
55
56
57
58
59
60

License statement

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive license (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in BMJ Open and any other BMJPGJ products to exploit all subsidiary rights, as set out in our license (<http://group.bmj.com/products/journals/instructions-for-authors/license-forms>).

Key words: Bee venom acupuncture, rheumatoid arthritis, complementary and alternative medicine, systematic review

Abstract

Objectives: This systematic review was performed to assess the clinical evidence for bee venom acupuncture (BVA) for rheumatoid arthritis (RA).

Design: Systematic review of randomised clinical trials (RCTs)

Methods and analysis: We searched 14 databases up to March 2014 without a language restriction. The methodological quality of all included studies was assessed using the Cochrane Risk of Bias tool. We included all RCTs on BVA used alone or in combination with conventional therapy versus the same conventional therapy alone.

Results: A total of 304 potentially relevant studies were identified; only one RCT met our inclusion criteria. Compared to placebo, BVA may more effectively improve joint pain, swollen joint counts, tender joint counts, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) but were not shown the improvement of morning stiffness.

Conclusions: There is low-quality evidence, based on one trial, that BVA can significantly reduce pain, morning stiffness, tender joint counts, swollen joint counts and improve the quality of life of RA patients compared to placebo (normal saline injection) control. However, the number of trials, their quality, and the total sample size were too low to draw firm conclusions.

Trial registration: PROSPERO 2013: CRD42013005853

Article focus

- This systematic review aims to analyse the trial data on the effects of bee venom acupuncture for rheumatoid arthritis.

Key messages

- This systematic review performed with a comprehensive search strategy and established the current status of the evidence with unbiased methods.
- There is only one study that investigate the effects of bee venom acupuncture (BVA) for rheumatoid arthritis (RA).
- There is low evidence for BVA for management of RA.

Strengths and limitations of this study

- The strength of this systematic review is its extensive, unbiased search of various databases without a language restriction.
- The trial screening and data extraction conducted independently by two authors.
- We used of the GRADE approach to assess confidence in estimates of effect.
- We identified only one study so that we could not draw strong conclusions.

Introduction

Description of the condition

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that results in pain and stiffness, joint swelling, deformity of joints and ankylosis develop. The complex, systemic nature of the disease makes RA treatment complex and involving a variety of approaches. The major aims of treatment are to relieve pain and swelling, reduce inflammation and joint damage, prevent disability and preserve or improve patients' well-being and function.¹

Untreated RA leads to joint destruction, functional limitation and severe disability^{2,3} and has a significant impact on health-related quality of life (HRQoL).^{4,5}

Description of the intervention

Bee venom (BV) therapy has been used since ancient times. Different forms of the therapy include the administration of honeybee stings, injections of BV, and BV acupuncture (BVA).⁶ Bee venom acupuncture (BVA) involves injecting purified and diluted bee venom into acupoints.⁷

How the intervention might work

BVA exhibits several pharmacological actions, including analgesic, anti-inflammatory, anti-arthritis, and anti-cancer effects through multiple mechanisms, such as activation of the central inhibitory and excitatory systems and modulation of the immune system.⁸ The analgesic effects of BVA have been reported in animal experiments^{9,10} and clinical settings.⁷

¹¹ According to animal experiments, BV exhibits anti-arthritis, anti-inflammatory and

1
2
3
4 analgesic effects attributable to the suppression of cyclooxygenase-2 and phospholipase A2
5
6 expression and a decrease in the levels of tumour necrosis factor alpha, interleukin (IL)-1, IL-
7
8 6, nitric oxide and oxygen reactive species. It is also widely assumed that bioactive BV
9
10 compounds including enzymes (phospholipase A2), peptides (melittin, adolapin, and
11
12 apamin), and amines are associated with these actions.^{7 8 12-14} However, most therapeutic
13
14 uses are not based on evidence.
15
16

17
18
19 One study was conducted to elucidate whether the synergistic anti-arthritic effects produced
20
21 by a combination of BV and conventional therapy enhances the therapeutic potency and
22
23 minimises the adverse effects of methotrexate.¹⁵
24
25
26

27 28 ***Why this review is important***

29
30 Bee venom (BV) therapy or BV acupuncture (BVA) has been used for reducing pain caused
31
32 by inflammatory diseases such as osteoarthritis and rheumatoid arthritis (RA) in some Asian
33
34 countries.¹¹
35
36

37 However, there is no critically appraised evidence, such as a systematic review or meta-
38
39 analysis, of the potential benefits and risks of BVA for RA. A comprehensive evaluation of
40
41 the efficacy and safety of BVA for RA will inform the recommendation to patients to pursue
42
43 BVA treatment.
44
45
46

47 48 ***Objectives***

49
50 Although BVA for RA is used as an effective method for reducing RA-related symptoms and
51
52 improving functioning, there is no critically appraised evidence regarding the safety and
53
54 effectiveness of BVA for RA from a systematic review or meta-analysis.
55
56
57

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

We performed a systematic review to assess the safety and efficacy of BVA for the treatment of RA.

For peer review only

Materials and Methods

The protocol of this SRs is registered on PROSPERO 2013 (registration number: CRD42013005853) and published as a protocol.¹⁶

Data source

The following electronic databases were searched from the study's inception to March 2014: Medline, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), AMED, and CINAHL. We also searched 6 Korean medical databases (OASIS, Korean Traditional Knowledge Portal, Korean Studies Information Service System, KoreaMed, Korean Medical Database and DBPIA) and 3 Chinese databases including CNKI (China Academic Journal, China Doctoral Dissertations and Master's Theses Full-text Database, China Proceedings of Conference Full Text Database and the Century Journal Project), Wanfang and VIP. Further, we conducted non-electronic searches of conference proceedings, our own files of articles and 9 Korean traditional medical journals (Journal of Korean Medicine, The Journal of Korean Acupuncture and Moxibustion Society, Korean Journal of Acupuncture, Journal of Acupuncture and Meridian Studies, Journal of Pharmacopuncture, Journal of Oriental Rehabilitation Medicine, The Journal of Korea Chuna Manual Medicine for Spine and Nerves, Korean Journal of Oriental Physiology and Pathology and The Journal of Korean Oriental Internal Medicine). The strategy for searching the MEDLINE database is presented in appendix 1. Similar search strategies were applied for the other databases.

Types of studies

All prospective randomised controlled clinical trials (RCTs) were included if they were randomised studies of BV injections at acupoints as the sole treatment, or as an adjunct to other treatments if the control group received the same treatment as the BVA group. Trials

1
2
3
4 comparing BVA with any type of control intervention were also included. We excluded trials
5
6 of BV injections into parts of the body other than acupoints. Trials were also excluded if only
7
8 immunological or biological parameters were assessed. Trials comparing two different types
9
10 of BVA were also excluded. No language restrictions were imposed. Hard copies of all
11
12 articles were obtained and read in full.
13

14 15 16 17 **Types of participants**

18
19 All articles describing an RCT with patients suffering from RA were included.
20
21

22 23 24 **Types of interventions**

25
26 We included trials on BVA used alone or in combination with a conventional therapy versus
27
28 the conventional therapy alone. BVA involved injecting purified, diluted BV into acupoints.
29
30 Conventional therapies included medications such as nonsteroidal anti-inflammatory drugs,
31
32 steroids, disease-modifying anti-rheumatic drugs, immunosuppressants, and TNF-alpha
33
34 inhibitors.
35
36
37
38
39

40 41 **Types of outcomes measured**

42 Primary outcomes were symptoms (morning stiffness, pain and joint swelling) experienced.
43
44 Secondary outcomes included erythrocyte sedimentation rate (ESR), C-reactive protein
45
46 (CRP), rheumatoid factor (RF), the number of joints affected by RA and adverse effects
47
48 likely related to RA.
49

50 51 52 53 **Data extraction and quality assessment**

54
55 Hard copies of all articles were obtained and read in full. Two authors (MJS and JHJ)
56
57 performed the data extraction and quality assessment using a predefined data extraction form.
58
59

1
2
3
4 The risk of bias was assessed using the assessment tool for risk of bias from the Cochrane
5 Handbook version 5.1.0, which includes random sequence generation, allocation concealment,
6 blinding of participants and personnel, blinding of outcome assessments, incomplete outcome
7 data, selective reporting and other sources of bias.¹⁷ Our review used 'L', 'U', and 'H' as
8 results of the assessment; 'L' indicated a low risk of bias, 'U' indicated that the risk of bias
9 was unclear, and 'H' indicated a high risk of bias. Disagreements were resolved by a
10 discussion between all of the authors. When disagreements on the selection were not resolved
11 through discussions, the arbiter (MSL) made the final decision.
12
13
14
15
16
17
18
19
20
21
22
23

24 **Data collection and synthesis**

25 *Data extraction and management*

26
27
28 The data extraction and quality assessment were conducted by three authors (JAL, MJS and
29 JHJ) using a predefined data extraction form. Any disagreement among the authors was
30 resolved by a discussion between all of the authors. When the data were insufficient or
31 ambiguous, MSL contacted the corresponding authors by e-mail or telephone to request
32 additional information or clarification. The data screening and selection process was
33 performed independently by four authors and then was verified by a fifth author, JHJ, who is
34 fluent in Chinese. We used GRADEpro software in the Cochrane Systematic Reviews to
35 create a Summary of Findings table. When disagreements on the selections were not resolved
36 through discussions, the arbiter (MSL) made the final decision.
37
38
39
40
41
42
43
44
45
46
47
48
49

50 *Assessment of bias in the included studies*

51
52 We independently assessed bias in the included studies according to criteria from the
53 Cochrane Handbook, version 5.1.0, which includes random sequence generation, allocation
54 concealment, blinding of participants and personnel, blinding of outcome assessments,
55
56
57
58
59
60

1
2
3
4 incomplete outcome data, selective reporting and other sources of bias.¹⁷The quality of each
5
6 trial was categorised into a low, unclear, or high risk of bias, and the authors of the assessed
7
8 trials were contacted for clarification as needed. We resolved any differences in opinion
9
10 through discussion or consultation with a third author.
11
12

13 14 15 *Data synthesis*

16
17 The differences between the intervention and control groups were assessed. For the
18
19 continuous data, we used mean differences (MDs) with 95% confidence intervals (CIs) to
20
21 measure the treatment effects. We converted other forms of data into MDs. In the case of
22
23 outcome variables with different scales, we used the standard mean difference (SMD) with
24
25 95% CIs. For dichotomous data, we presented the treatment effect as a relative risk (RR) with
26
27 95% CIs. For dichotomous data, we presented the treatment effect as a relative risk (RR) with
28
29 95% CIs. We converted other binary data into an RR value.
30
31

32
33 All of the statistical analyses were conducted using Cochrane Collaboration's software
34
35 program, Review Manager (RevMan), Version 5.2.7 for Windows (Copenhagen, The Nordic
36
37 Cochrane Centre, the Cochrane Collaboration, 2012). For studies with insufficient
38
39 information, we contacted the corresponding authors to acquire and verify data when possible.
40
41 If appropriate, we pooled data across studies for a meta-analysis using fixed-effects or
42
43 random-effects.
44
45

46 47 48 *Unit of analysis issues*

49
50 For cross-over trials, data from the first treatment period were used. For trials in which more
51
52 than one control group was assessed, the primary analysis combined the data from each
53
54 control group. Subgroup analyses of the control groups were performed. Each patient was
55
56 counted only once in the analysis.
57
58

Addressing the missing data

Intention-to-treat analyses that included all of the randomised patients were performed. For patients with missing outcome data, a carry-forward of the last observed response was used. The individual patient data were sought from the original source or the published trial reports when the individual patient data were initially unavailable.

Assessment of heterogeneity

We used the random-effect or fixed-effect model for the meta-analysis according to the data analysis. Chi-squared and I-squared tests were used to evaluate the heterogeneity of the included studies and $I^2 > 50$ were considered to have high heterogeneity. If heterogeneity was observed, we conducted a subgroup analysis to explore the possible causes.¹⁸

Assessment of reporting biases

If a sufficient number of included studies (at least 10 trials) were available, we used funnel plots to detect reporting biases.¹⁹ However, funnel plot asymmetry was not the same as publication bias; therefore, we attempted to determine the possible reasons for the asymmetry, such as small-study effects, poor methodological quality and true heterogeneity in the included studies.^{19 20}

Results

Study selection and description

The search generated a total of 304 hits, of which only one met our inclusion criteria (Figure 1). The key data from the eligible RCT are summarised in Table 1. This trial was conducted in Korea.²¹ Four RCTs, which were conducted in China, were excluded because the BVA were not made with purified, diluted bee venom but with live bee stings, as shown in supplement 2 and 3.²²⁻²⁵

Risk of bias in the included studies

The RCT used²¹ has an uncertain risk of bias due to its random sequence generation, allocation concealment, outcome assessment blinding, selective reporting and other biases. This study used blinding of participants and personal employing placebo as a comparison and to address incomplete outcome data.

Outcomes

The study tested the efficacy of BVA on morning stiffness, Health Assessment Questionnaire (HAQ) scores, pain, tender joint counts, swollen joint counts, ESR, and CRP in RA patients.²¹ Patients were randomised into two groups: one receiving BVA at ashi points and the other receiving normal saline injections at ashi points. After two months, the scores for morning stiffness, HAQ, pain on VAS, tender joint counts, swollen joint counts, ESR, and CRP were significantly better in the BVA group than in the placebo control group.

Adverse events

This trial did not assess adverse events related to BVA used for RA.²¹

Discussion

Only one trial testing the effects of BVA for RA is currently available.²¹ There is low-quality evidence based on this one trial that BVA significantly reduces pain, morning stiffness, tender joint counts, swollen joint counts and improves the quality of life of RA patients compared to placebo (normal saline injection) control subjects. To date, however, the effects of BVA for RA have not been confirmed because of small sample sizes and high risks of bias.

This systematic review has several limitations. First, although extensive efforts were made to retrieve all of the RCTs with no language and publication status limitations, only one study of BVA for RA qualified for our review. Second, the included RCT was conducted in East Asian countries, and studies from East Asian countries do not apply globally because of their lack of external validity. Third, Korean researchers tend to have positive results,²⁶ but we could not minimise the results because of the lack of methodology. Fourth, despite the possibility of delayed-type hypersensitivity occurring, there was no prolonged follow-up.

The included RCT used saline injections at the same acupoints used in the BVA group for the placebo control treatment.²¹ The use of placebo is essential for differentiating nonspecific from specific treatment effects. If we consider that the effects of BVA could come from stimulating acupoints with the immune-modulative effect of bee venom, it is necessary to implement further RCTs that use the appropriate placebo. This study has some potential caveats. One is that a normal saline injection at the same acupoints used in the experimental group could be an inappropriate placebo. BVA combines biochemical effects of the bee venom and mechanical effects from the needles. As a result, this placebo could invoke mechanical effects from the acupoint injection. The other is that there was no reporting of previous experiences with BVA. BVA has uncomfortable sensations such as swelling and

1
2
3
4 burning during the treatment. Some participants who have previously experienced BVA
5
6 treatment could know what they were treated with, thereby interrupting patient blinding. To
7
8 use normal saline injections as a placebo, it is important to recruit patients who have not
9
10 experienced BVA.
11

12
13
14
15 BVA can cause diverse clinical responses depending on the amount of venom used and the
16
17 frequency and duration of the treatment. The acute or delayed adverse reaction is an
18
19 inflammatory reaction, such as anaphylaxis or urticarial.²⁷ Although trials are conducted
20
21 safely, some problems remain in using BVA in clinical practice.
22
23

24
25
26 In the absence of a sufficient number of RCTs, other types of evidence might be helpful.
27
28 There was one non-randomised trial that showed favourable effects of BVA for several
29
30 symptoms of RA.²⁸ However, this type of study, lacking in randomisation, was open to
31
32 selection bias, which could lead to false-positive results.
33
34

35
36
37 The other type of BV therapy may be more commonly used when treating patients with RA.
38
39 In considering this type of trial, we found 4 additional RCTs that compared live bee sting
40
41 acupuncture combined with conventional drugs to conventional treatments alone for the
42
43 treatment of RA symptoms.^{22 24 25 29} Three RCTs^{22 24 29} showed favourable effects of BVA on
44
45 at least one of the main outcomes including total improvement, morning stiffness, pain, joint
46
47 pain, or joint swelling, while one RCT failed to do so.²⁵ Although these RCTs did not report
48
49 serious adverse effects, live bee stings can cause fatal adverse events including anaphylaxis.²²
50
51

52
53 24 25 29
54
55
56
57
58
59
60

Contributorship statement

Conceived and designed the review: MSL and JAL. Extracted the data: JHJ, and MJS. Analyzed the data: MJS, JC and JIK. Wrote the paper: JAL, MJS, JC, JIK, and MSL. Searched and selected studies: JHJ, MJS, JC. Revised the paper: JAL, MSL. Monitored data collection: MSL. The final manuscript was approved by all authors.

Competing interests

None

Funding

No external funding was received. Lee JA, Choi J, Jun JH, and Lee MS were supported by Korea Institute of Oriental Medicine (K14281, K14400). Son MJ was supported by same institute (K14380).

Data Sharing

No additional data available

References

1. Han A, Robinson V, Judd M, Taixiang W, Wells G, Tugwell P. Tai chi for treating rheumatoid arthritis. *Cochrane Database Syst Rev* 2004(3):CD004849.
2. Odegard S, Finset A, Kvien TK, Mowinckel P, Uhlig T. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register. *Scand J Rheumatol* 2005;34(6):441-7.
3. Yelin E. Work disability in rheumatic diseases. *Curr Opin Rheumatol* 2007;19(2):91-6.
4. Kvien TK, Uhlig T. Quality of life in rheumatoid arthritis. *Scand J Rheumatol* 2005;34(5):333-41.
5. Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. *Pharmacoeconomics* 2004;22(2 Suppl 1):27-38.
6. Munstedt K, Hackethal A, Schmidt K. Bee venom therapy, bee venom acupuncture of apipuncture: What is the evidence behind the various health claims? *Am Bee J* 2005;145:665-68.
7. Lee MS, Pittler MH, Shin BC, Kong JC, Ernst E. Bee venom acupuncture for musculoskeletal pain: a review. *J Pain* 2008;9(4):289-97.
8. Son DJ, Lee JW, Lee YH, Song HS, Lee CK, Hong JT. Therapeutic application of anti-arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent compounds. *Pharmacol Ther* 2007;115:246-70.
9. Baek YH, Huh JE, Lee JD, Choi DY, Park DS. Antinociceptive effect and the mechanism of bee venom acupuncture (Apipuncture) on inflammatory pain in the rat model of collagen-induced arthritis: mediation by alpha2-adrenoceptors. *Brain Research* 2006;1073-1074:305-10.
10. Chen HS, Qu F, He X, Liao D, Kang SM, Lu SJ. The anti-nociceptive effect and the possible mechanism of acupoint stimulation caused by chemical irritants in the bee

- 1
2
3
4 venom pain model *Brain Research* 2010;1355:61-69.
5
6
7 11. Lee JD, Park HJ, Chae Y, Lim S. An overview of bee venom acupuncture in the treatment
8 of arthritis. *Evid Based Complement Alternat Med* 2005;2(1):79-84.
9
10
11 12. Lim BS, Moon HJ, Li DX, Gil M, Min JK, Lee G, et al. Effect of bee venom acupuncture
12 on oxaliplatin-induced cold allodynia in rats. *Evid Based Complement Alternat Med*
13 2013;2013:369324.
14
15
16
17 13. Moon DO, Park SY, Lee KJ, Heo MS, Kim KC, Kim MO, et al. Bee venom and melittin
18 reduce proinflammatory mediators in lipopolysaccharide-stimulated BV2 microglia. *Int*
19 *Immunopharmacol* 2007;7(8):1092-101.
20
21
22
23 14. Nah SS, Ha E, Mun SH, Won HJ, Chung JH. Effects of melittin on the production of
24 matrix metalloproteinase-1 and -3 in rheumatoid arthritic fibroblast-like synoviocytes. *J*
25 *Pharmacol Sci* 2008;106(1):162-6.
26
27
28
29 15. Darwish SF, El-Bakly WM, Arafa HM, El-Demerdash E. Targeting TNF-alpha and NF-
30 kappaB activation by bee venom: role in suppressing adjuvant induced arthritis and
31 methotrexate hepatotoxicity in rats. *PloS one* 2013;8(11):e79284.
32
33
34
35 16. Lee JA, Son MJ, Choi J, Yun K-J, Jun JH, Lee MS. Bee venom acupuncture for
36 rheumatoid arthritis: a systematic review protocol. *BMJ Open* 2014;4(4).
37
38
39
40 17. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included
41 studies. In: Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic Reviews*
42 *of Interventions Version 5.1.0 (updated March 2011)*: The Cochrane Collaboration,
43 2011. Available from www.cochrane-handbook.org, 2011.
44
45
46
47 18. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-
48 analyses. In: Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic*
49 *Reviews of Interventions Version 5.1.0 (updated March 2011)*: The Cochrane
50 Collaboration. Available from www.cochrane-handbook.org, 2011.
51
52
53
54
55
56
57
58
59
60

19. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)*: The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org, 2011.
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315(7109):629-34.
21. Lee SH, Hong SJ, Kim SY. Randomized controlled double blind study of bee venom therapy on rheumatoid arthritis. *J Korean Acupunct Mox Soc*, 2003:80-88.
22. Deng M, Zhang WN. Clinical observation on 20 cases of bee needle therapy in the treatment of rheumatoid arthritis. *Guiding J Tradit Chin Med Pharm* 2011;17(6):71-73.
23. Liu XD, Zhang jl, Zheng HG, Li Z, D., Cai L, Liu FY, et al. Effect of bee-sting therapy on TNF- α and IL-1 β in peripheral blood of rheumatoid arthritis patients. *Chin Arch Tradit Chin Med* 2008;26(5):996-97.
24. Zhang JL, Liu XD, Ye LH, Zhang P. Clinical padomized comparison study of bee-sting therapy for knee synovitis caused by rheumatoid arthritis. *Chin Arch Tradit Chin Med* 2011;29(8):1904-06.
25. Zhou YF, Li WY. Effect of needle on hypothalamic-pituitary-adrenal axis of patient with rheumatoid arthritis. *Nei Mongol J Tradit Chin Med* 2012;26(5):1-3.
26. Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. *Control Clin Trials* 1998;19(2):159-66.
27. Yao H. Bee needle therapy. *J Shanxi Elderly* 2000(09):39.
28. Hwang YJ, Lee GM, Hwang WJ, Seo EM, Jang JD, Yang GB, et al. Clinical research of bee-venom acupuncture effects on rheumatoid arthritis. *J Korean Acupunct Mox Soc* 2001;18(5):33-42.
29. Liu XD, Zhang JL, Zheng HG, Liu FY, Chen Y. Clinical randomized study of bee-sting

1
2
3
4 therapy for rheumatoid arthritis. *Acupunct Res* 2008;33(3):197-200.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legend

Figure 1. Flow chart of trial selection process. NRS: non-randomised trial; RCT: randomised controlled trials.

For peer review only

Table 1. Characteristics of included randomized controlled trials of bee venom acupuncture for rheumatoid arthritis

<i>Lee 2003</i>	
Methods	Design: prospective randomized controlled trial
Participants	Country: South Korea Number of patients included(completed / randomized): (A) 37/40 (B) 32/40 Mean age (years): (A) 49.2±9.6 (B) 47.3±8.9 Duration of disease (years): (A) 9.2±7.0 (B) 7.3±4.6 Follow-up: 1 and 2 months
Intervention	(A) BVA (Ashi points, acupoints near the inflammation point, two times a week for 2 months)
Control	(B) Placebo (normal saline injection on ashi points, acupoints near the inflammation point, two times a week for 2 months)
Outcomes	<i>Primary outcomes:</i> 1) Morning stiffness, MD, -0.70[-2.00, 0.60], P<0.05 2) HAQ, MD, 0.00[-0.08, 0.08], P<0.05 3) VAS-pain, MD, -18.10[-23.71, -12.49], P<0.05 <i>Secondary outcomes:</i> 1) Tender joint count, MD, -1.30[-1.91, -0.69], P<0.0001 2) Swollen joint count, MD, -1.10[-1.72, -0.48], P=0.005 3) ESR, MD, 20.10[-22.80, -17.40], P<0.00001 4) CRP, MD, -1.90[-2.86, -0.94], P=0.0001
Note	Treatment Rationale: CM theory, Clinical experience Adverse effect: n.r. Funding: Korea Research Foundation Grant and Kyung Hee University Language: Korean Publication: full paper Withdrawal/dropouts:yes Intention-to-treat: No Author comment: These results suggests that bee venom therapy could be an effective method in the treatment of patients with RA

<i>Risk of bias</i>		
Item	Authors' judgement	Description
Random sequence generation (selection bias)	Unclear risk	Described as randomized but information not available
Allocation concealment (selection bias)	Unclear risk	Not stated.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Described as double blinding
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated.
Incomplete outcome data (attrition bias) All outcomes	High risk	Data from 11 participants were not included in the analysis.
Selective reporting (reporting bias)	Low risk	Protocol not available, but all expected outcomes reported
Other bias	Unclear risk	Small sample size

BVA: Bee Venom Acupuncture; CRP: C - reactive protein; CM: Chinese medicine; ESR: erythrocyte sedimentation rate; HAQ: health assessment questionnaire; n.r.: not reported; RA: rheumatoid arthritis VAS: visual analogue scale

Table 2. Summary of findings

Bee venom acupuncture for patients with rheumatoid arthritis					
Patient or population: patients with rheumatoid arthritis					
Settings: Korea					
Intervention: Bee venom acupuncture vs. normal saline injection as placebo					
Outcomes	Illustrative comparative risks* (95% CI)		No of Participants (studies)	Quality of the evidence (Grade)	Comments
	Assumed risk	Corresponding risk			
	Control (Normal Saline injection)	Bee venom acupuncture			
Pain (VAS)		16.9 WMD lower¹ (26.57 to 7.23 lower)	69 (1 study)	⊕⊕⊖⊖ low ^{2,3}	After 1 month -10.40 (-16.47 to -4.33)
Morning stiffness		12.1 WMD higher¹ (11.61 to 12.59 higher)	69 (1 study)	⊕⊕⊖⊖ low ^{2,3}	After 1 month -0.30 (-1.01 to 0.41)
Swollen joint count		0.9 WMD lower¹ (1.97 lower to 0.17 higher)	69 (1 study)	⊕⊕⊖⊖ low ^{2,3}	After 1 month 0.50 (-0.70 to -1.70)
Tender joint count		0.9 WMD lower¹ (1.97 lower to 0.17 higher)	69 (1 study)	⊕⊕⊖⊖ low ^{2,3}	After 1 month 0.50 (-0.73 to -1.73)
Quality of Life (HAQ)		0.3 WMD higher¹ (0.08 to 0.52 higher)	69 (1 study)	⊕⊕⊖⊖ low ^{2,3}	After 1 month 0.20 (-0.06 to 0.46)
ESR		19.4 WMD lower¹ (28.51 to 10.29 lower)	69 (1 study)	⊕⊕⊖⊖ low ^{2,3}	After 1 month -2.30 (-10.17 to 5.57)
CRP		1.7 WMD lower¹ (2.6 to 0.8 lower)	69 (1 study)	⊕⊕⊖⊖ low ^{2,3}	After 1 month 1.40 (-8.27 to 5.47)


*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; **CRP:** C-reactive protein; **ESR:** Erythrocyte sedimentation rate; **HAQ:** Health Assessment Questionnaire; **VAS:** Visual analogue scale; **WMD:** weight mean difference

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

¹ After 2 months treatment
² Poorly reported paper (See 'Risk of bias' table)
³ Small sample size

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



188x196mm (300 x 300 DPI)



Supplement 1. Search Strategy**MEDLINE**

1. exp arthritis, rheumatoid/
2. ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat\$ or reumat\$ or revmarthrit\$) adj3 (arthrit\$ or artrit\$ or diseas\$ or condition\$ or nodule\$)).tw.
3. (felty\$ adj2 syndrome).tw.
4. (caplan\$ adj2 syndrome).tw.
5. (sjogren\$ adj2 syndrome).tw.
6. (sicca adj2 syndrome).tw.
7. still\$ disease.tw.
8. bechterew\$ disease.tw.
9. or/1-8
10. bee venom\$.tw.
11. bee sting.tw.
12. wasp venom\$.tw.
13. bee venom acupuncture.tw.
14. bee venom therapy.tw.
15. bee sting therapy.tw.
16. apitoxin.tw.
17. apitherapy.tw.
18. or/10-17
19. 9 and 18

EMBASE

1. exp arthritis, rheumatoid/
2. ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat\$ or reumat\$ or revmarthrit\$) adj3 (arthrit\$ or artrit\$ or diseas\$ or condition\$ or nodule\$)).tw.

3. (felty\$ adj2 syndrome).tw.
4. (caplan\$ adj2 syndrome).tw.
5. (sjogren\$ adj2 syndrome).tw.
6. (sicca adj2 syndrome).tw.
7. still\$ disease.tw.
8. bechterew\$ disease.tw.
9. or/1-8
10. bee venom\$.tw.
11. bee sting\$.tw.
12. wasp venom\$.tw.
13. bee venom acupuncture.tw.
14. bee venom therapy.tw.
15. bee sting therapy.tw.
16. apitoxin.tw.
17. apitherapy.tw.
18. or/10-17
19. 9 and 18

The Cochrane Library (Wiley InterScience)

- #1 MeSH descriptor Arthritis, Rheumatoid explode all trees
- #2 ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat* or reumat* or revmarthrit*) near/3(arthrit* or artrit* or diseas* or condition* or nodule*)):ti,ab
- #3 felty* NEAR/2 syndrome:ti,ab
- #4 caplan* NEAR/2 syndrome:ti,ab
- #6 sjogren* near/2 syndrome:ti,ab
- #7 sicca near/2 syndrome:ti,ab
- #8 still* next disease:ti,ab
- #9 bechterew\$ disease.tw.
- #10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)
- #11 bee venom* :ti,ab
- #12 bee sting :ti,ab

1
2
3
4 #13 wasp venom* :ti,ab

5 #14 bee venom acupuncture :ti,ab

6
7 #15 bee venom therapy:ti,ab

8
9 #16 bee sting therapy:ti,ab

10
11 #17 apitoxin:ti,ab

12
13 #18 apitherapy:ti,ab

14 #19 (#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18)

15
16 #20 #10 AND #19

17
18
19 **CINAHL (EBSCOhost)**

20 S7 S3 and S6

21
22 S6 S4 or S5

23
24 S5 TI “apitoxin” or AB “apitoxin” or TI “apitherapy” or AB “apitherapy”

25
26 S4 TI “bee venom*” or AB “bee venom*” or TI “bee sting” or AB “bee sting” or TI “wasp
27 venom*” or AB “wasp venom*” or TI “bee venom acupuncture” or AB “bee venom
28 acupuncture” or TI “bee venom therapy” or AB “bee venom therapy”

29
30 #17 apitoxin:ti,ab

31
32 #18 apitherapy:ti,ab

33
34 S3 S1 or S2

35
36 S2 TI “bechterew* disease” or AB “bechterew* disease” or TI (arthritis N2 rheumat*) or AB
37 (arthritis N2 rheumat*)

38
39 S1 (MH “Arthritis, Rheumatoid+”) or TI (felty* N2 syndrome) or AB (felty* N2 syndrome)
40 or TI (caplan* N2 syndrome) or AB(caplan* N2 syndrome) or TI (rheumatoid nodule) or AB
41 (rheumatoid nodule) or TI (sjogren* N2 syndrome) or AB (sjogren* N2 syndrome) or TI
42 (sicca N2 syndrome) or AB (sicca N2 syndrome)

Supplement 1. Summary of randomized controlled trials of direct-Bee Sting acupuncture for [rheumatoid arthritis](#)

First author (Year) country	Mean age (years); Duration of disease (years)	Experimental intervention (Regimen)	Control intervention (Regimen)	Primary outcome		Secondary outcome		Adverse Effects
				measurement	result	measurement	result	
Liu (2008) China	(A) 47.4±10.0; 5.0±3.0 (B) 48.3±9.4; 4.9±2.6	(A) BVA (Ashi points, dialectical acupoints, 8~15bees, n.r., once every other day for 3 months, n=50), plus (B)	(B) WM (Oral:MTX:7.5mg, once a week for 3 months; SASP:0.5g, third daily for 3 months; Meloxicam:7.5mg, twice daily for 3 months, n=50)	(1) Total improvement score (2) Joint swelling score (3) Joint pain score	(1) RR, 1.22[1.01, 1.47], P=0.04 (2) MD, -0.24[-0.42, -0.06], P=0.010 (3) MD, -0.34[-0.37, -0.31], P<0.00001	(1) Number of Joint-swelling (2) RF (3) ESR	(1) MD, -0.46[-0.62, -0.30], P<0.00001 (2) MD, -7.74[-14.10, -1.38], P=0.02 (3) MD, -4.38[-6.28, -2.48], P<0.00001	Dizziness (B:4), fever(A:1), hypersensitivity(A:4), leukopenia(B:3), loss of appetite and nausea(B:6)
Zhang (2011) China	(A) 33.8; 3.6 (B) 32.2; 3.4	(A) BVA (Ashis points near the knee, 5~15bees, n.r., two or three times a week for 3months, n=23) plus (B)	(B) WM (Oral:MTX:7.5mg, once a week for 3 months; SASP:0.5g, third daily for 3 months; Meloxicam:7.5mg, once daily for 3 months, n=23)	(1) Total improvement score (2) VAS (3) HSS	(1) RR, 1.17[0.91, 1.50] (2) MD, -1.00[-1.20, -0.80], P<0.00001 (3) MD, 3.37[3.24, 3.50], P<0.00001	(1) ESR (2) CRP	(1) MD, -4.20[-7.35, -1.05], P=0.009 (2) MD, -2.50[-5.56, 0.56], P=0.11	Dizziness(A:1), epigastric discomfort(A:4), fever(A:2), hypersensitivity(A:1), leukopenia(B:3), rash(A:3)
Deng (2011) China	n.r.	(A) BVA (Ashi points, dialectical acupoints, before 15-25d: 2~3bees; after 15-25d: 1~3bees increase every time, n.r., three times a week for 2 months, n=20) plus (B)	(B) WM (Oral:MTX:10mg, once a week for 2 months, n=20) (C) WM (Oral: Prednisone Acetate:7.5mg, once daily for 2 months, n=20) plus (B)	(1) Total improvement score (2) Morning stiffness (3) Joint pain score (4) Joint swelling score	(1) - A vs. B RR, 1.46[1.04, 2.05], P=0.03 - A vs. C RR, 1.36[1.00, 1.84], P=0.05 (2) - A vs. B MD, -0.29[-0.42, -0.17], P<0.00001 - A vs. C MD, -0.11[-0.25, 0.02], P=0.05 (3) - A vs. B MD, -0.50[-0.64, -0.36], P<0.00001 - A vs. C MD, -0.13[-0.26, 0.00], P=0.05 (4) - A vs. B MD, -0.33[-0.47, -0.19], P<0.00001 - A vs. C MD, 0.05[-0.12, 0.21], P=0.56	(1) RF (2) ESR (3) CRP	(1) - A vs. B MD, -28.00[-37.21, -18.79], P<0.00001 - A vs. C MD, -14.30[-17.60, -11.00], P<0.00001 (2) - A vs. B MD, -18.60[-27.04, -10.16], P<0.00001 - A vs. C MD, -8.10[-15.41, -0.79], P=0.03 (3) - A vs. B MD, -10.30[-12.46, -8.14], P<0.00001 - A vs. C MD, -3.70[-5.99, -1.41], P=0.002	Epigastric discomfort (C:6),hypersensitivity (A:3), insomnia(C:3), leukopenia(B:1), nausea(A:2,B:3)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Zhou (2012) China	(A) 37.86±14.15; 15.58±5.24 (B) 36.43±10.18; 13.95±5.21 (C) 40.66±14.01; 16.58±5.32	(A) BVA (Ashi points, acupoints near the pain point, 5~10bees, n.r., three times a week for 3 months, n=40) plus NSAIDS	(B) EA (Ashi points, LI15, LI14, LI11, LI 10, SJ5, BL36, SP10, BL40, GB34, ST36, GB39, DU14, BL52, DU3, BL32, 30min, three times a week y for 3 months, n=30) plus NSAIDS (C) WM (Oral:MTX:5-10mg, once a week for 3 months; Folic acid: 10mg, once a week for 3 months, n=30) plus NSAIDS	(1) Total improvement score	(1) - A vs. B RR, 1.23[0.97, 1.56], P=0.09 - A vs. C RR, 1.04[0.87, 1.24], P=0.67	(1) ESR (2) CRP	(1) - A vs. B MD, -13.70[-15.08, -12.32], P<0.00001 - A vs. C MD, -2.72[-6.54, 1.10] P=0.16 (2) - A vs. B MD, -9.18[-11.47, -6.89], P<0.00001 - A vs. C MD, 3.93[-0.07, 7.93], P=-0.05	n.r.
-------------------	---	---	---	-----------------------------	---	--------------------	---	------

BVA: Bee Venom Acupuncture; CRP: C - reactive protein; EA: electro acupuncture; ESR: erythrocyte sedimentation rate; HSS: hss knee score; HAQ: health assessment questionnaire; MTX: methotrexate; n.r.: not reported; NSAIDS: nonsteroidal anti-inflammatory drugs; RF: rheumatoid factor; SASP: sulfasalazine; VAS: visual analogue scale; TNF-α: tumor necrosis factor-alpha; WM: Western medicine

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Supplement 2. Summary of treatment direct-Bee Sting acupuncture points and other information

First author (Year)	Type of acupuncture	Total treatment (sessions)	Main acupoints	Dialectical acupoints	Treatment Rationale	Adverse events
Liu (2008)	BVA (Live bee, 8~15bees)	3 months	Ashi points	Cold dampness invasion, joint pain: CV6, RN4; Hot and humid embodiment, joint swelling pain: LI11, GV14; Phlegm and blood stasis in the resistance, Joint deformities pain:ST40,GB39;	CM theory, Clinical experience	Hypersensitivity(4), fever(1)
Zhang (2011)	BVA (Live bee, 5~15bees)	3 months	Ashis points near knee	n.r.	CM theory, Clinical experience	Fever(2), hypersensitivity(1), rash(3)
Deng (2011)	BVA (Live bee, before 15-25d: 2~3bees; after 15-25d: 1~3bees increase every time)	2 months	Ashi points	Ankle:BL62, KI6, BL60, GB40; back: GV26, V12, GV3; elbow: LI11, LI4, SJ10, SJ5, LU5; knee:ST35, ST34, GB34, GB33; Shoulders:LI16, SJ14, SI10; wrist:SI4, SJ5 LI5, SI4	CM theory, Clinical experience	Hypersensitivity (3), nausea(2)
Zhou (2012)	BVA (Live bee, 5~10bees)	3 months	Ashi points, acupoints in near in the pain point	n.r.	CM theory, Clinical experience	n.r.
Lee (2003)	BVA (Injection, Bee venom extract diluted with saline to 1:3000, from 0.2ml increase to 1.0ml)	2 months	Ashi points , acupoints near the inflammation point	Metacarpophalangeal joint, Distal interphalangeal joint, Proximal interphalangeal joint, wrist: SI5, SI5, TE4, L15 PC7; elbow:LI11, TE10, SI8, HT3, S18; shoulder: LI15, TE14; knee: ST36, GB34, SP9; ankle: GB40, BL62, SP5, K16	CM theory, Clinical experience	n.r

BVA: Bee Venom Acupuncture; CM: Chinese medicine; n.r.: not reported

Supplement 1. Summary of randomized controlled trials of direct-Bee Sting acupuncture for rheumatoid arthritis

First author (Year) country	Mean age (years); Duration of disease (years)	Experimental intervention (Regimen)	Control intervention (Regimen)	Primary outcome		Secondary outcome		Adverse Effects
				measurement	result	measurement	result	
Liu (2008) China	(A) 47.4±10.0; 5.0±3.0 (B) 48.3±9.4; 4.9±2.6	(A) BVA (Ashi points, dialectical acupoints, 8~15bees, n.r., once every other day for 3 months, n=50), plus (B)	(B) WM (Oral:MTX:7.5mg, once a week for 3 months; SASP:0.5g, third daily for 3 months; Meloxicam:7.5mg, twice daily for 3 months, n=50)	(1) Total improvement score (2) Joint swelling score (3) Joint pain score	(1) RR, 1.22[1.01, 1.47], P=0.04 (2) MD, -0.24[-0.42, -0.06], P=0.010 (3) MD, -0.34[-0.37, -0.31], P<0.00001	(1) Number of Joint-swelling (2) RF (3) ESR	(1) MD, -0.46[-0.62, -0.30], P<0.00001 (2) MD, -7.74[-14.10, -1.38], P=0.02 (3) MD, -4.38[-6.28, -2.48], P<0.00001	Dizziness (B:4), fever(A:1), hypersensitivity(A:4), leukopenia(B:3), loss of appetite and nausea(B:6)
Zhang (2011) China	(A) 33.8; 3.6 (B) 32.2; 3.4	(A) BVA (Ashis points near the knee, 5~15bees, n.r., two or three times a week for 3months, n=23) plus (B)	(B) WM (Oral:MTX:7.5mg, once a week for 3 months; SASP:0.5g, third daily for 3 months; Meloxicam:7.5mg, once daily for 3 months, n=23)	(1) Total improvement score (2) VAS (3) HSS	(1) RR, 1.17[0.91, 1.50] (2) MD, -1.00[-1.20, -0.80], P<0.00001 (3) MD, 3.37[3.24, 3.50], P<0.00001	(1) ESR (2) CRP	(1) MD, -4.20[-7.35, -1.05], P=0.009 (2) MD, -2.50[-5.56, 0.56], P=0.11	Dizziness(A:1), epigastric discomfort(A:4), fever(A:2), hypersensitivity(A:1), leukopenia(B:3), rash(A:3)
Deng (2011) China	n.r.	(A) BVA (Ashi points, dialectical acupoints, before 15-25d: 2~3bees; after 15-25d: 1~3bees increase every time, n.r., three times a week for 2 months, n=20) plus (B)	(B) WM (Oral:MTX:10mg, once a week for 2 months, n=20) (C) WM (Oral: Prednisone Acetate:7.5mg, once daily for 2 months, n=20) plus (B)	(1) Total improvement score (2) Morning stiffness (3) Joint pain score (4) Joint swelling score	(1) - A vs. B RR, 1.46[1.04, 2.05], P=0.03 - A vs. C RR, 1.36[1.00, 1.84], P=0.05 (2) - A vs. B MD, -0.29[-0.42, -0.17], P<0.00001 - A vs. C MD, -0.11[-0.25, 0.02], P=0.05 (3) - A vs. B MD, -0.50[-0.64, -0.36], P<0.00001 - A vs. C MD, -0.13[-0.26, 0.00], P=0.05 (4) - A vs. B MD, -0.33[-0.47, -0.19], P<0.00001 - A vs. C MD, 0.05[-0.12, 0.21], P=0.56	(1) RF (2) ESR (3) CRP	(1) - A vs. B MD, -28.00[-37.21, -18.79], P<0.00001 - A vs. C MD, -14.30[-17.60, -11.00], P<0.00001 (2) - A vs. B MD, -18.60[-27.04, -10.16], P<0.00001 - A vs. C MD, -8.10[-15.41, -0.79], P=0.03 (3) - A vs. B MD, -10.30[-12.46, -8.14], P<0.00001 - A vs. C MD, -3.70[-5.99, -1.41], P=0.002	Epigastric discomfort (C:6),hypersensitivity (A:3), insomnia(C:3), leukopenia(B:1), nausea(A:2,B:3)

5	Zhou (2012) China	(A) 37.86±14.15; 15.58±5.24 (B) 36.43±10.18; 13.95±5.21 (C) 40.66±14.01; 16.58±5.32	(A) BVA (Ashi points, acupoints near the pain point, 5~10bees, n.r., three times a week for 3 months, n=40) plus NSAIDS	(B) EA (Ashi points, LI15, LI14, LI11, LI 10, SJ5, BL36, SP10, BL40, GB34, ST36, GB39, DU14, BL52, DU3, BL32, 30min, three times a week y for 3 months, n=30) plus NSAIDS (C) WM (Oral:MTX:5-10mg, once a week for 3 months; Folic acid: 10mg, once a week for 3 months, n=30) plus NSAIDS	(1) Total improvement score	(1) - A vs. B RR, 1.23[0.97, 1.56], P=0.09 - A vs. C RR, 1.04[0.87, 1.24], P=0.67	(1) ESR (2) CRP	(1) - A vs. B MD, -13.70[-15.08, -12.32], P<0.00001 - A vs. C MD, -2.72[-6.54, 1.10] P=0.16 (2) - A vs. B MD, -9.18[-11.47, -6.89], P<0.00001 - A vs. C MD, 3.93[-0.07, 7.93], P=-0.05	n.r.
---	-------------------	---	---	---	-----------------------------	---	--------------------	---	------

BVA: Bee Venom Acupuncture; CRP: C - reactive protein; EA: electro acupuncture; ESR: erythrocyte sedimentation rate; HSS: hss knee score; HAQ: health assessment questionnaire; MTX: methotrexate; n.r.: not reported; NSAIDS: nonsteroidal anti-inflammatory drugs; RF: rheumatoid factor; SASP: sulfasalazine; VAS: visual analogue scale; TNF-α: tumor necrosis factor-alpha; WM: Western medicine

References

Deng M, Zhang WN. Clinical observation on 20 cases of bee needle therapy in the treatment of rheumatoid arthritis. *Guiding J Tradit Chin Med Pharm* 2011;17(6):71-73.
 Liu XD, Zhang jl, Zheng HG, Li Z, D., Cai L, Liu FY, et al. Effect of bee-sting therapy on TNF-α and IL-1β in peripheral blood of rheumatoid arthritis patients. *Chin Arch Tradit Chin Med* 2008;26(5):996-97.
 Zhang JL, Liu XD, Ye LH, Zhang P. Clinical padomized comparison study of bee-sting therapy for knee synovitis caused by rheumatoid arthritis. *Chin Arch Tradit Chin Med* 2011;29(8):1904-06.
 Zhou YF, Li WY. Effect of needle on hypothalamic-pituitary-adrenal axis of patient with rheumatoid arthritis. *Nei Mongol J Tradit Chin Med* 2012;26(5):1-3.

Supplement 3. ummary of treatment direct-Bee Sting acupuncture points and other information

First author (Year)	Type of acupuncture	Total treatment (sessions)	Main acupoints	Dialectical acupoints	Treatment Rationale	Adverse events
Liu (2008)	BVA (Live bee, 8~15bees)	3 months	Ashi points	Cold dampness invasion, joint pain: CV6, RN4; Hot and humid embodiment, joint swelling pain: LI11, GV14; Phlegm and blood stasis in the resistance, Joint deformities pain:ST40,GB39;	CM theory, Clinical experience	Hypersensitivity(4), fever(1)
Zhang (2011)	BVA (Live bee, 5~15bees)	3 months	Ashis points near knee	n.r.	CM theory, Clinical experience	Fever(2), hypersensitivity(1), rash(3)
Deng (2011)	BVA (Live bee, before 15-25d: 2~3bees; after 15-25d: 1~3bees increase every time)	2 months	Ashi points	Ankle:BL62, KI6, BL60, GB40; back: GV26, V12, GV3; elbow: LI11, LI4, SJ10, SJ5, LU5; knee:ST35, ST34, GB34, GB33; Shoulders:LI16, SJ14, SI10; wrist:SJ4, SJ5 LI5, SI4	CM theory, Clinical experience	Hypersensitivity (3), nausea(2)
Zhou (2012)	BVA (Live bee, 5~10bees)	3 months	Ashi points, acupoints in near in the pain point	n.r.	CM theory, Clinical experience	n.r.
Lee (2003)	BVA (Injection, Bee venom extract diluted with saline to 1:3000, from 0.2ml increase to 1.0ml)	2 months	Ashi points , acupoints near the inflammation point	Metacarpophalangeal joint, Distal interphalangeal joint, Proximal interphalangeal joint, wrist: SI5, SI5, TE4, L15 PC7; elbow:LI11, TE10, SI8, HT3, S18; shoulder: LI15, TE14; knee: ST36, GB34, SP9; ankle: GB40, BL62, SP5, K16	CM theory, Clinical experience	n.r

BVA: Bee Venom Acupuncture; CM: Chinese medicine; n.r.: not reported

References

- Deng M, Zhang WN. Clinical observation on 20 cases of bee needle therapy in the treatment of rheumatoid arthritis. *Guiding J Tradit Chin Med Pharm* 2011;17(6):71-73.
- Liu XD, Zhang jl, Zheng HG, Li Z, D., Cai L, Liu FY, et al. Effect of bee-sting therapy on TNF- α and IL-1 β in peripheral blood of rheumatoid arthritis patients. *Chin Arch Tradit Chin Med* 2008;26(5):996-97.
- Zhang JL, Liu XD, Ye LH, Zhang P. Clinical padomized comparison study of bee-sting therapy for knee synovitis caused by rheumatoid arthritis. *Chin Arch Tradit Chin Med* 2011;29(8):1904-06.
- Zhou YF, Li WY. Effect of needle on hypothalamic-pituitary-adrenal axis of patient with rheumatoid arthritis. *Nei Mongol J Tradit Chin Med* 2012;26(5):1-3.



PRISMA 2009 Checklist: Bee venom acupuncture for rheumatoid arthritis: A systematic review of randomised clinical trials

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	4
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	7
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	8
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	8
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	8
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	10
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	10
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	9
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	10
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	Table 1,2



PRISMA 2009 Checklist: Bee venom acupuncture for rheumatoid arthritis: A systematic review of randomised clinical trials

Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	na
----------------------	----	---	----

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	12
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	na
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	12, Figure 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	13
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	13
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	na
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	13
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	na
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	14
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	16
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	17

BMJ Open

Bee venom acupuncture for rheumatoid arthritis: a systematic review of randomised clinical trials

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006140.R1
Article Type:	Research
Date Submitted by the Author:	23-Sep-2014
Complete List of Authors:	Lee, Ju Ah; Korea Institute of Oriental Medicine, Son, Mi-Ju; Korea Institute of Oriental Medicine, Literature & Informatics Research Division Choi, Jiae; Korea Institute of Oriental Medicine, Medical research division Jun, Ji Hee; Korea Institute of Oriental Medicine, Kim, Jong-In; Kyung Hee University, Department of Acupuncture and Moxibustion, College of Korean Medicine Lee, Myeong Soo; Korea Institute of Oriental Medicine,
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Complementary medicine
Keywords:	Rheumatology < INTERNAL MEDICINE, COMPLEMENTARY MEDICINE, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY

SCHOLARONE™
Manuscripts

1
2
3
4 **Bee venom acupuncture for rheumatoid arthritis:**
5
6
7 **a systematic review of randomised clinical trials**
8
9

10
11 Ju Ah Lee,^{1,†} Mi Ju Son,^{2,†} Jiae Choi,¹ Ji Hee Jun,¹ Jong-In Kim,³ Myeong Soo Lee^{1,*}
12
13

14
15
16 ¹*Medical Research Division, Korea Institute of Oriental Medicine, Daejeon, South Korea,*
17

18
19 ²*Medical Culture & Informatics Research Division, Korea Institute of Oriental Medicine,*
20
21 *Daejeon, South Korea*
22

23 ³*Division of Acupuncture & Moxibustion medicine, Kyung Hee Korean Medicine Hospital,*
24
25 *Kyung Hee University, Seoul, Korea*
26
27

28
29
30 † Contributed equally
31

32
33 ***Correspondence to:**

34 Myeong Soo Lee, PhD
35 Medical Research Division,
36 Korea Institute of Oriental Medicine,
37 Daejeon, 305-811, South Korea
38
39 Tel: 82-(0)42-868-9266
40
41 Fax: 82-(0)42-868-9299
42
43 E-mail: drmslee@gmail.com
44
45
46

47
48 Lee JA: motoong@kiom.re.kr

49 Son MJ: mj714@kiom.re.kr

50 Choi J: ksjiae@kiom.re.kr

51 Jun JH: zhixi04@kiom.re.kr

52 JIK: hann8400@hanmail.net
53
54
55
56
57
58
59
60

License statement

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive license (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in BMJ Open and any other BMJ PGL products to exploit all subsidiary rights, as set out in our license (<http://group.bmj.com/products/journals/instructions-for-authors/license-forms>).

For peer review only

Article focus

- This systematic review aims to analyse the trial data on the effects of bee venom acupuncture for rheumatoid arthritis.

Key messages

- This systematic review performed with a comprehensive search strategy and established the current status of the evidence with unbiased methods.

Strengths and limitations of this study

- The strength of this systematic review is its extensive, unbiased search of various databases without a language restriction.
- The trial screening and data extraction conducted independently by two authors.
- We used of the GRADE approach to assess confidence in estimates of effect
- We identified only one study so that we could not draw strong conclusions.

Abstract

Objective: This systematic review was performed to assess the clinical evidence for bee venom acupuncture (BVA) for rheumatoid arthritis (RA).

Design: Systematic review of randomised controlled trials (RCTs).

Setting: We searched 14 databases up to March 2014 without a language restriction.

Participants: Patients with RA.

Intervention: BVA involved injecting purified, diluted BV into acupoints. We included trials on BVA used alone or in combination with a conventional therapy versus the conventional therapy alone.

Primary outcome: Morning stiffness, pain and joint swelling

Secondary outcomes: Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), the number of joints affected by RA and adverse effects likely related to RA.

Results: A total of 304 potentially relevant studies were identified; only one RCT met our inclusion criteria. Compared to placebo, BVA may more effectively improve joint pain, swollen joint counts, tender joint counts, erythrocyte sedimentation rate (ESR) and C - reactive protein (CRP) but were not shown the improvement of morning stiffness.

Conclusions: There is low-quality evidence, based on one trial, that BVA can significantly reduce pain, morning stiffness, tender joint counts, swollen joint counts and improve the quality of life of RA patients compared to placebo (normal saline injection) control. However, the number of trials, their quality, and the total sample size were too low to draw firm conclusions.

Trial registration number: PROSPERO 2013: CRD42013005853

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Key words: Bee venom acupuncture, rheumatoid arthritis, complementary and alternative medicine, systematic review

For peer review only

Introduction

Description of the condition

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that results in pain and stiffness, joint swelling, deformity of joints and ankylosis develop. The complex, systemic nature of the disease makes RA treatment complex and involving a variety of approaches. The major aims of treatment are to relieve pain and swelling, reduce inflammation and joint damage, prevent disability and preserve or improve patients' well-being and function.¹

Untreated RA leads to joint destruction, functional limitation and severe disability²³ and has a significant impact on health-related quality of life (HRQoL).⁴⁵

Description of the intervention

Bee venom (BV) therapy has been used since ancient times. Different forms of the therapy include the administration of honeybee stings, injections of BV, and BV acupuncture (BVA).⁶ Bee venom acupuncture (BVA) involves injecting purified and diluted bee venom into acupoints.⁷

How the intervention might work

BVA exhibits several pharmacological actions, including analgesic, anti-inflammatory, anti-arthritis, and anti-cancer effects through multiple mechanisms, such as activation of the central inhibitory and excitatory systems and modulation of the immune system.⁸ The analgesic effects of BVA have been reported in animal experiments⁹¹⁰ and clinical settings.⁷

¹¹ According to animal experiments, BV exhibits anti-arthritis, anti-inflammatory and analgesic effects attributable to the suppression of cyclooxygenase-2 and phospholipase A2

1
2
3
4 expression and a decrease in the levels of tumour necrosis factor alpha, interleukin (IL)-1, IL-
5
6 6, nitric oxide and oxygen reactive species. It is also widely assumed that bioactive BV
7
8 compounds including enzymes (phospholipase A2), peptides (melittin, adolapin, and
9
10 apamin), and amines are associated with these actions.^{7 8 12-14} However, most therapeutic
11
12 uses are not based on evidence.
13
14

15
16
17 One study was conducted to elucidate whether the synergistic anti-arthritic effects produced
18
19 by a combination of BV and conventional therapy enhances the therapeutic potency and
20
21 minimises the adverse effects of methotrexate.¹⁵
22
23

24 25 26 ***Why this review is important*** 27

28 Bee venom (BV) therapy or BV acupuncture (BVA) has been used for reducing pain caused
29
30 by inflammatory diseases such as osteoarthritis and rheumatoid arthritis (RA) in some Asian
31
32 countries.¹¹
33

34
35 However, there is no critically appraised evidence, such as a systematic review or meta-
36
37 analysis, of the potential benefits and risks of BVA for RA. A comprehensive evaluation of
38
39 the efficacy and safety of BVA for RA will inform the recommendation to patients to pursue
40
41 BVA treatment.
42
43

44 45 46 ***Objectives*** 47

48 Although BVA for RA is used as an effective method for reducing RA-related symptoms and
49
50 improving functioning, there is no critically appraised evidence regarding the safety and
51
52 effectiveness of BVA for RA from a systematic review or meta-analysis.
53
54

55 We performed a systematic review to assess the safety and efficacy of BVA for the treatment
56
57 of RA.
58
59

Materials and Methods

The protocol of this SRs is registered on PROSPERO 2013 (registration number: CRD42013005853) and published as a protocol.¹⁶

Data source

The following electronic databases were searched from the study's inception to March 2014: Medline, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), AMED, and CINAHL. We also searched 6 Korean medical databases (OASIS, Korean Traditional Knowledge Portal, Korean Studies Information Service System, KoreaMed, Korean Medical Database and DBPIA) and 3 Chinese databases including CNKI (China Academic Journal, China Doctoral Dissertations and Master's Theses Full-text Database, China Proceedings of Conference Full Text Database and the Century Journal Project), Wanfang and VIP. Further, we conducted non-electronic searches of conference proceedings, our own files of articles and 9 Korean traditional medical journals (Journal of Korean Medicine, The Journal of Korean Acupuncture and Moxibustion Society, Korean Journal of Acupuncture, Journal of Acupuncture and Meridian Studies, Journal of Pharmacopuncture, Journal of Oriental Rehabilitation Medicine, The Journal of Korea Chuna Manual Medicine for Spine and Nerves, Korean Journal of Oriental Physiology and Pathology and The Journal of Korean Oriental Internal Medicine). The strategy for searching the MEDLINE database is presented in Supplement 1. Similar search strategies were applied for the other databases.

Types of studies

All prospective randomised controlled clinical trials (RCTs) were included if they were randomised studies of BV injections at acupoints as the sole treatment, or as an adjunct to other treatments if the control group received the same treatment as the BVA group. Trials

1
2
3
4 comparing BVA with any type of control intervention were also included. We excluded trials
5
6 of BV injections into parts of the body other than acupoints. Trials were also excluded if only
7
8 immunological or biological parameters were assessed. Trials comparing two different types
9
10 of BVA were also excluded. No language restrictions were imposed. Hard copies of all
11
12 articles were obtained and read in full.
13

14 15 16 17 **Types of participants**

18
19 Patients suffering from RA were included.
20
21

22 23 24 **Types of interventions**

25
26 We included trials on BVA used alone or in combination with a conventional therapy versus
27
28 the conventional therapy alone. BVA involved injecting purified, diluted BV into acupoints.
29
30 Conventional therapies included medications such as nonsteroidal anti-inflammatory drugs,
31
32 steroids, disease-modifying anti-rheumatic drugs, immunosuppressants, and TNF-alpha
33
34 inhibitors.
35
36
37
38
39

40 41 **Types of outcomes measured**

42 Primary outcomes were symptoms (morning stiffness, pain and joint swelling) experienced.
43
44 Secondary outcomes included erythrocyte sedimentation rate (ESR), C-reactive protein
45
46 (CRP), rheumatoid factor (RF), the number of joints affected by RA and adverse effects
47
48 likely related to RA.
49
50

51 52 53 **Data extraction and quality assessment**

54
55 Hard copies of all articles were obtained and read in full. Two authors (MJS and JHJ)
56
57 performed the data extraction and quality assessment using a predefined data extraction form.
58
59
60

1
2
3
4 The risk of bias was assessed using the assessment tool for risk of bias from the Cochrane
5 Handbook version 5.1.0, which includes random sequence generation, allocation concealment,
6 blinding of participants and personnel, blinding of outcome assessments, incomplete outcome
7 data, selective reporting and other sources of bias.¹⁷ Our review used 'L', 'U', and 'H' as
8 results of the assessment; 'L' indicated a low risk of bias, 'U' indicated that the risk of bias
9 was unclear, and 'H' indicated a high risk of bias. Disagreements were resolved by a
10 discussion between all of the authors. When disagreements on the selection were not resolved
11 through discussions, the arbiter (MSL) made the final decision.
12
13
14
15
16
17
18
19
20
21
22
23

24 **Data collection and synthesis**

25 *Data extraction and management*

26
27
28 The data extraction and quality assessment were conducted by three authors (JAL, MJS and
29 JHJ) using a predefined data extraction form. Any disagreement among the authors was
30 resolved by a discussion between all of the authors. When the data were insufficient or
31 ambiguous, MSL contacted the corresponding authors by e-mail or telephone to request
32 additional information or clarification. The data screening and selection process was
33 performed independently by four authors and then was verified by a fifth author, JHJ, who is
34 fluent in Chinese. We used GRADEpro software in the Cochrane Systematic Reviews to
35 create a Summary of Findings table. When disagreements on the selections were not resolved
36 through discussions, the arbiter (MSL) made the final decision.
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 *Assessment of bias in the included studies*

52
53 We independently assessed bias in the included studies according to criteria from the
54 Cochrane Handbook, version 5.1.0, which includes random sequence generation, allocation
55 concealment, blinding of participants and personnel, blinding of outcome assessments,
56
57
58
59
60

1
2
3
4 incomplete outcome data, selective reporting and other sources of bias.¹⁷The quality of each
5
6 trial was categorised into a low, unclear, or high risk of bias, and the authors of the assessed
7
8 trials were contacted for clarification as needed. We resolved any differences in opinion
9
10 through discussion or consultation with a third author.
11
12

13 14 15 *Data synthesis*

16
17 The differences between the intervention and control groups were assessed. For the
18
19 continuous data, we used mean differences (MDs) with 95% confidence intervals (CIs) to
20
21 measure the treatment effects. We converted other forms of data into MDs. In the case of
22
23 outcome variables with different scales, we used the standard mean difference (SMD) with
24
25 95% CIs. For dichotomous data, we presented the treatment effect as a relative risk (RR) with
26
27 95% CIs. For dichotomous data, we presented the treatment effect as a relative risk (RR) with
28
29 95% CIs. We converted other binary data into an RR value.
30
31

32
33 All of the statistical analyses were conducted using Cochrane Collaboration's software
34
35 program, Review Manager (RevMan), Version 5.2.7 for Windows (Copenhagen, The Nordic
36
37 Cochrane Centre, the Cochrane Collaboration, 2012). For studies with insufficient
38
39 information, we contacted the corresponding authors to acquire and verify data when possible.
40
41 If appropriate, we pooled data across studies for a meta-analysis using fixed-effects or
42
43 random-effects.
44
45

46 47 48 *Unit of analysis issues*

49
50 For cross-over trials, data from the first treatment period were used. For trials in which more
51
52 than one control group was assessed, the primary analysis combined the data from each
53
54 control group. Subgroup analyses of the control groups were performed. Each patient was
55
56 counted only once in the analysis.
57
58

Addressing the missing data

Intention-to-treat analyses that included all of the randomised patients were performed. For patients with missing outcome data, a carry-forward of the last observed response was used. The individual patient data were sought from the original source or the published trial reports when the individual patient data were initially unavailable.

Assessment of heterogeneity

We used the random-effect or fixed-effect model for the meta-analysis according to the data analysis. Chi-squared and I-squared tests were used to evaluate the heterogeneity of the included studies and $I^2 > 50$ were considered to have high heterogeneity. If heterogeneity was observed, we conducted a subgroup analysis to explore the possible causes.¹⁸

Assessment of reporting biases

If a sufficient number of included studies (at least 10 trials) were available, we used funnel plots to detect reporting biases.¹⁹ However, funnel plot asymmetry was not the same as publication bias; therefore, we attempted to determine the possible reasons for the asymmetry, such as small-study effects, poor methodological quality and true heterogeneity in the included studies.^{19 20}

Results

Study selection and description

The search generated a total of 304 hits, of which only one met our inclusion criteria (Figure 1). Thirteen RCTs were among the excluded articles for the following reasons: Four RCTs, which were conducted in China, were excluded because the BVA were not made with purified, diluted bee venom but with live bee stings (Supplement 2 and 3).²¹⁻²⁴ Four RCTs employed herbal medicine as co-administrator,²⁵⁻²⁸ 2 RCTs included herbal medicine as control treatment,^{29,30} 1 RCT compared two different acupoints,³¹ 1 RCT was not related RA,³² and the other 1 RCT was duplicated publication.³³ The key data from the eligible RCT are summarised in Table 1. This trial was conducted in Korea.³⁴

Risk of bias in the included studies

The RCT used³⁴ has an uncertain risk of bias due to its random sequence generation, allocation concealment, outcome assessment blinding, selective reporting and other biases. This study used blinding of participants and personal employing placebo as a comparison and to address incomplete outcome data.

Outcomes

The study tested the efficacy of BVA on morning stiffness, Health Assessment Questionnaire (HAQ) scores, pain, tender joint counts, swollen joint counts, ESR, and CRP in RA patients.³⁴ Patients were randomised into two groups: one receiving BVA at ashi points and the other receiving normal saline injections at ashi points. After two months, the scores for morning stiffness, HAQ, pain on VAS, tender joint counts, swollen joint counts, ESR, and CRP were significantly better in the BVA group than in the placebo control group.

1
2
3
4 *Adverse events*
5

6 This trial did not assess adverse events related to BVA used for RA.³⁴
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Discussion

Only one trial testing the effects of BVA for RA is currently available.³⁴ There is low-quality evidence based on this one trial that BVA significantly reduces pain, morning stiffness, tender joint counts, swollen joint counts and improves the quality of life of RA patients compared to placebo (normal saline injection) control subjects. To date, however, the effects of BVA for RA have not been confirmed because of small sample sizes and high risks of bias.

This systematic review has several limitations. First, although extensive efforts were made to retrieve all of the RCTs with no language and publication status limitations, only one study of BVA for RA qualified for our review. Second, the included RCT was conducted in East Asian countries, and studies from East Asian countries do not apply globally because of their lack of external validity. Third, Korean researchers tend to have positive results,³⁵ but we could not minimise the results because of the lack of methodology. Fourth, despite the possibility of delayed-type hypersensitivity occurring, there was no prolonged follow-up.

The included RCT used saline injections at the same acupoints used in the BVA group for the placebo control treatment.³⁴ The use of placebo is essential for differentiating nonspecific from specific treatment effects. If we consider that the effects of BVA could come from stimulating acupoints with the immune-modulative effect of bee venom, it is necessary to implement further RCTs that use the appropriate placebo. This study has some potential caveats. One is that a normal saline injection at the same acupoints used in the experimental group could be an inappropriate placebo. BVA combines biochemical effects of the bee venom and mechanical effects from the needles. As a result, this placebo could invoke mechanical effects from the acupoint injection. The other is that there was no reporting of previous experiences with BVA. BVA has uncomfortable sensations such as swelling and

1
2
3
4 burning during the treatment. Some participants who have previously experienced BVA
5
6 treatment could know what they were treated with, thereby interrupting patient blinding. To
7
8 use normal saline injections as a placebo, it is important to recruit patients who have not
9
10 experienced BVA.
11

12
13
14
15 BVA can cause diverse clinical responses depending on the amount of venom used and the
16
17 frequency and duration of the treatment. The acute or delayed adverse reaction is an
18
19 inflammatory reaction, such as anaphylaxis or urticarial.³⁶ Although trials are conducted
20
21 safely, some problems remain in using BVA in clinical practice.
22
23

24
25
26 In the absence of a sufficient number of RCTs, other types of evidence might be helpful.
27
28 There was one observational study that showed favourable effects of BVA for several
29
30 symptoms of RA (Supplement 4).³⁷ However, this type of study, lacking in control treatment,
31
32 was open to selection bias, which could lead to false-positive results.
33
34

35
36
37 The other type of BV therapy may be more commonly used when treating patients with RA.
38
39 In considering this type of trial, we found 4 additional RCTs that compared live bee sting
40
41 acupuncture combined with conventional drugs to conventional treatments alone for the
42
43 treatment of RA symptoms.^{21 23 24 38} Three RCTs^{21 23 38} showed favourable effects of BVA on
44
45 at least one of the main outcomes including total improvement, morning stiffness, pain, joint
46
47 pain, or joint swelling, while one RCT failed to do so.²⁴ Although these RCTs did not report
48
49 serious adverse effects,^{22 24 25 29} live bee stings can cause fatal adverse events including
50
51 anaphylaxis.^{39 40} Adverse events should be examined in future studies. The injection parts
52
53 may be one issue for the assessment because it is very common to inject on the painful point
54
55 (Ashi point) in RA patients. Even if we expand the inclusion criteria to this points, no further
56
57
58
59
60

1
2
3
4 studies were found.
5
6
7

8
9 One could question the validity of the conclusion by pointing to the review method used
10 (reviewing a small number of trials with many limitations). However, reasons for doing a
11 systematic review would be to answer question not posted by individual studies, to settle
12 controversies arising from apparently conflicting studies, or to generate new hypotheses.⁴¹
13
14

15
16
17 The systematic review with a small number of trials can be done.
18
19

20
21
22 In conclusion, currently, very few trials have tested the effects of BVA in the management of
23 RA. Collectively, the evidence is insufficient to suggest that BVA is an effective therapy for
24 RA. Further studies should be of high quality, with a particular emphasis on designing
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

adequate and appropriate control groups.

Author Contributions

Conceived and designed the review: MSL and JAL. Extracted the data: JHJ, and MJS.

Analyzed the data: MJS, JC and JIK. Wrote the paper: JAL, MJS, JC, JIK, and MSL.

Searched and selected studies: JHJ, MJS, JC. Revised the paper: JAL, MSL. Monitored data collection: MSL.

Financial support

No external funding was received. Lee JA, Choi J, Jun JH, and Lee MS were supported by Korea Institute of Oriental Medicine (K14281, K14400). Son MJ was supported by same institute (K14380).

Conflict of interest

None

References

1. Han A, Robinson V, Judd M, et al. Tai chi for treating rheumatoid arthritis. *Cochrane Database Syst Rev* 2004(3):CD004849.
2. Odegard S, Finset A, Kvien TK, et al. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register. *Scand J Rheumatol* 2005;**34**(6):441-7.
3. Yelin E. Work disability in rheumatic diseases. *Curr Opin Rheumatol* 2007;**19**(2):91-6.
4. Kvien TK, Uhlig T. Quality of life in rheumatoid arthritis. *Scand J Rheumatol* 2005;**34**(5):333-41.
5. Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. *Pharmacoeconomics* 2004;**22**(2 Suppl 1):27-38.
6. Munstedt K, Hackethal A, Schmidt K. Bee venom therapy, bee venom acupuncture of apipuncture: What is the evidence behind the various health claims? *Am Bee J* 2005;**145**:665-68.
7. Lee MS, Pittler MH, Shin BC, et al. Bee venom acupuncture for musculoskeletal pain: a review. *J Pain* 2008;**9**(4):289-97.
8. Son DJ, Lee JW, Lee YH, et al. Therapeutic application of anti-arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent compounds. *Pharmacol Ther* 2007;**115**:246-70.
9. Baek YH, Huh JE, Lee JD, et al. Antinociceptive effect and the mechanism of bee venom acupuncture (Apipuncture) on inflammatory pain in the rat model of collagen-induced arthritis: mediation by alpha2-adrenoceptors. *Brain Research* 2006;**1073-1074**:305-10.
10. Chen HS, Qu F, He X, et al. The anti-nociceptive effect and the possible mechanism of acupoint stimulation caused by chemical irritants in the bee venom pain model *Brain*

- 1
2
3
4 Research 2010;**1355**:61-69.
5
6
7 11. Lee JD, Park HJ, Chae Y, et al. An overview of bee venom acupuncture in the treatment
8 of arthritis. *Evid Based Complement Alternat Med* 2005;**2**(1):79-84.
9
10
11 12. Lim BS, Moon HJ, Li DX, et al. Effect of bee venom acupuncture on oxaliplatin-induced
12 cold allodynia in rats. *Evid Based Complement Alternat Med* 2013;**2013**:369324.
13
14
15 13. Moon DO, Park SY, Lee KJ, et al. Bee venom and melittin reduce proinflammatory
16 mediators in lipopolysaccharide-stimulated BV2 microglia. *International*
17 *immunopharmacology* 2007;**7**(8):1092-101.
18
19
20
21
22 14. Nah SS, Ha E, Mun SH, et al. Effects of melittin on the production of matrix
23 metalloproteinase-1 and -3 in rheumatoid arthritic fibroblast-like synoviocytes. *J*
24 *Pharmacol Sci* 2008;**106**(1):162-6.
25
26
27
28
29 15. Darwish SF, El-Bakly WM, Arafa HM, et al. Targeting TNF-alpha and NF-kappaB
30 activation by bee venom: role in suppressing adjuvant induced arthritis and
31 methotrexate hepatotoxicity in rats. *PloS one* 2013;**8**(11):e79284.
32
33
34
35
36 16. Lee JA, Son MJ, Choi J, et al. Bee venom acupuncture for rheumatoid arthritis: a
37 systematic review protocol. *BMJ Open* 2014;**4**(4).
38
39
40
41 17. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included
42 studies. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews*
43 *of Interventions* Version 510 (updated March 2011): The Cochrane Collaboration,
44 2011. Available from www.cochrane-handbook.org, 2011.
45
46
47
48
49 18. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-
50 analyses. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews*
51 *of Interventions* Version 510 (updated March 2011): The Cochrane Collaboration.
52 Available from www.cochrane-handbook.org, 2011.
53
54
55
56
57 19. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins
58
59
60

- 1
2
3
4 JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions
5
6 Version 510 (updated March 2011): The Cochrane Collaboration, 2011. Available
7
8 from www.cochrane-handbook.org, 2011.
9
- 10
11 20. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,
12
13 graphical test. *Bmj* 1997;**315**(7109):629-34.
14
- 15
16 21. Deng M, Zhang WN. Clinical observation on 20 cases of bee needle therapy in the
17
18 treatment of rheumatoid arthritis. *Guiding J Tradit Chin Med Pharm* 2011;**17**(6):71-
19
20 73.
21
- 22
23 22. Liu XD, Zhang jl, Zheng HG, et al. Effect of bee-sting therapy on TNF- α and IL-1 β in
24
25 peripheral blood of rheumatoid arthritis patients. *Chin Arch Tradit Chin Med*
26
27 2008;**26**(5):996-97.
28
- 29
30 23. Zhang JL, Liu XD, Ye LH, et al. Clinical padomized comparison study of bee-sting
31
32 therapy for knee synovitis caused by rheumatoid arthritis. *Chin Arch Tradit Chin Med*
33
34 2011;**29**(8):1904-06.
35
- 36
37 24. Zhou YF, Li WY. Effect of needle on hypothalamic-pituitary-adrenal axis of patient with
38
39 rheumatoid arthritis. *Nei Mongol J Tradit Chin Med* 2012;**26**(5):1-3.
40
- 41
42 25. Zhu HJ, Huang SG, Tan N, et al. Clinical observation of apiotherapy combined with
43
44 Chinese drug fumigation for rheumatoid arthritis. *J Tradit Chin Med Univ Hunan*
45
46 2010;**30**(1):70-72.
47
- 48
49 26. Zhou XM, Xie XL. Bee needle combined with nursing and effect of external application
50
51 of Chinese medicine in the treatment of rheumatoid arthritis. *Nurs Res Pract*
52
53 2013;**10**(07):11-12.
54
- 55
56 27. Kuang HT, Lan HQ, Zhou K, et al. Clinical observation on combination of yangxuetongbi
57
58 decoction and bee pricking for the treatment of 32 cases of atrophic arthritis. *Hunan*
59
60 *Guiding J Tradit Chin Med Pharmacol* 2004;**10**(10):6-8.

- 1
2
3
4 28. Ji W, Zhang MJ, Ma YZ. Clinical observation of tripterygiumforrestii and bee venom in
5
6 treating rheumatoid arthritis. Zhongguo Zhong Xi Yi Jie He Za Zhi [Chinese Journal
7
8 of Integrated Traditional and Western Medicine] 1993;**13**(12):743-44.
9
10
11 29. Cai J. Clinical observation on 42 cases of needle treatment of rheumatoid arthritis. Clin J
12
13 Anhui Tradit Chin Med 1997;**9**(1):16-17.
14
15 30. Xu J, Pan ZG, Chen LL, et al. Clinical study on apistoxin injection direct current electric
16
17 acupoint introduction for the treatment of Bi syndrome. J Bee 1999(02):3-5.
18
19 31. Li L, Yi R, Wang YM, et al. Clinical observation on bee-sting therapy with ashi points
20
21 and with points of corresponding meridians in treating rheumatoid arthritis. Shanghai
22
23 J Acu-mox 2013;**32**(2):121-22.
24
25
26 32. Pertsulenko VA. Bee venom in the treatment of infectious non-specific (rheumatoid)
27
28 arthritis. Sovetskaia meditsina 1961;**25**:94-101.
29
30
31 33. Li L, Yi R, Wang YM, et al. Clinical observation on bee-sting therapy with Ashi Points
32
33 and with Points of Corresponding Meridians in Treating Rheumatoid Arthritis.
34
35 Shanghai J Acupunct Mox 2013(2):121-22.
36
37
38 34. Lee SH, Hong SJ, Kim SY. Randomized controlled double blind study of bee venom
39
40 therapy on rheumatoid arthritis. J Korean Acupunct Mox Soc 2003;**20**:80-88.
41
42
43 35. Vickers A, Goyal N, Harland R, et al. Do certain countries produce only positive results?
44
45 A systematic review of controlled trials. Control Clin Trials 1998;**19**(2):159-66.
46
47
48 36. Yao H. Bee needle therapy. Journal of shanxi elderly 2000(09):39.
49
50
51 37. Hwang YJ, Lee GM, Hwang WJ, et al. Clinical research of bee-venom acupuncture
52
53 effects on rheumatoid arthritis. J Korean Acupunct Mox Soc 2001;**18**(5):33-42.
54
55
56 38. Liu XD, Zhang JL, Zheng HG, et al. Clinical randomized study of bee-sting therapy for
57
58 rheumatoid arthritis. Acupunct Res 2008;**33**(3):197-200.
59
60

1
2
3
4 acupuncture. Allergy, asthma & immunology research 2012;4(2):107-9.
5

6 40. Kim YK, Jang YS, Jung JW, et al. Prevalence of bee venom allergy in children and adults
7
8 living in rural area of Cheju Island. Journal of Asthma, Allergy and Clinical
9
10 Immunology 1998;18(3):451-57.
11

12 41. Green S, Higgins JPT, Alderson P, et al. Chapter 1: Introduction. . In: T. HJP, Green S,
13
14 eds. Cochrane Handbook for Systematic Reviews of Interventions Version 510
15
16 (updated March 2011) The Cochrane Collaboration, 2011 Available from
17
18 wwwcochrane-handbookorg, 2008.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Figure legend**

5
6 Figure 1. Flow chart of trial selection process. CCT: case series trials; RCT: randomised
7
8 controlled trials.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Characteristics of included randomized controlled trials of bee venom acupuncture for rheumatoid arthritis

<i>Lee 2003</i>		
Methods	Design: prospective randomized controlled trial	
Participants	Country: South Korea Number of patients included(completed / randomized): (A) 37/40 (B) 32/40 Mean age (years): (A) 49.2±9.6 (B) 47.3±8.9 Duration of disease (years): (A) 9.2±7.0 (B) 7.3±4.6 Follow-up: 1 and 2 months	
Intervention	(A) BVA (Ashi points, acupoints near the inflammation point, two times a week for 2 months)	
Control	(B) Placebo (normal saline injection on ashi points, acupoints near the inflammation point, two times a week for 2 months)	
Outcomes	<i>Primary outcomes:</i> 1) Morning stiffness, MD, -0.70[-2.00, 0.60], P<0.05 2) HAQ, MD, 0.00[-0.08, 0.08], P<0.05 3) VAS-pain, MD, -18.10[-23.71, -12.49], P<0.05 <i>Secondary outcomes:</i> 1) Tender joint count, MD, -1.30[-1.91, -0.69], P<0.0001 2) Swollen joint count, MD, -1.10[-1.72, -0.48], P=0.005 3) ESR, MD, 20.10[-22.80, -17.40], P<0.00001 4) CRP, MD, -1.90[-2.86, -0.94], P=0.0001	
Note	Treatment Rationale: CM theory, Clinical experience Adverse effect: n.r. Funding: Korea Research Foundation Grant and Kyung Hee University Language: Korean Publication: full paper Withdrawal/dropouts:yes Intention-to-treat: No Author comment: These results suggests that bee venom therapy could be an effective method in the treatment of patients with RA	
<i>Risk of bias</i>		
Item	Authors' judgement	Description
Random sequence generation (selection bias)	Unclear risk	Described as randomized but information not available
Allocation concealment (selection bias)	Unclear risk	Not stated.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Described as double blinding
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated.
Incomplete outcome data (attrition bias) All outcomes	High risk	Data from 11 participants were not included in the analysis.
Selective reporting (reporting bias)	Low risk	Protocol not available, but all expected outcomes reported
Other bias	Unclear risk	Small sample size

BVA: Bee Venom Acupuncture; CRP: C - reactive protein; CM: Chinese medicine; ESR: erythrocyte sedimentation rate; HAQ: health assessment questionnaire; n.r.: not reported; RA: rheumatoid arthritis VAS: visual analogue scale

Table 2. Summary of findings


Bee venom acupuncture for patients with rheumatoid arthritis					
Patient or population: patients with rheumatoid arthritis					
Settings: Korea					
Intervention: Bee venom acupuncture vs. normal saline injection as placebo					
Outcomes	Illustrative comparative risks* (95% CI)		No of Participants (studies)	Quality of the evidence (Grade)	Comments
	Assumed risk Control (Normal Saline injection)	Corresponding risk Bee venom acupuncture			
Pain (VAS)		16.9 WMD lower ¹ (26.57 to 7.23 lower)	69 (1 study)	⊕⊕⊖⊖ low ^{2,3}	After 1 month -10.40 (-16.47 to -4.33)
Morning stiffness		12.1 WMD higher ¹ (11.61 to 12.59 higher)	69 (1 study)	⊕⊕⊖⊖ low ^{2,3}	After 1 month -0.30 (-1.01 to 0.41)
Swollen joint count		0.9 WMD lower ¹ (1.97 lower to 0.17 higher)	69 (1 study)	⊕⊕⊖⊖ low ^{2,3}	After 1 month 0.50 (-0.70 to -1.70)
Tender joint count		0.9 WMD lower ¹ (1.97 lower to 0.17 higher)	69 (1 study)	⊕⊕⊖⊖ low ^{2,3}	After 1 month 0.50 (-0.73 to -1.73)
Quality of Life (HAQ)		0.3 WMD higher ¹ (0.08 to 0.52 higher)	69 (1 study)	⊕⊕⊖⊖ low ^{2,3}	After 1 month 0.20 (-0.06 to 0.46)
ESR		19.4 WMD lower ¹ (28.51 to 10.29 lower)	69 (1 study)	⊕⊕⊖⊖ low ^{2,3}	After 1 month -2.30 (-10.17 to 5.57)
CRP		1.7 WMD lower ¹ (2.6 to 0.8 lower)	69 (1 study)	⊕⊕⊖⊖ low ^{2,3}	After 1 month 1.40 (-8.27 to 5.47)

*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).
CI: Confidence interval; **CRP:** C-reactive protein; **ESR:** Erythrocyte sedimentation rate; **HAQ:** Health Assessment Questionnaire; **VAS:** Visual analogue scale; **WMD:** weight mean difference

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

¹ After 2 months treatment
² Poorly reported paper (See 'Risk of bias' table)
³ Small sample size

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



188x196mm (300 x 300 DPI)



Supplement 1. Search Strategy

MEDLINE

1. exp arthritis, rheumatoid/
2. ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat\$ or reumat\$ or revmarthrit\$) adj3 (arthrit\$ or artrit\$ or diseas\$ or condition\$ or nodule\$)).tw.
3. (felty\$ adj2 syndrome).tw.
4. (caplan\$ adj2 syndrome).tw.
5. (sjogren\$ adj2 syndrome).tw.
6. (sicca adj2 syndrome).tw.
7. still\$ disease.tw.
8. bechterew\$ disease.tw.
9. or/1-8
10. bee venom\$.tw.
11. bee sting.tw.
12. wasp venom\$.tw.
13. bee venom acupuncture.tw.
14. bee venom therapy.tw.
15. bee sting therapy.tw.
16. apitoxin.tw.
17. apitherapy.tw.
18. or/10-17
19. 9 and 18

EMBASE

1. exp arthritis, rheumatoid/
2. ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat\$ or reumat\$ or revmarthrit\$) adj3 (arthrit\$ or artrit\$ or diseas\$ or condition\$ or nodule\$)).tw.

3. (felty\$ adj2 syndrome).tw.
4. (caplan\$ adj2 syndrome).tw.
5. (sjogren\$ adj2 syndrome).tw.
6. (sicca adj2 syndrome).tw.
7. still\$ disease.tw.
8. bechterew\$ disease.tw.
9. or/1-8
10. bee venom\$.tw.
11. bee sting\$.tw.
12. wasp venom\$.tw.
13. bee venom acupuncture.tw.
14. bee venom therapy.tw.
15. bee sting therapy.tw.
16. apitoxin.tw.
17. apitherapy.tw.
18. or/10-17
19. 9 and 18

The Cochrane Library (Wiley InterScience)

- #1 MeSH descriptor Arthritis, Rheumatoid explode all trees
- #2 ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat* or reumat* or revmarthrit*) near/3(arthrit* or artrit* or diseas* or condition* or nodule*)):ti,ab
- #3 felty* NEAR/2 syndrome:ti,ab
- #4 caplan* NEAR/2 syndrome:ti,ab
- #6 sjogren* near/2 syndrome:ti,ab
- #7 sicca near/2 syndrome:ti,ab
- #8 still* next disease:ti,ab
- #9 bechterew\$ disease.tw.
- #10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)
- #11 bee venom* :ti,ab
- #12 bee sting :ti,ab

1
2
3
4 #13 wasp venom* :ti,ab
5

6 #14 bee venom acupuncture :ti,ab
7

8 #15 bee venom therapy:ti,ab
9

10 #16 bee sting therapy:ti,ab
11

12 #17 apitoxin:ti,ab
13

14 #18 apitherapy:ti,ab
15

16 #19 (#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18)
17

18 #20 #10 AND #19
19

20 **CINAHL (EBSCOhost)**

21 S7 S3 and S6
22

23 S6 S4 or S5
24

25 S5 TI “apitoxin” or AB “apitoxin” or TI “apitherapy” or AB “apitherapy”
26

27 S4 TI “bee venom*” or AB “bee venom*” or TI “bee sting” or AB “bee sting” or TI “wasp
28 venom*” or AB “wasp venom*” or TI “bee venom acupuncture” or AB “bee venom
29 acupuncture” or TI “bee venom therapy” or AB “bee venom therapy”
30

31 #17 apitoxin:ti,ab
32

33 #18 apitherapy:ti,ab
34

35 S3 S1 or S2
36

37 S2 TI “bechterew* disease” or AB “bechterew* disease” or TI (arthritis N2 rheumat*) or AB
38 (arthritis N2 rheumat*)

39 S1 (MH “Arthritis, Rheumatoid+”) or TI (felty* N2 syndrome) or AB (felty* N2 syndrome)
40 or TI (caplan* N2 syndrome) or AB(caplan* N2 syndrome) or TI (rheumatoid nodule) or AB
41 (rheumatoid nodule) or TI (sjogren* N2 syndrome) or AB (sjogren* N2 syndrome) or TI
42 (sicca N2 syndrome) or AB (sicca N2 syndrome)
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplement 2. Summary of randomized controlled trials of direct bee sting acupuncture for rheumatoid arthritis

First author (Year) country	Mean age (years); Duration of disease (years)	Experimental intervention (Regimen)	Control intervention (Regimen)	Primary outcome		Secondary outcome		Adverse Effects
				measurement	result	measurement	result	
Liu (2008) China	(A) 47.4±10.0; 5.0±3.0 (B) 48.3±9.4; 4.9±2.6	(A) BVA (Ashi points, dialectical acupoints, 8~15bees, n.r., once every other day for 3 months, n=50), plus (B)	(B) WM (Oral:MTX:7.5mg, once a week for 3 months; SASP:0.5g, third daily for 3 months; Meloxicam:7.5mg, twice daily for 3 months, n=50)	(1) Total improvement score (2) Joint swelling score (3) Joint pain score	(1) RR, 1.22[1.01, 1.47], P=0.04 (2) MD, -0.24[-0.42, -0.06], P=0.010 (3) MD, -0.34[-0.37, -0.31], P<0.00001	(1) Number of Joint-swelling (2) RF (3) ESR	(1) MD, -0.46[-0.62, -0.30], P<0.00001 (2) MD, -7.74[-14.10, -1.38], P=0.02 (3) MD, -4.38[-6.28, -2.48], P<0.00001	Dizziness (B:4), fever(A:1), hypersensitivity(A:4), leukopenia(B:3), loss of appetite and nausea(B:6)
Zhang (2011) China	(A) 33.8; 3.6 (B) 32.2; 3.4	(A) BVA (Ashis points near the knee, 5~15bees, n.r., two or three times a week for 3months, n=23) plus (B)	(B) WM (Oral:MTX:7.5mg, once a week for 3 months; SASP:0.5g, third daily for 3 months; Meloxicam:7.5mg, once daily for 3 months, n=23)	(1) Total improvement score (2) VAS (3) HSS	(1) RR, 1.17[0.91, 1.50] (2) MD, -1.00[-1.20, -0.80], P<0.00001 (3) MD, 3.37[3.24, 3.50], P<0.00001	(1) ESR (2) CRP	(1) MD, -4.20[-7.35, -1.05], P=0.009 (2) MD, -2.50[-5.56, 0.56], P=0.11	Dizziness(A:1), epigastric discomfort(A:4), fever(A:2), hypersensitivity(A:1), leukopenia(B:3), rash(A:3)
Deng (2011) China	n.r.	(A) BVA (Ashi points, dialectical acupoints, before 15-25d: 2~3bees; after 15-25d: 1~3bees increase every time, n.r., three times a week for 2 months, n=20) plus (B)	(B) WM (Oral:MTX:10mg, once a week for 2 months, n=20) (C) WM (Oral: Prednisone Acetate:7.5mg, once daily for 2 months, n=20) plus (B)	(1) Total improvement score (2) Morning stiffness (3) Joint pain score (4) Joint swelling score	(1) - A vs. B RR, 1.46[1.04, 2.05], P=0.03 - A vs. C RR, 1.36[1.00, 1.84], P=0.05 (2) - A vs. B MD, -0.29[-0.42, -0.17], P<0.00001 - A vs. C MD, -0.11[-0.25, 0.02], P=0.05 (3) - A vs. B MD, -0.50[-0.64, -0.36], P<0.00001 - A vs. C MD, -0.13[-0.26, 0.00], P=0.05 (4) - A vs. B MD, -0.33[-0.47, -0.19], P<0.00001 - A vs. C MD, 0.05[-0.12, 0.21], P=0.56	(1) RF (2) ESR (3) CRP	(1) - A vs. B MD, -28.00[-37.21, -18.79], P<0.00001 - A vs. C MD, -14.30[-17.60, -11.00], P<0.00001 (2) - A vs. B MD, -18.60[-27.04, -10.16], P<0.00001 - A vs. C MD, -8.10[-15.41, -0.79], P=0.03 (3) - A vs. B MD, -10.30[-12.46, -8.14], P<0.00001 - A vs. C MD, -3.70[-5.99, -1.41], P=0.002	Epigastric discomfort (C:6),hypersensitivity (A:3), insomnia(C:3), leukopenia(B:1), nausea(A:2,B:3)

5	Zhou (2012) China	(A) 37.86±14.15; 15.58±5.24 (B) 36.43±10.18; 13.95±5.21 (C) 40.66±14.01; 16.58±5.32	(A) BVA (Ashi points, acupoints near the pain point, 5~10bees, n.r., three times a week for 3 months, n=40) plus NSAIDS	(B) EA (Ashi points, LI15, LI14, LI11, LI 10, SJ5, BL36, SP10, BL40, GB34, ST36, GB39, DU14, BL52, DU3, BL32, 30min, three times a week y for 3 months, n=30) plus NSAIDS (C) WM (Oral:MTX:5-10mg, once a week for 3 months; Folic acid: 10mg, once a week for 3 months, n=30) plus NSAIDS	(1) Total improvement score	(1) - A vs. B RR, 1.23[0.97, 1.56], P=0.09 - A vs. C RR, 1.04[0.87, 1.24], P=0.67	(1) ESR (2) CRP	(1) - A vs. B MD, -13.70[-15.08, -12.32], P<0.00001 - A vs. C MD, -2.72[-6.54, 1.10] P=0.16 (2) - A vs. B MD, -9.18[-11.47, -6.89], P<0.00001 - A vs. C MD, 3.93[-0.07, 7.93], P=0.05	n.r.
---	-------------------	---	---	---	-----------------------------	---	--------------------	---	------

BVA: Bee Venom Acupuncture; CRP: C - reactive protein; EA: electro acupuncture; ESR: erythrocyte sedimentation rate; HSS: hss knee score; HAQ: health assessment questionnaire; MTX: methotrexate; n.r.: not reported; NSAIDS: nonsteroidal anti-inflammatory drugs; RF: rheumatoid factor; SASP: sulfasalazine; VAS: visual analogue scale; TNF-α: tumor necrosis factor-alpha; WM: Western medicine

References

Deng M, Zhang WN. Clinical observation on 20 cases of bee needle therapy in the treatment of rheumatoid arthritis. *Guiding J Tradit Chin Med Pharm* 2011;17(6):71-73.
 Liu XD, Zhang jl, Zheng HG, Li Z, D., Cai L, Liu FY, et al. Effect of bee-sting therapy on TNF-α and IL-1β in peripheral blood of rheumatoid arthritis patients. *Chin Arch Tradit Chin Med* 2008;26(5):996-97.
 Zhang JL, Liu XD, Ye LH, Zhang P. Clinical padomized comparison study of bee-sting therapy for knee synovitis caused by rheumatoid arthritis. *Chin Arch Tradit Chin Med* 2011;29(8):1904-06.
 Zhou YF, Li WY. Effect of needle on hypothalamic-pituitary-adrenal axis of patient with rheumatoid arthritis. *Nei Mongol J Tradit Chin Med* 2012;26(5):1-3.

Supplement 3. Summary of treatment direct bee sting acupuncture points and other information

First author (Year)	Type of acupuncture	Total treatment (sessions)	Main acupoints	Dialectical acupoints	Treatment Rationale	Adverse events
Liu (2008)	BVA (Live bee, 8~15bees)	3 months	Ashi points	Cold dampness invasion, joint pain: CV6, RN4; Hot and humid embodiment, joint swelling pain: LI11, GV14; Phlegm and blood stasis in the resistance, Joint deformities pain:ST40,GB39;	CM theory, Clinical experience	Hypersensitivity(4), fever(1)
Zhang (2011)	BVA (Live bee, 5~15bees)	3 months	Ashis points near knee	n.r.	CM theory, Clinical experience	Fever(2), hypersensitivity(1), rash(3)
Deng (2011)	BVA (Live bee, before 15-25d: 2~3bees; after 15-25d: 1~3bees increase every time)	2 months	Ashi points	Ankle:BL62, KI6, BL60, GB40; back: GV26, V12, GV3; elbow: LI11, LI4, SJ10, SJ5, LU5; knee:ST35, ST34, GB34, GB33; Shoulders:LI16, SJ14, SI10; wrist:SJ4, SJ5 LI5, SI4	CM theory, Clinical experience	Hypersensitivity (3), nausea(2)
Zhou (2012)	BVA (Live bee, 5~10bees)	3 months	Ashi points, acupoints in near in the pain point	n.r.	CM theory, Clinical experience	n.r.
Lee (2003)	BVA (Injection, Bee venom extract diluted with saline to 1:3000, from 0.2ml increase to 1.0ml)	2 months	Ashi points, acupoints near the inflammation point	Metacarpophalangeal joint, Distal interphalangeal joint, Proximal interphalangeal joint, wrist: SI5, SI5, TE4, L15 PC7; elbow:LI11, TE10, SI8, HT3, S18; shoulder: LI15, TE14; knee: ST36, GB34, SP9; ankle: GB40, BL62, SP5, K16	CM theory, Clinical experience	n.r

BVA: Bee Venom Acupuncture; CM: Chinese medicine; n.r.: not reported

References

Deng M, Zhang WN. Clinical observation on 20 cases of bee needle therapy in the treatment of rheumatoid arthritis. *Guiding J Tradit Chin Med Pharm* 2011;17(6):71-73.

Liu XD, Zhang jl, Zheng HG, Li Z, D., Cai L, Liu FY, et al. Effect of bee-sting therapy on TNF- α and IL-1 β in peripheral blood of rheumatoid arthritis patients. *Chin Arch Tradit Chin Med* 2008;26(5):996-97.

Zhang JL, Liu XD, Ye LH, Zhang P. Clinical padomized comparison study of bee-sting therapy for knee synovitis caused by rheumatoid arthritis. *Chin Arch Tradit Chin Med* 2011;29(8):1904-06.

Zhou YF, Li WY. Effect of needle on hypothalamic-pituitary-adrenal axis of patient with rheumatoid arthritis. *Nei Mongol J Tradit Chin Med* 2012;26(5):1-3.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Supplement 4. Summary of non-randomized controlled trials of bee venom acupuncture for rheumatoid arthritis

<i>Hwang 2001</i>	
Methods	Design: case series
Participants	Country: South Korea Number of patients included(male / female): 15(4/11) Duration of disease (weeks): (A) < 4 (n=4), (B) 8~20 (n=2), (C) >24 (n=9) Follow-up: n.r
Intervention	BVA (Ashi points, acupoints near the inflammation point, two times a week)
Outcomes	1)VAS-pain, improvement index(score of after treatment-score of before treatment/ score of after treatment): (A) 0.80; (B) 0.68; (C) 0.51 2) Improvement of symptom(patient' assesment), Excellent(n=6); Good(n=7); Maderate(n=2)
Note	Treatment Rationale: Chines Medicine theory, Clinical experience Adverse effect: n.r. Funding: none Language: Korean Publication: full paper Withdrawal/dropouts: no

n.r.: not reported



PRISMA 2009 Checklist: Bee venom acupuncture for rheumatoid arthritis: A systematic review of randomised clinical trials

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	4
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	7
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	8
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	8
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	8
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	10
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	10
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	9
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	10
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	Table 1,2



PRISMA 2009 Checklist: Bee venom acupuncture for rheumatoid arthritis: A systematic review of randomised clinical trials

Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	na
----------------------	----	---	----

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	12
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	na
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	12, Figure 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	13
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	13
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	na
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	13
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	na
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	14
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	16
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	17

1
2
3
4 **Bee venom acupuncture for rheumatoid arthritis:**
5
6
7 **a systematic review of randomised clinical trials**
8
9

10
11 Ju Ah Lee,^{1,†} Mi Ju Son,^{2,†} Jiae Choi,¹ Ji Hee Jun,¹ Jong-In Kim,³ Myeong Soo Lee^{1,*}
12
13

14
15
16 ¹*Medical Research Division, Korea Institute of Oriental Medicine, Daejeon, South Korea,*
17

18 ²*Medical Culture & Informatics Research Division, Korea Institute of Oriental Medicine,*
19
20
21 *Daejeon, South Korea*
22

23 ³*Division of Acupuncture & Moxibustion medicine, Kyung Hee Korean Medicine Hospital,*
24
25 *Kyung Hee University, Seoul, Korea*
26
27

28
29
30 † Contributed equally
31

32
33 ***Correspondence to:**

34 Myeong Soo Lee, PhD
35 Medical Research Division,
36 Korea Institute of Oriental Medicine,
37 Daejeon, 305-811, South Korea
38
39 Tel: 82-(0)42-868-9266
40
41 Fax: 82-(0)42-868-9299
42
43 E-mail: drmslee@gmail.com
44
45
46

47
48 Lee JA: motoong@kiom.re.kr

49 Son MJ: mj714@kiom.re.kr

50 Choi J: ksjiae@kiom.re.kr

51 Jun JH: zhixi04@kiom.re.kr

52 JIK: hann8400@hanmail.net
53
54
55
56
57
58
59
60

License statement

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive license (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in BMJ Open and any other BMJ PGL products to exploit all subsidiary rights, as set out in our license (<http://group.bmj.com/products/journals/instructions-for-authors/license-forms>).

For peer review only

Article focus

- This systematic review aims to analyse the trial data on the effects of bee venom acupuncture for rheumatoid arthritis.

Key messages

- This systematic review performed with a comprehensive search strategy and established the current status of the evidence with unbiased methods.

Strengths and limitations of this study

- The strength of this systematic review is its extensive, unbiased search of various databases without a language restriction.
- The trial screening and data extraction conducted independently by two authors.
- We used of the GRADE approach to assess confidence in estimates of effect
- We identified only one study so that we could not draw strong conclusions.

Abstract

Objective: To assess the clinical evidence for bee venom acupuncture (BVA) for rheumatoid arthritis (RA).

Design: Systematic review of randomised controlled trials (RCTs).

Setting: We searched 14 databases up to March 2014 without a language restriction.

Participants: Patients with RA.

Intervention: BVA involved injecting purified, diluted BV into acupoints. We included trials on BVA used alone or in combination with a conventional therapy versus the conventional therapy alone.

Primary outcome: Morning stiffness, pain and joint swelling

Secondary outcomes: Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), the number of joints affected by RA and adverse effects likely related to RA.

Results: A total of 304 potentially relevant studies were identified; only one RCT met our inclusion criteria. Compared to placebo, BVA may more effectively improve joint pain, swollen joint counts, tender joint counts, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) but were not shown the improvement of morning stiffness.

Conclusions: There is low-quality evidence, based on one trial, that BVA can significantly reduce pain, morning stiffness, tender joint counts, swollen joint counts and improve the quality of life of RA patients compared to placebo (normal saline injection) control. However, the number of trials, their quality, and the total sample size were too low to draw firm conclusions.

Trial registration number: PROSPERO 2013: CRD42013005853

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Key words: Bee venom acupuncture, rheumatoid arthritis, complementary and alternative medicine, systematic review

For peer review only

Introduction

Description of the condition

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that results in pain and stiffness, joint swelling, deformity of joints and ankylosis develop. The complex, systemic nature of the disease makes RA treatment complex and involving a variety of approaches. The major aims of treatment are to relieve pain and swelling, reduce inflammation and joint damage, prevent disability and preserve or improve patients' well-being and function.¹

Untreated RA leads to joint destruction, functional limitation and severe disability²³ and has a significant impact on health-related quality of life (HRQoL).⁴⁵

Description of the intervention

Bee venom (BV) therapy has been used since ancient times. Different forms of the therapy include the administration of honeybee stings, injections of BV, and BV acupuncture (BVA).⁶ Bee venom acupuncture (BVA) involves injecting purified and diluted bee venom into acupoints.⁷

How the intervention might work

BVA exhibits several pharmacological actions, including analgesic, anti-inflammatory, anti-arthritis, and anti-cancer effects through multiple mechanisms, such as activation of the central inhibitory and excitatory systems and modulation of the immune system.⁸ The analgesic effects of BVA have been reported in animal experiments⁹¹⁰ and clinical settings.⁷

¹¹ According to animal experiments, BV exhibits anti-arthritis, anti-inflammatory and analgesic effects attributable to the suppression of cyclooxygenase-2 and phospholipase A2

1
2
3
4 expression and a decrease in the levels of tumour necrosis factor alpha, interleukin (IL)-1, IL-
5
6 6, nitric oxide and oxygen reactive species. It is also widely assumed that bioactive BV
7
8 compounds including enzymes (phospholipase A2), peptides (melittin, adolapin, and
9
10 apamin), and amines are associated with these actions.^{7 8 12-14} However, most therapeutic
11
12 uses are not based on evidence.
13
14

15
16
17 One study was conducted to elucidate whether the synergistic anti-arthritic effects produced
18
19 by a combination of BV and conventional therapy enhances the therapeutic potency and
20
21 minimises the adverse effects of methotrexate.¹⁵
22
23

24 25 26 *Why this review is important*

27
28 Bee venom (BV) therapy or BV acupuncture (BVA) has been used for reducing pain caused
29
30 by inflammatory diseases such as osteoarthritis and rheumatoid arthritis (RA) in some Asian
31
32 countries.¹¹
33
34

35 However, there is no critically appraised evidence, such as a systematic review or meta-
36
37 analysis, of the potential benefits and risks of BVA for RA. A comprehensive evaluation of
38
39 the efficacy and safety of BVA for RA will inform the recommendation to patients to pursue
40
41 BVA treatment.
42
43
44

45 46 *Objectives*

47
48 Although BVA for RA is used as an effective method for reducing RA-related symptoms and
49
50 improving functioning, there is no critically appraised evidence regarding the safety and
51
52 effectiveness of BVA for RA from a systematic review or meta-analysis.
53
54

55 We performed a systematic review to assess the safety and efficacy of BVA for the treatment
56
57 of RA.
58
59
60

Materials and Methods

The protocol of this SRs is registered on PROSPERO 2013 (registration number: CRD42013005853) and published as a protocol.¹⁶

Data source

The following electronic databases were searched from the study's inception to March 2014: Medline, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), AMED, and CINAHL. We also searched 6 Korean medical databases (OASIS, Korean Traditional Knowledge Portal, Korean Studies Information Service System, KoreaMed, Korean Medical Database and DBPIA) and 3 Chinese databases including CNKI (China Academic Journal, China Doctoral Dissertations and Master's Theses Full-text Database, China Proceedings of Conference Full Text Database and the Century Journal Project), Wanfang and VIP. Further, we conducted non-electronic searches of conference proceedings, our own files of articles and 9 Korean traditional medical journals (Journal of Korean Medicine, The Journal of Korean Acupuncture and Moxibustion Society, Korean Journal of Acupuncture, Journal of Acupuncture and Meridian Studies, Journal of Pharmacopuncture, Journal of Oriental Rehabilitation Medicine, The Journal of Korea Chuna Manual Medicine for Spine and Nerves, Korean Journal of Oriental Physiology and Pathology and The Journal of Korean Oriental Internal Medicine). The strategy for searching the MEDLINE database is presented in **Supplement 1**. Similar search strategies were applied for the other databases.

Types of studies

All prospective randomised controlled clinical trials (RCTs) were included if they were randomised studies of BV injections at acupoints as the sole treatment, or as an adjunct to other treatments if the control group received the same treatment as the BVA group. Trials

1
2
3
4 comparing BVA with any type of control intervention were also included. We excluded trials
5
6 of BV injections into parts of the body other than acupoints. Trials were also excluded if only
7
8 immunological or biological parameters were assessed. Trials comparing two different types
9
10 of BVA were also excluded. No language restrictions were imposed. Hard copies of all
11
12 articles were obtained and read in full.
13

14 15 16 17 **Types of participants**

18
19 Patients suffering from RA were included.
20
21

22 23 24 **Types of interventions**

25
26 We included trials on BVA used alone or in combination with a conventional therapy versus
27
28 the conventional therapy alone. BVA involved injecting purified, diluted BV into acupoints.
29
30 Conventional therapies included medications such as nonsteroidal anti-inflammatory drugs,
31
32 steroids, disease-modifying anti-rheumatic drugs, immunosuppressants, and TNF-alpha
33
34 inhibitors.
35
36
37
38
39

40 41 **Types of outcomes measured**

42 Primary outcomes were symptoms (morning stiffness, pain and joint swelling) experienced.
43
44 Secondary outcomes included erythrocyte sedimentation rate (ESR), C-reactive protein
45
46 (CRP), rheumatoid factor (RF), the number of joints affected by RA and adverse effects
47
48 likely related to RA.
49
50

51 52 53 **Data extraction and quality assessment**

54
55 Hard copies of all articles were obtained and read in full. Two authors (MJS and JHJ)
56
57 performed the data extraction and quality assessment using a predefined data extraction form.
58
59

1
2
3
4 The risk of bias was assessed using the assessment tool for risk of bias from the Cochrane
5 Handbook version 5.1.0, which includes random sequence generation, allocation concealment,
6 blinding of participants and personnel, blinding of outcome assessments, incomplete outcome
7 data, selective reporting and other sources of bias.¹⁷ Our review used 'L', 'U', and 'H' as
8 results of the assessment; 'L' indicated a low risk of bias, 'U' indicated that the risk of bias
9 was unclear, and 'H' indicated a high risk of bias. Disagreements were resolved by a
10 discussion between all of the authors. When disagreements on the selection were not resolved
11 through discussions, the arbiter (MSL) made the final decision.
12
13
14
15
16
17
18
19
20
21
22
23

24 **Data collection and synthesis**

25 *Data extraction and management*

26
27
28 The data extraction and quality assessment were conducted by three authors (JAL, MJS and
29 JHJ) using a predefined data extraction form. Any disagreement among the authors was
30 resolved by a discussion between all of the authors. When the data were insufficient or
31 ambiguous, MSL contacted the corresponding authors by e-mail or telephone to request
32 additional information or clarification. The data screening and selection process was
33 performed independently by four authors and then was verified by a fifth author, JHJ, who is
34 fluent in Chinese. We used GRADEpro software in the Cochrane Systematic Reviews to
35 create a Summary of Findings table. When disagreements on the selections were not resolved
36 through discussions, the arbiter (MSL) made the final decision.
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 *Assessment of bias in the included studies*

52
53 We independently assessed bias in the included studies according to criteria from the
54 Cochrane Handbook, version 5.1.0, which includes random sequence generation, allocation
55 concealment, blinding of participants and personnel, blinding of outcome assessments,
56
57
58
59
60

1
2
3
4 incomplete outcome data, selective reporting and other sources of bias.¹⁷The quality of each
5
6 trial was categorised into a low, unclear, or high risk of bias, and the authors of the assessed
7
8 trials were contacted for clarification as needed. We resolved any differences in opinion
9
10 through discussion or consultation with a third author.
11
12

13 14 15 *Data synthesis*

16
17 The differences between the intervention and control groups were assessed. For the
18
19 continuous data, we used mean differences (MDs) with 95% confidence intervals (CIs) to
20
21 measure the treatment effects. We converted other forms of data into MDs. In the case of
22
23 outcome variables with different scales, we used the standard mean difference (SMD) with
24
25 95% CIs. For dichotomous data, we presented the treatment effect as a relative risk (RR) with
26
27 95% CIs. For dichotomous data, we presented the treatment effect as a relative risk (RR) with
28
29 95% CIs. We converted other binary data into an RR value.
30
31

32
33 All of the statistical analyses were conducted using Cochrane Collaboration's software
34
35 program, Review Manager (RevMan), Version 5.2.7 for Windows (Copenhagen, The Nordic
36
37 Cochrane Centre, the Cochrane Collaboration, 2012). For studies with insufficient
38
39 information, we contacted the corresponding authors to acquire and verify data when possible.
40
41 If appropriate, we pooled data across studies for a meta-analysis using fixed-effects or
42
43 random-effects.
44
45

46 47 48 *Unit of analysis issues*

49
50 For cross-over trials, data from the first treatment period were used. For trials in which more
51
52 than one control group was assessed, the primary analysis combined the data from each
53
54 control group. Subgroup analyses of the control groups were performed. Each patient was
55
56 counted only once in the analysis.
57
58

Addressing the missing data

Intention-to-treat analyses that included all of the randomised patients were performed. For patients with missing outcome data, a carry-forward of the last observed response was used. The individual patient data were sought from the original source or the published trial reports when the individual patient data were initially unavailable.

Assessment of heterogeneity

We used the random-effect or fixed-effect model for the meta-analysis according to the data analysis. Chi-squared and I-squared tests were used to evaluate the heterogeneity of the included studies and $I^2 > 50$ were considered to have high heterogeneity. If heterogeneity was observed, we conducted a subgroup analysis to explore the possible causes.¹⁸

Assessment of reporting biases

If a sufficient number of included studies (at least 10 trials) were available, we used funnel plots to detect reporting biases.¹⁹ However, funnel plot asymmetry was not the same as publication bias; therefore, we attempted to determine the possible reasons for the asymmetry, such as small-study effects, poor methodological quality and true heterogeneity in the included studies.^{19 20}

Results

Study selection and description

The search generated a total of 304 hits, of which only one met our inclusion criteria (Figure 1). Thirteen RCTs were among the excluded articles for the following reasons: Four RCTs, which were conducted in China, were excluded because the BVA were not made with purified, diluted bee venom but with live bee stings (Supplement 2 and 3).²¹⁻²⁴ Four RCTs employed herbal medicine as co-administrator,²⁵⁻²⁸ 2 RCTs included herbal medicine as control treatment,^{29 30} 1 RCT compared two different acupoints,³¹ 1 RCT was not related RA,³² and the other 1 RCT was duplicated publication.³³ The key data from the eligible RCT are summarised in Table 1. This trial was conducted in Korea.³⁴

Risk of bias in the included studies

The RCT used³⁴ has an uncertain risk of bias due to its random sequence generation, allocation concealment, outcome assessment blinding, selective reporting and other biases. This study used blinding of participants and personal employing placebo as a comparison and to address incomplete outcome data.

Outcomes

The study tested the efficacy of BVA on morning stiffness, Health Assessment Questionnaire (HAQ) scores, pain, tender joint counts, swollen joint counts, ESR, and CRP in RA patients.³⁴ Patients were randomised into two groups: one receiving BVA at ashi points and the other receiving normal saline injections at ashi points. After two months, the scores for morning stiffness, HAQ, pain on VAS, tender joint counts, swollen joint counts, ESR, and CRP were significantly better in the BVA group than in the placebo control group.

1
2
3
4 *Adverse events*
5

6 This trial did not assess adverse events related to BVA used for RA.³⁴
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Discussion

Only one trial testing the effects of BVA for RA is currently available.³⁴ There is low-quality evidence based on this one trial that BVA significantly reduces pain, morning stiffness, tender joint counts, swollen joint counts and improves the quality of life of RA patients compared to placebo (normal saline injection) control subjects (Table 2). To date, however, the effects of BVA for RA have not been confirmed because of small sample sizes and high risks of bias.

This systematic review has several limitations. First, although extensive efforts were made to retrieve all of the RCTs with no language and publication status limitations, only one study of BVA for RA qualified for our review. Second, the included RCT was conducted in East Asian countries, and studies from East Asian countries do not apply globally because of their lack of external validity. Third, Korean researchers tend to have positive results,³⁵ but we could not minimise the results because of the lack of methodology. Fourth, despite the possibility of delayed-type hypersensitivity occurring, there was no prolonged follow-up.

The included RCT used saline injections at the same acupoints used in the BVA group for the placebo control treatment.³⁴ The use of placebo is essential for differentiating nonspecific from specific treatment effects. If we consider that the effects of BVA could come from stimulating acupoints with the immune-modulative effect of bee venom, it is necessary to implement further RCTs that use the appropriate placebo. This study has some potential caveats. One is that a normal saline injection at the same acupoints used in the experimental group could be an inappropriate placebo. BVA combines biochemical effects of the bee venom and mechanical effects from the needles. As a result, this placebo could invoke mechanical effects from the acupoint injection. The other is that there was no reporting of previous experiences with BVA. BVA has uncomfortable sensations such as swelling and

1
2
3
4 burning during the treatment. Some participants who have previously experienced BVA
5
6 treatment could know what they were treated with, thereby interrupting patient blinding. To
7
8 use normal saline injections as a placebo, it is important to recruit patients who have not
9
10 experienced BVA.
11

12
13
14
15 BVA can cause diverse clinical responses depending on the amount of venom used and the
16
17 frequency and duration of the treatment. The acute or delayed adverse reaction is an
18
19 inflammatory reaction, such as anaphylaxis or urticarial.³⁶ Although trials are conducted
20
21 safely, some problems remain in using BVA in clinical practice.
22

23
24
25
26 In the absence of a sufficient number of RCTs, other types of evidence might be helpful.
27
28 There was one observational study that showed favourable effects of BVA for several
29
30 symptoms of RA (Supplement 4).³⁷ However, this type of study, lacking in controls, was open
31
32 to selection bias, which could lead to false-positive results.
33

34
35
36
37 The other type of BV therapy may be more commonly used when treating patients with RA.
38
39 In considering this type of trial, we found 4 additional RCTs that compared live bee sting
40
41 acupuncture combined with conventional drugs to conventional treatments alone for the
42
43 treatment of RA symptoms.^{21 23 24 38} Three RCTs^{21 23 38} showed favourable effects of BVA on
44
45 at least one of the main outcomes including total improvement, morning stiffness, pain, joint
46
47 pain, or joint swelling, while one RCT failed to do so.²⁴ Although these RCTs did not report
48
49 serious adverse effects,^{22 24 25 29} live bee stings can cause fatal adverse events including
50
51 anaphylaxis.^{39 40} Adverse events should be examined in future studies. The injection parts
52
53 may be one issue for the assessment because it is very common to inject on the painful point
54
55 (Ashi point) in RA patients. Even if we expand the inclusion criteria to this points, no further
56
57
58
59
60

1
2
3
4 studies were found.
5
6
7

8 One could question the validity of the conclusion by pointing to the review method used
9 (reviewing a small number of trials with many limitations). However, reasons for doing a
10 systematic review would be to answer question not posted by individual studies, to settle
11 controversies arising from apparently conflicting studies, or to generate new hypotheses.⁴¹
12
13
14

15 The systematic review with a small number of trials can be done.
16
17
18

19
20
21 In conclusion, currently, very few trials have tested the effects of BVA in the management of
22 RA. Collectively, the evidence is insufficient to suggest that BVA is an effective therapy for
23 RA. Further studies should be of high quality, with a particular emphasis on designing
24 adequate and appropriate control groups.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Author Contributions

Conceived and designed the review: MSL and JAL. Extracted the data: JHJ, and MJS.

Analyzed the data: MJS, JC and JIK. Wrote the paper: JAL, MJS, JC, JIK, and MSL.

Searched and selected studies: JHJ, MJS, JC. Revised the paper: JAL, MSL. Monitored data collection: MSL.

Financial support

No external funding was received. Lee JA, Choi J, Jun JH, and Lee MS were supported by Korea Institute of Oriental Medicine (K14281, K14400). Son MJ was supported by same institute (K14380).

Conflict of interest

None

References

1. Han A, Robinson V, Judd M, et al. Tai chi for treating rheumatoid arthritis. *Cochrane Database Syst Rev* 2004(3):CD004849.
2. Odegard S, Finset A, Kvien TK, et al. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register. *Scand J Rheumatol* 2005;**34**(6):441-7.
3. Yelin E. Work disability in rheumatic diseases. *Curr Opin Rheumatol* 2007;**19**(2):91-6.
4. Kvien TK, Uhlig T. Quality of life in rheumatoid arthritis. *Scand J Rheumatol* 2005;**34**(5):333-41.
5. Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. *Pharmacoeconomics* 2004;**22**(2 Suppl 1):27-38.
6. Munstedt K, Hackethal A, Schmidt K. Bee venom therapy, bee venom acupuncture of apipuncture: What is the evidence behind the various health claims? *Am Bee J* 2005;**145**:665-68.
7. Lee MS, Pittler MH, Shin BC, et al. Bee venom acupuncture for musculoskeletal pain: a review. *J Pain* 2008;**9**(4):289-97.
8. Son DJ, Lee JW, Lee YH, et al. Therapeutic application of anti-arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent compounds. *Pharmacol Ther* 2007;**115**:246-70.
9. Baek YH, Huh JE, Lee JD, et al. Antinociceptive effect and the mechanism of bee venom acupuncture (Apipuncture) on inflammatory pain in the rat model of collagen-induced arthritis: mediation by alpha2-adrenoceptors. *Brain Research* 2006;**1073-1074**:305-10.
10. Chen HS, Qu F, He X, et al. The anti-nociceptive effect and the possible mechanism of acupoint stimulation caused by chemical irritants in the bee venom pain model *Brain*

- 1
2
3
4 Research 2010;**1355**:61-69.
5
6
7 11. Lee JD, Park HJ, Chae Y, et al. An overview of bee venom acupuncture in the treatment
8 of arthritis. *Evid Based Complement Alternat Med* 2005;**2**(1):79-84.
9
10
11 12. Lim BS, Moon HJ, Li DX, et al. Effect of bee venom acupuncture on oxaliplatin-induced
12 cold allodynia in rats. *Evid Based Complement Alternat Med* 2013;**2013**:369324.
13
14
15 13. Moon DO, Park SY, Lee KJ, et al. Bee venom and melittin reduce proinflammatory
16 mediators in lipopolysaccharide-stimulated BV2 microglia. *International*
17 *immunopharmacology* 2007;**7**(8):1092-101.
18
19
20
21
22 14. Nah SS, Ha E, Mun SH, et al. Effects of melittin on the production of matrix
23 metalloproteinase-1 and -3 in rheumatoid arthritic fibroblast-like synoviocytes. *J*
24 *Pharmacol Sci* 2008;**106**(1):162-6.
25
26
27
28
29 15. Darwish SF, El-Bakly WM, Arafa HM, et al. Targeting TNF-alpha and NF-kappaB
30 activation by bee venom: role in suppressing adjuvant induced arthritis and
31 methotrexate hepatotoxicity in rats. *PloS one* 2013;**8**(11):e79284.
32
33
34
35
36 16. Lee JA, Son MJ, Choi J, et al. Bee venom acupuncture for rheumatoid arthritis: a
37 systematic review protocol. *BMJ Open* 2014;**4**(4).
38
39
40
41 17. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included
42 studies. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews*
43 *of Interventions* Version 510 (updated March 2011): The Cochrane Collaboration,
44 2011. Available from www.cochrane-handbook.org, 2011.
45
46
47
48
49 18. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-
50 analyses. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews*
51 *of Interventions* Version 510 (updated March 2011): The Cochrane Collaboration.
52 Available from www.cochrane-handbook.org, 2011.
53
54
55
56
57 19. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins
58
59
60

- 1
2
3
4 JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions
5
6 Version 510 (updated March 2011): The Cochrane Collaboration, 2011. Available
7
8 from www.cochrane-handbook.org, 2011.
9
10
11 20. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,
12
13 graphical test. *Bmj* 1997;**315**(7109):629-34.
14
15 21. Deng M, Zhang WN. Clinical observation on 20 cases of bee needle therapy in the
16
17 treatment of rheumatoid arthritis. *Guiding J Tradit Chin Med Pharm* 2011;**17**(6):71-
18
19 73.
20
21 22. Liu XD, Zhang jl, Zheng HG, et al. Effect of bee-sting therapy on TNF- α and IL-1 β in
22
23 peripheral blood of rheumatoid arthritis patients. *Chin Arch Tradit Chin Med*
24
25 2008;**26**(5):996-97.
26
27 23. Zhang JL, Liu XD, Ye LH, et al. Clinical padomized comparison study of bee-sting
28
29 therapy for knee synovitis caused by rheumatoid arthritis. *Chin Arch Tradit Chin Med*
30
31 2011;**29**(8):1904-06.
32
33 24. Zhou YF, Li WY. Effect of needle on hypothalamic-pituitary-adrenal axis of patient with
34
35 rheumatoid arthritis. *Nei Mongol J Tradit Chin Med* 2012;**26**(5):1-3.
36
37 25. Zhu HJ, Huang SG, Tan N, et al. Clinical observation of apiotherapy combined with
38
39 Chinese drug fumigation for rheumatoid arthritis. *J Tradit Chin Med Univ Hunan*
40
41 2010;**30**(1):70-72.
42
43 26. Zhou XM, Xie XL. Bee needle combined with nursing and effect of external application
44
45 of Chinese medicine in the treatment of rheumatoid arthritis. *Nurs Res Pract*
46
47 2013;**10**(07):11-12.
48
49 27. Kuang HT, Lan HQ, Zhou K, et al. Clinical observation on combination of yangxuetongbi
50
51 decoction and bee pricking for the treatment of 32 cases of atrophic arthritis. *Hunan*
52
53 *Guiding J Tradit Chin Med Pharmacol* 2004;**10**(10):6-8.
54
55
56
57
58
59
60

- 1
2
3
4 28. Ji W, Zhang MJ, Ma YZ. Clinical observation of tripterygiumforrestii and bee venom in
5
6 treating rheumatoid arthritis. Zhongguo Zhong Xi Yi Jie He Za Zhi [Chinese Journal
7
8 of Integrated Traditional and Western Medicine] 1993;**13**(12):743-44.
9
- 10 29. Cai J. Clinical observation on 42 cases of needle treatment of rheumatoid arthritis. Clin J
11
12 Anhui Tradit Chin Med 1997;**9**(1):16-17.
13
- 14 30. Xu J, Pan ZG, Chen LL, et al. Clinical study on apistoxin injection direct current electric
15
16 acupoint introduction for the treatment of Bi syndrome. J Bee 1999(02):3-5.
17
- 18 31. Li L, Yi R, Wang YM, et al. Clinical observation on bee-sting therapy with ashi points
19
20 and with points of corresponding meridians in treating rheumatoid arthritis. Shanghai
21
22 J Acu-mox 2013;**32**(2):121-22.
23
- 24 32. Pertsulenko VA. Bee venom in the treatment of infectious non-specific (rheumatoid)
25
26 arthritis. Sovetskaia meditsina 1961;**25**:94-101.
27
- 28 33. Li L, Yi R, Wang YM, et al. Clinical observation on bee-sting therapy with Ashi Points
29
30 and with Points of Corresponding Meridians in Treating Rheumatoid Arthritis.
31
32 Shanghai J Acupunct Mox 2013(2):121-22.
33
- 34 34. Lee SH, Hong SJ, Kim SY. Randomized controlled double blind study of bee venom
35
36 therapy on rheumatoid arthritis. J Korean Acupunct Mox Soc 2003;**20**:80-88.
37
- 38 35. Vickers A, Goyal N, Harland R, et al. Do certain countries produce only positive results?
39
40 A systematic review of controlled trials. Control Clin Trials 1998;**19**(2):159-66.
41
- 42 36. Yao H. Bee needle therapy. Journal of shanxi elderly 2000(09):39.
43
- 44 37. Hwang YJ, Lee GM, Hwang WJ, et al. Clinical research of bee-venom acupuncture
45
46 effects on rheumatoid arthritis. J Korean Acupunct Mox Soc 2001;**18**(5):33-42.
47
- 48 38. Liu XD, Zhang JL, Zheng HG, et al. Clinical randomized study of bee-sting therapy for
49
50 rheumatoid arthritis. Acupunct Res 2008;**33**(3):197-200.
51
- 52 39. Jung JW, Jeon EJ, Kim JW, et al. A fatal case of intravascular coagulation after bee sting
53
54
55
56
57
58
59
60

1
2
3
4 acupuncture. Allergy, asthma & immunology research 2012;4(2):107-9.
5

6 40. Kim YK, Jang YS, Jung JW, et al. Prevalence of bee venom allergy in children and adults
7
8 living in rural area of Cheju Island. Journal of Asthma, Allergy and Clinical
9
10 Immunology 1998;18(3):451-57.
11

12 41. Green S, Higgins JPT, Alderson P, et al. Chapter 1: Introduction. . In: T. HJP, Green S,
13
14 eds. Cochrane Handbook for Systematic Reviews of Interventions Version 510
15
16 (updated March 2011) The Cochrane Collaboration, 2011 Available from
17
18 wwwcochrane-handbookorg, 2008.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Figure legend**

5
6 Figure 1. Flow chart of trial selection process. CCT: case series trials; RCT: randomised
7
8 controlled trials.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Characteristics of included randomized controlled trials of bee venom acupuncture for rheumatoid arthritis

<i>Lee 2003</i>	
Methods	Design: prospective randomized controlled trial
Participants	Country: South Korea Number of patients included(completed / randomized): (A) 37/40 (B) 32/40 Mean age (years): (A) 49.2±9.6 (B) 47.3±8.9 Duration of disease (years): (A) 9.2±7.0 (B) 7.3±4.6 Follow-up: 1 and 2 months
Intervention	(A) BVA (Ashi points, acupoints near the inflammation point, two times a week for 2 months)
Control	(B) Placebo (normal saline injection on ashi points, acupoints near the inflammation point, two times a week for 2 months)
Outcomes	<i>Primary outcomes:</i> 1) Morning stiffness, MD, -0.70[-2.00, 0.60], P<0.05 2) HAQ, MD, 0.00[-0.08, 0.08], P<0.05 3) VAS-pain, MD, -18.10[-23.71, -12.49], P<0.05 <i>Secondary outcomes:</i> 1) Tender joint count, MD, -1.30[-1.91, -0.69], P<0.0001 2) Swollen joint count, MD, -1.10[-1.72, -0.48], P=0.005 3) ESR, MD, 20.10[-22.80, -17.40], P<0.00001 4) CRP, MD, -1.90[-2.86, -0.94], P=0.0001
Note	Treatment Rationale: CM theory, Clinical experience Adverse effect: n.r. Funding: Korea Research Foundation Grant and Kyung Hee University Language: Korean Publication: full paper Withdrawal/dropouts:yes Intention-to-treat: No Author comment: These results suggests that bee venom therapy could be an effective method in the treatment of patients with RA

<i>Risk of bias</i>		
Item	Authors' judgement	Description
Random sequence generation (selection bias)	Unclear risk	Described as randomized but information not available
Allocation concealment (selection bias)	Unclear risk	Not stated.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Described as double blinding
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated.
Incomplete outcome data (attrition bias) All outcomes	High risk	Data from 11 participants were not included in the analysis.
Selective reporting (reporting bias)	Low risk	Protocol not available, but all expected outcomes reported
Other bias	Unclear risk	Small sample size

BVA: Bee Venom Acupuncture; CRP: C - reactive protein; CM: Chinese medicine; ESR: erythrocyte sedimentation rate; HAQ: health assessment questionnaire; n.r.: not reported; RA: rheumatoid arthritis VAS: visual analogue scale

Table 2. Summary of findings

Bee venom acupuncture for patients with rheumatoid arthritis					
Patient or population: patients with rheumatoid arthritis					
Settings: Korea					
Intervention: Bee venom acupuncture vs. normal saline injection as placebo					
Outcomes	Illustrative comparative risks* (95% CI)		No of Participants (studies)	Quality of the evidence (Grade)	Comments
	Assumed risk Control (Normal Saline injection)	Corresponding risk Bee venom acupuncture			
Pain (VAS)		16.9 WMD lower ¹ (26.57 to 7.23 lower)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month -10.40 (-16.47 to -4.33)
Morning stiffness		12.1 WMD higher ¹ (11.61 to 12.59 higher)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month -0.30 (-1.01 to 0.41)
Swollen joint count		0.9 WMD lower ¹ (1.97 lower to 0.17 higher)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month 0.50 (-0.70 to -1.70)
Tender joint count		0.9 WMD lower ¹ (1.97 lower to 0.17 higher)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month 0.50 (-0.73 to -1.73)
Quality of Life (HAQ)		0.3 WMD higher ¹ (0.08 to 0.52 higher)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month 0.20 (-0.06 to 0.46)
ESR		19.4 WMD lower ¹ (28.51 to 10.29 lower)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month -2.30 (-10.17 to 5.57)
CRP		1.7 WMD lower ¹ (2.6 to 0.8 lower)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month 1.40 (-8.27 to 5.47)

*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).
CI: Confidence interval; **CRP:** C-reactive protein; **ESR:** Erythrocyte sedimentation rate; **HAQ:** Health Assessment Questionnaire; **VAS:** Visual analogue scale; **WMD:** weight mean difference

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

¹ After 2 months treatment
² Poorly reported paper (See 'Risk of bias' table)
³ Small sample size

BMJ Open

Bee venom acupuncture for rheumatoid arthritis: a systematic review of randomised clinical trials

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006140.R2
Article Type:	Research
Date Submitted by the Author:	14-Oct-2014
Complete List of Authors:	Lee, Ju Ah; Korea Institute of Oriental Medicine, Son, Mi-Ju; Korea Institute of Oriental Medicine, Literature & Informatics Research Division Choi, Jiae; Korea Institute of Oriental Medicine, Medical research division Jun, Ji Hee; Korea Institute of Oriental Medicine, Kim, Jong-In; Kyung Hee University, Department of Acupuncture and Moxibustion, College of Korean Medicine Lee, Myeong Soo; Korea Institute of Oriental Medicine,
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Complementary medicine
Keywords:	Rheumatology < INTERNAL MEDICINE, COMPLEMENTARY MEDICINE, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY

SCHOLARONE™
Manuscripts

1
2
3
4 **Bee venom acupuncture for rheumatoid arthritis:**
5
6
7 **a systematic review of randomised clinical trials**
8
9

10
11 Ju Ah Lee,^{1,†} Mi Ju Son,^{2,†} Jiae Choi,¹ Ji Hee Jun,¹ Jong-In Kim,³ Myeong Soo Lee^{1,*}
12
13

14
15
16 ¹*Medical Research Division, Korea Institute of Oriental Medicine, Daejeon, South Korea,*
17

18 ²*Medical Culture & Informatics Research Division, Korea Institute of Oriental Medicine,*
19
20
21 *Daejeon, South Korea*

22
23 ³*Division of Acupuncture & Moxibustion medicine, Kyung Hee Korean Medicine Hospital,*
24
25 *Kyung Hee University, Seoul, Korea*
26
27

28
29
30 † Contributed equally
31

32
33 ***Correspondence to:**

34 Myeong Soo Lee, PhD
35 Medical Research Division,
36 Korea Institute of Oriental Medicine,
37 Daejeon, 305-811, South Korea
38
39 Tel: 82-(0)42-868-9266
40
41 Fax: 82-(0)42-868-9299
42
43 E-mail: drmslee@gmail.com
44
45

46
47
48 Lee JA: motoong@kiom.re.kr

49 Son MJ: mj714@kiom.re.kr

50 Choi J: ksjiae@kiom.re.kr

51 Jun JH: zhixi04@kiom.re.kr

52 JIK: hann8400@hanmail.net
53
54
55
56
57
58
59
60

License statement

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive license (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in BMJ Open and any other BMJPGJ products to exploit all subsidiary rights, as set out in our license (<http://group.bmj.com/products/journals/instructions-for-authors/license-forms>).

Key words: Bee venom acupuncture, rheumatoid arthritis, complementary and alternative medicine, systematic review

Abstract

Objective: To assess the clinical evidence for bee venom acupuncture (BVA) for rheumatoid arthritis (RA).

Design: Systematic review of randomised controlled trials (RCTs).

Setting: We searched 14 databases up to March 2014 without a language restriction.

Participants: Patients with RA.

Intervention: BVA involved injecting purified, diluted BV into acupoints. We included trials on BVA used alone or in combination with a conventional therapy versus the conventional therapy alone.

Primary outcome: Morning stiffness, pain and joint swelling

Secondary outcomes: Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), the number of joints affected by RA and adverse effects likely related to RA.

Results: A total of 304 potentially relevant studies were identified; only one RCT met our inclusion criteria. Compared to placebo, BVA may more effectively improve joint pain, swollen joint counts, tender joint counts, erythrocyte sedimentation rate (ESR) and C - reactive protein (CRP) but were not shown the improvement of morning stiffness.

Conclusions: There is low-quality evidence, based on one trial, that BVA can significantly reduce pain, morning stiffness, tender joint counts, swollen joint counts and improve the quality of life of RA patients compared to placebo (normal saline injection) control. However, the number of trials, their quality, and the total sample size were too low to draw firm conclusions.

Trial registration number: PROSPERO 2013: CRD42013005853

Article focus

- This systematic review aims to analyse the trial data on the effects of bee venom acupuncture for rheumatoid arthritis.

Key messages

- This systematic review performed with a comprehensive search strategy and established the current status of the evidence with unbiased methods.

Strengths and limitations of this study

- The strength of this systematic review is its extensive, unbiased search of various databases without a language restriction.
- The trial screening and data extraction conducted independently by two authors.
- We used of the GRADE approach to assess confidence in estimates of effect
- We identified only one study so that we could not draw strong conclusions.

Introduction

Description of the condition

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that results in pain and stiffness, joint swelling, deformity of joints and ankylosis develop. The complex, systemic nature of the disease makes RA treatment complex and involving a variety of approaches. The major aims of treatment are to relieve pain and swelling, reduce inflammation and joint damage, prevent disability and preserve or improve patients' well-being and function.¹

Untreated RA leads to joint destruction, functional limitation and severe disability^{2,3} and has a significant impact on health-related quality of life (HRQoL).^{4,5}

Description of the intervention

Bee venom (BV) therapy has been used since ancient times. Different forms of the therapy include the administration of live bee stings, injections of BV, and BV acupuncture (BVA).⁶ BVA involves injecting purified and diluted bee venom into acupoints.⁷

How the intervention might work

BVA exhibits several pharmacological actions, including analgesic, anti-inflammatory, anti-arthritis, and anti-cancer effects through multiple mechanisms, such as activation of the central inhibitory and excitatory systems and modulation of the immune system.⁸ The analgesic effects of BVA have been reported in animal experiments^{9,10} and clinical settings.⁷

¹¹ According to animal experiments, BV exhibits anti-arthritis, anti-inflammatory and analgesic effects attributable to the suppression of cyclooxygenase-2 and phospholipase A2 expression and a decrease in the levels of tumour necrosis factor alpha, interleukin (IL)-1, IL-

1
2
3
4 6, nitric oxide and oxygen reactive species. It is also widely assumed that bioactive BV
5
6 compounds including enzymes (phospholipase A2), peptides (melittin, adolapin, and
7
8 apamin), and amines are associated with these actions.^{7 8 12-14} However, most therapeutic
9
10 uses are not based on evidence.
11

12
13
14
15 One study was conducted to elucidate whether the synergistic anti-arthritic effects produced
16
17 by a combination of BV and conventional therapy enhances the therapeutic potency and
18
19 minimises the adverse effects of methotrexate.¹⁵
20
21

22 23 24 ***Why this review is important***

25
26 Bee venom (BV) therapy or BV acupuncture (BVA) has been used for reducing pain caused
27
28 by inflammatory diseases such as osteoarthritis and rheumatoid arthritis (RA) in some Asian
29
30 countries.¹¹
31

32
33 However, there is no critically appraised evidence, such as a systematic review or meta-
34
35 analysis, of the potential benefits and risks of BVA for RA. A comprehensive evaluation of
36
37 the efficacy and safety of BVA for RA will inform the recommendation to patients to pursue
38
39 BVA treatment.
40
41

42 43 44 ***Objectives***

45
46 Although BVA for RA is used as an effective method for reducing RA-related symptoms and
47
48 improving functioning, there is no critically appraised evidence regarding the safety and
49
50 effectiveness of BVA for RA from a systematic review or meta-analysis.
51

52
53 We performed a systematic review to assess the safety and efficacy of BVA for the treatment
54
55 of RA.
56

57 58 **Materials and Methods**

1
2
3
4 The protocol of this SRs is registered on PROSPERO 2013 (registration number:
5
6 CRD42013005853) and published as a protocol.¹⁶
7
8
9

10 11 **Data source**

12 The following electronic databases were searched from the study's inception to March 2014:
13
14 Medline, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), AMED,
15
16 and CINAHL. We also searched 6 Korean medical databases (OASIS, Korean Traditional
17
18 Knowledge Portal, Korean Studies Information Service System, KoreaMed, Korean Medical
19
20 Database and DBPIA) and 3 Chinese databases including CNKI (China Academic Journal,
21
22 China Doctoral Dissertations and Master's Theses Full-text Database, China Proceedings of
23
24 Conference Full Text Database and the Century Journal Project), Wanfang and VIP. Further,
25
26 we conducted non-electronic searches of conference proceedings, our own files of articles
27
28 and 9 Korean traditional medical journals (Journal of Korean Medicine, The Journal of
29
30 Korean Acupuncture and Moxibustion Society, Korean Journal of Acupuncture, Journal of
31
32 Acupuncture and Meridian Studies, Journal of Pharmacopuncture, Journal of Oriental
33
34 Rehabilitation Medicine, The Journal of Korea Chuna Manual Medicine for Spine and
35
36 Nerves, Korean Journal of Oriental Physiology and Pathology and The Journal of Korean
37
38 Oriental Internal Medicine). The strategy for searching the MEDLINE database is presented
39
40 in Supplement 1. Similar search strategies were applied for the other databases.
41
42
43
44
45
46
47

48 49 **Types of studies**

50 All prospective randomised controlled clinical trials (RCTs) were included if they were
51
52 randomised studies of BV injections at acupoints as the sole treatment, or as an adjunct to
53
54 other treatments if the control group received the same treatment as the BVA group. Trials
55
56 comparing BVA with any type of control intervention were also included. We excluded trials
57
58
59
60

1
2
3
4 of BV injections into parts of the body other than acupoints. Trials were also excluded if only
5
6 immunological or biological parameters were assessed. Trials comparing two different types
7
8 of BVA were also excluded. No language restrictions were imposed. Hard copies of all
9
10 articles were obtained and read in full.
11

12 13 14 15 **Types of participants**

16 Patients suffering from RA were included.
17
18
19

20 21 22 **Types of interventions**

23 We included trials on BVA used alone or in combination with a conventional therapy versus
24
25 the conventional therapy alone. BVA involved injecting purified, diluted BV into acupoints.
26
27 Conventional therapies included medications such as nonsteroidal anti-inflammatory drugs,
28
29 steroids, disease-modifying anti-rheumatic drugs, immunosuppressants, and TNF-alpha
30
31 inhibitors.
32
33
34
35
36

37 38 **Types of outcomes measured**

39 Primary outcomes were symptoms (morning stiffness, pain and joint swelling) experienced.
40
41 Secondary outcomes included erythrocyte sedimentation rate (ESR), C-reactive protein
42
43 (CRP), rheumatoid factor (RF), the number of joints affected by RA and adverse effects
44
45 likely related to RA.
46
47
48
49

50 51 **Data extraction and quality assessment**

52 Hard copies of all articles were obtained and read in full. Two authors (MJS and JHJ)
53
54 performed the data extraction and quality assessment using a predefined data extraction form.
55
56 The risk of bias was assessed using the assessment tool for risk of bias from the Cochrane
57
58
59
60

1
2
3
4 Handbook version 5.1.0, which includes random sequence generation, allocation concealment,
5
6 blinding of participants and personnel, blinding of outcome assessments, incomplete outcome
7
8 data, selective reporting and other sources of bias.¹⁷ Our review used 'L', 'U', and 'H' as
9
10 results of the assessment; 'L' indicated a low risk of bias, 'U' indicated that the risk of bias
11
12 was unclear, and 'H' indicated a high risk of bias. Disagreements were resolved by a
13
14 discussion between all of the authors. When disagreements on the selection were not resolved
15
16 through discussions, the arbiter (MSL) made the final decision.
17
18
19

20 21 **Data collection and synthesis**

22 *Data extraction and management*

23
24 The data extraction and quality assessment were conducted by three authors (JAL, MJS and
25
26 JHJ) using a predefined data extraction form. Any disagreement among the authors was
27
28 resolved by a discussion between all of the authors. When the data were insufficient or
29
30 ambiguous, MSL contacted the corresponding authors by e-mail or telephone to request
31
32 additional information or clarification. The data screening and selection process was
33
34 performed independently by four authors and then was verified by a fifth author, JHJ, who is
35
36 fluent in Chinese. We used GRADEpro software in the Cochrane Systematic Reviews to
37
38 create a Summary of Findings table. When disagreements on the selections were not resolved
39
40 through discussions, the arbiter (MSL) made the final decision.
41
42
43
44
45
46
47

48 *Assessment of bias in the included studies*

49
50 We independently assessed bias in the included studies according to criteria from the
51
52 Cochrane Handbook, version 5.1.0, which includes random sequence generation, allocation
53
54 concealment, blinding of participants and personnel, blinding of outcome assessments,
55
56 incomplete outcome data, selective reporting and other sources of bias.¹⁷The quality of each
57
58
59
60

1
2
3
4 trial was categorised into a low, unclear, or high risk of bias, and the authors of the assessed
5
6 trials were contacted for clarification as needed. We resolved any differences in opinion
7
8 through discussion or consultation with a third author.
9

10 11 12 13 *Data synthesis*

14
15 The differences between the intervention and control groups were assessed. For the
16
17 continuous data, we used mean differences (MDs) with 95% confidence intervals (CIs) to
18
19 measure the treatment effects. We converted other forms of data into MDs. In the case of
20
21 outcome variables with different scales, we used the standard mean difference (SMD) with
22
23 95% CIs. For dichotomous data, we presented the treatment effect as a relative risk (RR) with
24
25 95% CIs. We converted other binary data into an RR value.
26
27
28
29

30
31 All of the statistical analyses were conducted using Cochrane Collaboration's software
32
33 program, Review Manager (RevMan), Version 5.2.7 for Windows (Copenhagen, The Nordic
34
35 Cochrane Centre, the Cochrane Collaboration, 2012). For studies with insufficient
36
37 information, we contacted the corresponding authors to acquire and verify data when possible.
38
39 If appropriate, we pooled data across studies for a meta-analysis using fixed-effects or
40
41 random-effects.
42
43
44
45

46 47 *Unit of analysis issues*

48
49 For cross-over trials, data from the first treatment period were used. For trials in which more
50
51 than one control group was assessed, the primary analysis combined the data from each
52
53 control group. Subgroup analyses of the control groups were performed. Each patient was
54
55 counted only once in the analysis.
56
57
58
59
60

Addressing the missing data

Intention-to-treat analyses that included all of the randomised patients were performed. For patients with missing outcome data, a carry-forward of the last observed response was used. The individual patient data were sought from the original source or the published trial reports when the individual patient data were initially unavailable.

Assessment of heterogeneity

We used the random-effect or fixed-effect model for the meta-analysis according to the data analysis. Chi-squared and I-squared tests were used to evaluate the heterogeneity of the included studies and $I^2 > 50$ were considered to have high heterogeneity. If heterogeneity was observed, we conducted a subgroup analysis to explore the possible causes.¹⁸

Assessment of reporting biases

If a sufficient number of included studies (at least 10 trials) were available, we used funnel plots to detect reporting biases.¹⁹ However, funnel plot asymmetry was not the same as publication bias; therefore, we attempted to determine the possible reasons for the asymmetry, such as small-study effects, poor methodological quality and true heterogeneity in the included studies.^{19 20}

Results

Study selection and description

The search generated a total of 304 hits, of which only one met our inclusion criteria (Figure 1). Thirteen RCTs were among the excluded articles for the following reasons: Four RCTs, which were conducted in China, were excluded because the BVA were not made with purified, diluted bee venom but with live bee stings (Supplement 2 and 3).²¹⁻²⁴ Four RCTs employed herbal medicine as co-administrator,²⁵⁻²⁸ 2 RCTs included herbal medicine as control treatment,^{29,30} 1 RCT compared two different acupoints,³¹ 1 RCT was not related RA,³² and the other 1 RCT was duplicated publication.³³ The key data from the eligible RCT are summarised in Table 1. This trial was conducted in Korea.³⁴

Risk of bias in the included studies

The RCT used³⁴ has an uncertain risk of bias due to its random sequence generation, allocation concealment, outcome assessment blinding, selective reporting and other biases. This study used blinding of participants and personal employing placebo as a comparison and to address incomplete outcome data.

Outcomes

The study tested the efficacy of BVA on morning stiffness, Health Assessment Questionnaire (HAQ) scores, pain, tender joint counts, swollen joint counts, ESR, and CRP in RA patients.³⁴ Patients were randomised into two groups: one receiving BVA at ashi points and the other receiving normal saline injections at ashi points. After two months, the scores for morning stiffness, HAQ, pain on VAS, tender joint counts, swollen joint counts, ESR, and CRP were significantly better in the BVA group than in the placebo control group.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Adverse events

This trial did not assess adverse events related to BVA used for RA.³⁴

For peer review only

Discussion

Only one trial testing the effects of BVA for RA is currently available.³⁴ There is low-quality evidence based on this one trial that BVA significantly reduces pain, morning stiffness, tender joint counts, swollen joint counts and improves the quality of life of RA patients compared to placebo (normal saline injection) control subjects (Table 2). To date, however, the effects of BVA for RA have not been confirmed because of small sample sizes and high risks of bias.

This systematic review has several limitations. First, although extensive efforts were made to retrieve all of the RCTs with no language and publication status limitations, only one study of BVA for RA qualified for our review. Second, the included RCT was conducted in East Asian countries, and studies from East Asian countries do not apply globally because of their lack of external validity. Third, Korean researchers tend to have positive results,³⁵ but we could not minimise the results because of the lack of methodology. Fourth, despite the possibility of delayed-type hypersensitivity occurring, there was no prolonged follow-up.

The included RCT used saline injections at the same acupoints used in the BVA group for the placebo control treatment.³⁴ The use of placebo is essential for differentiating nonspecific from specific treatment effects. If we consider that the effects of BVA could come from stimulating acupoints with the immune-modulative effect of bee venom, it is necessary to implement further RCTs that use the appropriate placebo. This study has some potential caveats. One is that a normal saline injection at the same acupoints used in the experimental group could be an inappropriate placebo. BVA combines biochemical effects of the bee venom and mechanical effects from the needles. As a result, this placebo could invoke mechanical effects from the acupoint injection. The other is that there was no reporting of previous experiences with BVA. BVA has uncomfortable sensations such as swelling and

1
2
3
4 burning during the treatment. Some participants who have previously experienced BVA
5
6 treatment could know what they were treated with, thereby interrupting patient blinding. To
7
8 use normal saline injections as a placebo, it is important to recruit patients who have not
9
10 experienced BVA.
11

12
13
14
15 In the absence of a sufficient number of RCTs, other types of evidence might be helpful.
16
17 There was one observational study that showed favourable effects of BVA for several
18
19 symptoms of RA (Supplement 4).³⁶ However, this type of study, lacking in controls, was open
20
21 to selection bias, which could lead to false-positive results.
22

23
24
25
26 Traditional bee venom acupuncture include live bee sting acupuncture. It may be more
27
28 commonly used when treating patients with RA in China. In considering traditional BVA, we
29
30 found 4 additional RCTs that compared live bee sting acupuncture combined with
31
32 conventional drugs to conventional treatments alone for the treatment of RA symptoms.²¹⁻²⁴
33
34 Three RCTs²¹⁻²³ showed favourable effects of BVA on at least one of the main outcomes
35
36 including total improvement, morning stiffness, pain, joint pain, or joint swelling, while one
37
38 RCT failed to do so.²⁴ These RCTs did not report serious adverse effects.
39
40
41

42
43
44 Both BVA (diluted or purified) and live bee stings can also cause diverse clinical responses
45
46 depending on the amount of venom used and the frequency and duration of the treatment.³⁷⁻³⁹
47

48
49 The acute or delayed adverse reaction is an inflammatory reaction, such as anaphylaxis or
50
51 urticarial.³⁶⁻⁴⁰ No studies were done comparing the occurrence of adverse events between
52
53 traditional live bee sting acupuncture and BVA. Although trials are conducted safely, some
54
55 problems remain in using BVA in clinical practice.
56
57
58
59
60

1
2
3
4
5
6 The injection parts may be one issue for the assessment. Although it is very common to inject
7
8 on the painful point (Ashi point) in RA patients, we excluded studies used Ashi points only
9
10 because of assessing the evidence of efficacy of bee venom on acupoint. Even if we expand
11
12 the inclusion criteria to this points, no further studies were found. However, many trials used
13
14 acupoints with painful point. Further comparative studies are needed for finding the
15
16 difference of effects of BVA on acupoints and painful points.
17
18
19
20

21
22 One could question the validity of the conclusion by pointing to the review method used
23
24 (reviewing a small number of trials with many limitations). However, reasons for doing a
25
26 systematic review would be to answer question not posted by individual studies, to settle
27
28 controversies arising from apparently conflicting studies, or to generate new hypotheses.⁴¹
29

30
31 The systematic review with a small number of trials can be done.
32
33
34

35
36 In conclusion, currently, very few trials have tested the effects of BVA in the management of
37
38 RA. Collectively, the evidence is insufficient to suggest that BVA is an effective therapy for
39
40 RA. Further studies should be of high quality, with a particular emphasis on designing
41
42 adequate and appropriate control groups.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Author Contributions

Conceived and designed the review: MSL and JAL. Extracted the data: JHJ, and MJS. Analyzed the data: MJS, JC and JIK. Wrote the paper: JAL, MJS, JC, JIK, and MSL. Searched and selected studies: JHJ, MJS, JC. Revised the paper: JAL, MSL. Monitored data collection: MSL.

Financial support

No external funding was received. Lee JA, Choi J, Jun JH, and Lee MS were supported by Korea Institute of Oriental Medicine (K14281, K14400). Son MJ was supported by same institute (K14380).

Conflict of interest

None

Data Sharing Statement

No additional data available

Figure legend

Figure 1. Flow chart of trial selection process. CCT: case series trials; RCT: randomised controlled trials.

References

1. Han A, Robinson V, Judd M, Taixiang W, Wells G, Tugwell P. Tai chi for treating rheumatoid arthritis. *Cochrane Database Syst Rev* 2004(3):CD004849.
2. Odegard S, Finset A, Kvien TK, Mowinckel P, Uhlig T. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register. *Scand J Rheumatol* 2005;34(6):441-7.
3. Yelin E. Work disability in rheumatic diseases. *Curr Opin Rheumatol* 2007;19(2):91-6.
4. Kvien TK, Uhlig T. Quality of life in rheumatoid arthritis. *Scand J Rheumatol* 2005;34(5):333-41.
5. Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. *Pharmacoeconomics* 2004;22(2 Suppl 1):27-38.
6. Munstedt K, Hackethal A, Schmidt K. Bee venom therapy, bee venom acupuncture of apipuncture: What is the evidence behind the various health claims? *Am Bee J* 2005;145:665-68.
7. Lee MS, Pittler MH, Shin BC, Kong JC, Ernst E. Bee venom acupuncture for musculoskeletal pain: a review. *J Pain* 2008;9(4):289-97.
8. Son DJ, Lee JW, Lee YH, Song HS, Lee CK, Hong JT. Therapeutic application of anti-arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent compounds. *Pharmacol Ther* 2007;115:246-70.
9. Baek YH, Huh JE, Lee JD, Choi DY, Park DS. Antinociceptive effect and the mechanism of bee venom acupuncture (Apipuncture) on inflammatory pain in the rat model of collagen-induced arthritis: mediation by alpha2-adrenoceptors. *Brain Research* 2006;1073-1074:305-10.
10. Chen HS, Qu F, He X, Liao D, Kang SM, Lu SJ. The anti-nociceptive effect and the possible mechanism of acupoint stimulation caused by chemical irritants in the bee

- 1
2
3
4 venom pain model *Brain Research* 2010;1355:61-69.
- 5
6 11. Lee JD, Park HJ, Chae Y, Lim S. An overview of bee venom acupuncture in the treatment
7
8 of arthritis. *Evid Based Complement Alternat Med* 2005;2(1):79-84.
- 9
10 12. Lim BS, Moon HJ, Li DX, Gil M, Min JK, Lee G, et al. Effect of bee venom acupuncture
11
12 on oxaliplatin-induced cold allodynia in rats. *Evid Based Complement Alternat Med*
13
14 2013;2013:369324.
- 15
16 13. Moon DO, Park SY, Lee KJ, Heo MS, Kim KC, Kim MO, et al. Bee venom and melittin
17
18 reduce proinflammatory mediators in lipopolysaccharide-stimulated BV2 microglia.
19
20 *International immunopharmacology* 2007;7(8):1092-101.
- 21
22 14. Nah SS, Ha E, Mun SH, Won HJ, Chung JH. Effects of melittin on the production of
23
24 matrix metalloproteinase-1 and -3 in rheumatoid arthritic fibroblast-like synoviocytes. *J*
25
26 *Pharmacol Sci* 2008;106(1):162-6.
- 27
28 15. Darwish SF, El-Bakly WM, Arafa HM, El-Demerdash E. Targeting TNF-alpha and NF-
29
30 kappaB activation by bee venom: role in suppressing adjuvant induced arthritis and
31
32 methotrexate hepatotoxicity in rats. *PloS one* 2013;8(11):e79284.
- 33
34 16. Lee JA, Son MJ, Choi J, Yun K-J, Jun JH, Lee MS. Bee venom acupuncture for
35
36 rheumatoid arthritis: a systematic review protocol. *BMJ Open* 2014;4(4).
- 37
38 17. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included
39
40 studies. In: Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic Reviews*
41
42 *of Interventions Version 5.1.0 (updated March 2011): The Cochrane Collaboration,*
43
44 *2011. Available from www.cochrane-handbook.org, 2011.*
- 45
46 18. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-
47
48 analyses. In: Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic*
49
50 *Reviews of Interventions Version 5.1.0 (updated March 2011): The Cochrane*
51
52 *Collaboration. Available from www.cochrane-handbook.org, 2011.*
- 53
54
55
56
57
58
59
60

19. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011): The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org, 2011.
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *Bmj* 1997;315(7109):629-34.
21. Deng M, Zhang WN. Clinical observation on 20 cases of bee needle therapy in the treatment of rheumatoid arthritis. *Guiding J Tradit Chin Med Pharm* 2011;17(6):71-73.
22. Liu XD, Zhang J, Zheng HG, Li Z, D., Cai L, Liu FY, et al. Effect of bee-sting therapy on TNF- α and IL-1 β in peripheral blood of rheumatoid arthritis patients. *Chin Arch Tradit Chin Med* 2008;26(5):996-97.
23. Zhang JL, Liu XD, Ye LH, Zhang P. Clinical padomized comparison study of bee-sting therapy for knee synovitis caused by rheumatoid arthritis. *Chin Arch Tradit Chin Med* 2011;29(8):1904-06.
24. Zhou YF, Li WY. Effect of needle on hypothalamic-pituitary-adrenal axis of patient with rheumatoid arthritis. *Nei Mongol J Tradit Chin Med* 2012;26(5):1-3.
25. Zhu HJ, Huang SG, Tan N, Wen WQ. Clinical observation of apiotherapy combined with Chinese drug fumigation for rheumatoid arthritis. *J Tradit Chin Med Univ Hunan* 2010;30(1):70-72.
26. Zhou XM, Xie XL. Bee needle combined with nursing and effect of external application of Chinese medicine in the treatment of rheumatoid arthritis. *Nurs Res Pract* 2013;10(07):11-12.
27. Kuang HT, Lan HQ, Zhou K, Li ZQ. Clinical observation on combination of yangxuetongbi decoction and bee pricking for the treatment of 32 cases of atrophic arthritis. *Hunan Guiding J Tradit Chin Med Pharmacol* 2004;10(10):6-8.

- 1
2
3
4 28. Ji W, Zhang MJ, Ma YZ. Clinical observation of tripterygiumforrestii and bee venom in
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
28. Ji W, Zhang MJ, Ma YZ. Clinical observation of tripterygiumforrestii and bee venom in treating rheumatoid arthritis. *Zhongguo Zhong Xi Yi Jie He Za Zhi [Chinese Journal of Integrated Traditional and Western Medicine]* 1993;13(12):743-44.
29. Cai J. Clinical observation on 42 cases of needle treatment of rheumatoid arthritis. *Clin J Anhui Tradit Chin Med* 1997;9(1):16-17.
30. Xu J, Pan ZG, Chen LL, Guan ZH. Clinical study on apistoxin injection direct current electric acupoint introduction for the treatment of Bi syndrome. *J Bee* 1999(02):3-5.
31. Li L, Yi R, Wang YM, Tan BH. Clinical observation on bee-sting therapy with ashi points and with points of corresponding meridians in treating rheumatoid arthritis. *Shanghai J Acu-mox* 2013;32(2):121-22.
32. Pertsulenko VA. Bee venom in the treatment of infectious non-specific (rheumatoid) arthritis. *Sovetskaia meditsina* 1961;25:94-101.
33. Li L, Yi R, Wang YM, Tan BH. Clinical observation on bee-sting therapy with Ashi Points and with Points of Corresponding Meridians in Treating Rheumatoid Arthritis. *Shanghai J Acupunct Mox* 2013(2):121-22.
34. Lee SH, Hong SJ, Kim SY. Randomized controlled double blind study of bee venom therapy on rheumatoid arthritis. *J Korean Acupunct Mox Soc* 2003;20:80-88.
35. Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. *Control Clin Trials* 1998;19(2):159-66.
36. Hwang YJ, Lee GM, Hwang WJ, Seo EM, Jang JD, Yang GB, et al. Clinical research of bee-venom acupuncture effects on rheumatoid arthritis. *J Korean Acupunct Mox Soc* 2001;18(5):33-42.
37. Hwang YJ, Lee BC. Clinical study of anaphylaxis on bee-venom acupuncture. *J Korean Acupunct Mox Soc* 2000;17(4):149-59.
38. Jung JW, Jeon EJ, Kim JW, Choi JC, Shin JW, Kim JY, et al. A fatal case of intravascular

- 1
2
3
4 coagulation after bee sting acupuncture. *Allergy, asthma & immunology research*
5
6 2012;4(2):107-9.
7
- 8
9 39. Kim YK, Jang YS, Jung JW, Lee BJ, Kim HY, Son JW, et al. Prevalence of bee venom
10
11 allergy in children and adults living in rural area of Cheju Island. *Journal of Asthma,*
12
13 *Allergy and Clinical Immunology* 1998;18(3):451-57.
14
- 15
16 40. Yao H. Bee needle therapy. *J Shanxi Elderly* 2000(9):39.
17
- 18
19 41. Green S, Higgins JPT, Alderson P, Clarke M, Mulrow CD, Oxman AD. Chapter 1:
20
21 Introduction. . In: T. HJP, Green S, editors. *Cochrane Handbook for Systematic*
22
23 *Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane
24
25 Collaboration, 2011. Available from www.cochrane-handbook.org.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Characteristics of included randomised controlled trials of bee venom acupuncture for rheumatoid arthritis

<i>Lee 2003</i>	
Methods	Design: prospective randomised controlled trial
Participants	Country: South Korea Number of patients included(completed / randomised): (A) 37/40 (B) 32/40 Mean age (years): (A) 49.2±9.6 (B) 47.3±8.9 Duration of disease (years): (A) 9.2±7.0 (B) 7.3±4.6 Follow-up: 1 and 2 months
Intervention	(A) BVA (Ashi points, acupoints near the inflammation point, two times a week for 2 months)
Control	(B) Placebo (normal saline injection on ashi points, acupoints near the inflammation point, two times a week for 2 months)
Outcomes	<i>Primary outcomes:</i> 1) Morning stiffness, MD, -0.70[-2.00, 0.60], P<0.05 2) HAQ, MD, 0.00[-0.08, 0.08], P<0.05 3) VAS-pain, MD, -18.10[-23.71, -12.49], P<0.05 <i>Secondary outcomes:</i> 1) Tender joint count, MD, -1.30[-1.91, -0.69], P<0.0001 2) Swollen joint count, MD, -1.10[-1.72, -0.48], P=0.005 3) ESR, MD,20.10[-22.80,-17.40], P<0.00001 4) CRP, MD, -1.90[-2.86, -0.94], P=0.0001
Note	Treatment Rationale: CM theory, Clinical experience Adverse effect: n.r. Funding: Korea Research Foundation Grant and Kyung Hee University Language: Korean Publication: full paper Withdrawal/dropouts:yes Intention-to-treat: No Author comment: These results suggests that bee venom therapy could be an effective method in the treatment of patients with RA

<i>Risk of bias</i>		
Item	Authors' judgement	Description
Random sequence generation (selection bias)	Unclear risk	Described as randomised but information not available
Allocation concealment (selection bias)	Unclear risk	Not stated.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Described as double blinding
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated.
Incomplete outcome data (attrition bias) All outcomes	High risk	Data from 11 participants were not included in the analysis.
Selective reporting (reporting bias)	Low risk	Protocol not available, but all expected outcomes reported
Other bias	Unclear risk	Small sample size

BVA: Bee venom acupuncture; CRP: C - reactive protein; CM: Chinese medicine; ESR: erythrocyte sedimentation rate; HAQ: health assessment questionnaire; n.r.: not reported; RA: rheumatoid arthritis VAS: visual analogue scale

Table 2. Summary of findings

Bee venom acupuncture for patients with rheumatoid arthritis					
Patient or population: patients with rheumatoid arthritis					
Settings: Korea					
Intervention: Bee venom acupuncture vs. normal saline injection as placebo					
Outcomes	Illustrative comparative risks* (95% CI)		No of Participants (studies)	Quality of the evidence (Grade)	Comments
	Assumed risk	Corresponding risk			
	Control (Normal Saline injection)	Bee venom acupuncture			
Pain (VAS)		16.9 WMD lower¹ (26.57 to 7.23 lower)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month -10.40 (-16.47 to -4.33)
Morning stiffness		12.1 WMD higher¹ (11.61 to 12.59 higher)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month -0.30 (-1.01 to 0.41)
Swollen joint count		0.9 WMD lower¹ (1.97 lower to 0.17 higher)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month 0.50 (-0.70 to -1.70)
Tender joint count		0.9 WMD lower¹ (1.97 lower to 0.17 higher)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month 0.50 (-0.73 to -1.73)
Quality of Life (HAQ)		0.3 WMD higher¹ (0.08 to 0.52 higher)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month 0.20 (-0.06 to 0.46)
ESR		19.4 WMD lower¹ (28.51 to 10.29 lower)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month -2.30 (-10.17 to 5.57)
CRP		1.7 WMD lower¹ (2.6 to 0.8 lower)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month 1.40 (-8.27 to 5.47)

*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).
CI: Confidence interval; **CRP:** C-reactive protein; **ESR:** Erythrocyte sedimentation rate; **HAQ:** Health Assessment Questionnaire; **VAS:** Visual analogue scale; **WMD:** weight mean difference

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

¹ After 2 months treatment
² Poorly reported paper (See 'Risk of bias' table)
³ Small sample size

1
2
3
4
5
6
7
8 **Bee venom acupuncture for rheumatoid arthritis:**
9
10 **a systematic review of randomised clinical trials**
11

12
13
14 Ju Ah Lee,^{1,†} Mi Ju Son,^{2,†} Jiae Choi,¹ Ji Hee Jun,¹ Jong-In Kim,³ Myeong Soo Lee^{1,*}
15
16

17
18 ¹*Medical Research Division, Korea Institute of Oriental Medicine, Daejeon, South Korea,*
19

20 ²*Medical Culture & Informatics Research Division, Korea Institute of Oriental Medicine,*
21
22 *Daejeon, South Korea*
23

24 ³*Division of Acupuncture & Moxibustion medicine, Kyung Hee Korean Medicine Hospital,*
25
26 *Kyung Hee University, Seoul, Korea*
27

28
29
30 † Contributed equally
31

32
33 ***Correspondence to:**

34 Myeong Soo Lee, PhD
35 Medical Research Division,
36 Korea Institute of Oriental Medicine,
37 Daejeon, 305-811, South Korea
38
39 Tel: 82-(0)42-868-9266
40
41 Fax: 82-(0)42-868-9299
42
43 E-mail: drmslee@gmail.com
44

45
46 Lee JA: motoong@kiom.re.kr

47 Son MJ: mj714@kiom.re.kr

48 Choi J: ksjiae@kiom.re.kr

49 Jun JH: zhixi04@kiom.re.kr

50 JIK: hann8400@hanmail.net
51
52
53
54

1
2
3
4
5
6
7
8 **License statement**

9
10 *The Corresponding Author has the right to grant on behalf of all authors and does grant on*
11 *behalf of all authors, an exclusive license (or non-exclusive for government employees) on a*
12 *worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if*
13 *accepted) to be published in BMJ Open and any other BMJPGJL products to exploit all*
14 *subsidiary rights, as set out in our license ([http://group.bmj.com/products/journals/](http://group.bmj.com/products/journals/instructions-for-authors/license-forms)*
15 *instructions-for-authors/license-forms).*
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article focus

- This systematic review aims to analyse the trial data on the effects of bee venom acupuncture for rheumatoid arthritis.

Key messages

- This systematic review performed with a comprehensive search strategy and established the current status of the evidence with unbiased methods.

Strengths and limitations of this study

- The strength of this systematic review is its extensive, unbiased search of various databases without a language restriction.
- The trial screening and data extraction conducted independently by two authors.
- We used of the GRADE approach to assess confidence in estimates of effect
- We identified only one study so that we could not draw strong conclusions.

Abstract

Objective: To assess the clinical evidence for bee venom acupuncture (BVA) for rheumatoid arthritis (RA).

Formatted: Not Highlight

Design: Systematic review of randomised controlled trials (RCTs).

Setting: We searched 14 databases up to March 2014 without a language restriction.

Participants: Patients with RA.

Intervention: BVA involved injecting purified, diluted BV into acupoints. We included trials on BVA used alone or in combination with a conventional therapy versus the conventional therapy alone.

Formatted: Font: Font color: Black, Not Highlight

Formatted: Not Highlight

Primary outcome: Morning stiffness, pain and joint swelling

Secondary outcomes: Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), the number of joints affected by RA and adverse effects likely related to RA.

Results: A total of 304 potentially relevant studies were identified; only one RCT met our inclusion criteria. Compared to placebo, BVA may more effectively improve joint pain, swollen joint counts, tender joint counts, erythrocyte sedimentation rate (ESR) and C - reactive protein (CRP) but were not shown the improvement of morning stiffness.

Conclusions: There is low-quality evidence, based on one trial, that BVA can significantly reduce pain, morning stiffness, tender joint counts, swollen joint counts and improve the quality of life of RA patients compared to placebo (normal saline injection) control. However, the number of trials, their quality, and the total sample size were too low to draw firm conclusions.

Trial registration number: PROSPERO 2013: CRD42013005853

Formatted: Not Highlight

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Key words: Bee venom acupuncture, rheumatoid arthritis, complementary and alternative medicine, systematic review

For peer review only

Introduction

Description of the condition

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that results in pain and stiffness, joint swelling, deformity of joints and ankylosis develop. The complex, systemic nature of the disease makes RA treatment complex and involving a variety of approaches. The major aims of treatment are to relieve pain and swelling, reduce inflammation and joint damage, prevent disability and preserve or improve patients' well-being and function.¹

Untreated RA leads to joint destruction, functional limitation and severe disability^{2,3} and has a significant impact on health-related quality of life (HRQoL).^{4,5}

Description of the intervention

Bee venom (BV) therapy has been used since ancient times. Different forms of the therapy include the administration of ~~honeybee~~ **live bee** stings, injections of BV, and BV acupuncture (BVA).⁶ ~~Bee venom acupuncture (BVA)~~ involves injecting purified and diluted bee venom into acupoints.⁷

How the intervention might work

BVA exhibits several pharmacological actions, including analgesic, anti-inflammatory, anti-arthritic, and anti-cancer effects through multiple mechanisms, such as activation of the central inhibitory and excitatory systems and modulation of the immune system.⁸ The analgesic effects of BVA have been reported in animal experiments^{9,10} and clinical settings.⁷

¹¹ According to animal experiments, BV exhibits anti-arthritic, anti-inflammatory and analgesic effects attributable to the suppression of cyclooxygenase-2 and phospholipase A2

1
2
3
4
5
6
7
8 expression and a decrease in the levels of tumour necrosis factor alpha, interleukin (IL)-1, IL-
9 6, nitric oxide and oxygen reactive species. It is also widely assumed that bioactive BV
10 compounds including enzymes (phospholipase A2), peptides (melittin, adolapin, and
11 apamin), and amines are associated with these actions.^{7 8 12-14} However, most therapeutic
12 uses are not based on evidence.
13
14
15
16

17
18
19 One study was conducted to elucidate whether the synergistic anti-arthritic effects produced
20 by a combination of BV and conventional therapy enhances the therapeutic potency and
21 minimises the adverse effects of methotrexate.¹⁵
22
23
24
25

26 ***Why this review is important***

27
28 Bee venom (BV) therapy or BV acupuncture (BVA) has been used for reducing pain caused
29 by inflammatory diseases such as osteoarthritis and rheumatoid arthritis (RA) in some Asian
30 countries.¹¹
31
32
33

34 However, there is no critically appraised evidence, such as a systematic review or meta-
35 analysis, of the potential benefits and risks of BVA for RA. A comprehensive evaluation of
36 the efficacy and safety of BVA for RA will inform the recommendation to patients to pursue
37 BVA treatment.
38
39
40
41
42

43 ***Objectives***

44
45 Although BVA for RA is used as an effective method for reducing RA-related symptoms and
46 improving functioning, there is no critically appraised evidence regarding the safety and
47 effectiveness of BVA for RA from a systematic review or meta-analysis.
48
49
50

51 We performed a systematic review to assess the safety and efficacy of BVA for the treatment
52 of RA.
53
54

Materials and Methods

The protocol of this SRs is registered on PROSPERO 2013 (registration number: CRD42013005853) and published as a protocol.¹⁶

Data source

The following electronic databases were searched from the study's inception to March 2014: Medline, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), AMED, and CINAHL. We also searched 6 Korean medical databases (OASIS, Korean Traditional Knowledge Portal, Korean Studies Information Service System, KoreaMed, Korean Medical Database and DBPIA) and 3 Chinese databases including CNKI (China Academic Journal, China Doctoral Dissertations and Master's Theses Full-text Database, China Proceedings of Conference Full Text Database and the Century Journal Project), Wanfang and VIP. Further, we conducted non-electronic searches of conference proceedings, our own files of articles and 9 Korean traditional medical journals (Journal of Korean Medicine, The Journal of Korean Acupuncture and Moxibustion Society, Korean Journal of Acupuncture, Journal of Acupuncture and Meridian Studies, Journal of Pharmacopuncture, Journal of Oriental Rehabilitation Medicine, The Journal of Korea Chuna Manual Medicine for Spine and Nerves, Korean Journal of Oriental Physiology and Pathology and The Journal of Korean Oriental Internal Medicine). The strategy for searching the MEDLINE database is presented in Supplement 1. Similar search strategies were applied for the other databases.

Formatted: Not Highlight

Types of studies

All prospective randomised controlled clinical trials (RCTs) were included if they were randomised studies of BV injections at acupoints as the sole treatment, or as an adjunct to other treatments if the control group received the same treatment as the BVA group. Trials

1
2
3
4
5
6
7
8 comparing BVA with any type of control intervention were also included. We excluded trials
9 of BV injections into parts of the body other than acupoints. Trials were also excluded if only
10 immunological or biological parameters were assessed. Trials comparing two different types
11 of BVA were also excluded. No language restrictions were imposed. Hard copies of all
12 articles were obtained and read in full.
13
14
15
16

17 18 19 **Types of participants**

20 Patients suffering from RA were included.
21
22
23

24 25 **Types of interventions**

26 We included trials on BVA used alone or in combination with a conventional therapy versus
27 the conventional therapy alone. BVA involved injecting purified, diluted BV into acupoints.
28 Conventional therapies included medications such as nonsteroidal anti-inflammatory drugs,
29 steroids, disease-modifying anti-rheumatic drugs, immunosuppressants, and TNF-alpha
30 inhibitors.
31
32
33
34
35
36
37

38 39 **Types of outcomes measured**

40 Primary outcomes were symptoms (morning stiffness, pain and joint swelling) experienced.
41 Secondary outcomes included erythrocyte sedimentation rate (ESR), C-reactive protein
42 (CRP), rheumatoid factor (RF), the number of joints affected by RA and adverse effects
43 likely related to RA.
44
45
46
47
48
49

50 51 **Data extraction and quality assessment**

52 Hard copies of all articles were obtained and read in full. Two authors (MJS and JHJ)
53 performed the data extraction and quality assessment using a predefined data extraction form.
54
55

1
2
3
4
5
6
7
8 The risk of bias was assessed using the assessment tool for risk of bias from the Cochrane
9 Handbook version 5.1.0, which includes random sequence generation, allocation concealment,
10 blinding of participants and personnel, blinding of outcome assessments, incomplete outcome
11 data, selective reporting and other sources of bias.¹⁷ Our review used 'L', 'U', and 'H' as
12 results of the assessment; 'L' indicated a low risk of bias, 'U' indicated that the risk of bias
13 was unclear, and 'H' indicated a high risk of bias. Disagreements were resolved by a
14 discussion between all of the authors. When disagreements on the selection were not resolved
15 through discussions, the arbiter (MSL) made the final decision.
16
17
18
19
20
21
22
23

24 **Data collection and synthesis**

25 *Data extraction and management*

26
27 The data extraction and quality assessment were conducted by three authors (JAL, MJS and
28 JHJ) using a predefined data extraction form. Any disagreement among the authors was
29 resolved by a discussion between all of the authors. When the data were insufficient or
30 ambiguous, MSL contacted the corresponding authors by e-mail or telephone to request
31 additional information or clarification. The data screening and selection process was
32 performed independently by four authors and then was verified by a fifth author, JHJ, who is
33 fluent in Chinese. We used GRADEpro software in the Cochrane Systematic Reviews to
34 create a Summary of Findings table. When disagreements on the selections were not resolved
35 through discussions, the arbiter (MSL) made the final decision.
36
37
38
39
40
41
42
43
44
45
46
47

48 *Assessment of bias in the included studies*

49 We independently assessed bias in the included studies according to criteria from the
50 Cochrane Handbook, version 5.1.0, which includes random sequence generation, allocation
51 concealment, blinding of participants and personnel, blinding of outcome assessments,
52
53
54

1
2
3
4
5
6
7
8 incomplete outcome data, selective reporting and other sources of bias.¹⁷The quality of each
9 trial was categorised into a low, unclear, or high risk of bias, and the authors of the assessed
10 trials were contacted for clarification as needed. We resolved any differences in opinion
11 through discussion or consultation with a third author.
12
13
14

15 16 17 *Data synthesis*

18 The differences between the intervention and control groups were assessed. For the
19 continuous data, we used mean differences (MDs) with 95% confidence intervals (CIs) to
20 measure the treatment effects. We converted other forms of data into MDs. In the case of
21 outcome variables with different scales, we used the standard mean difference (SMD) with
22 95% CIs. For dichotomous data, we presented the treatment effect as a relative risk (RR) with
23 95% CIs. We converted other binary data into an RR value.
24
25
26
27
28
29
30
31

32 All of the statistical analyses were conducted using Cochrane Collaboration's software
33 program, Review Manager (RevMan), Version 5.2.7 for Windows (Copenhagen, The Nordic
34 Cochrane Centre, the Cochrane Collaboration, 2012). For studies with insufficient
35 information, we contacted the corresponding authors to acquire and verify data when possible.
36 If appropriate, we pooled data across studies for a meta-analysis using fixed-effects or
37 random-effects.
38
39
40
41
42
43
44
45

46 *Unit of analysis issues*

47 For cross-over trials, data from the first treatment period were used. For trials in which more
48 than one control group was assessed, the primary analysis combined the data from each
49 control group. Subgroup analyses of the control groups were performed. Each patient was
50 counted only once in the analysis.
51
52
53
54

1
2
3
4
5
6
7
8
9
10 *Addressing the missing data*

11 Intention-to-treat analyses that included all of the randomised patients were performed. For
12 patients with missing outcome data, a carry-forward of the last observed response was used.
13 The individual patient data were sought from the original source or the published trial reports
14 when the individual patient data were initially unavailable.
15
16
17
18
19

20
21 *Assessment of heterogeneity*

22 We used the random-effect or fixed-effect model for the meta-analysis according to the data
23 analysis. Chi-squared and I-squared tests were used to evaluate the heterogeneity of the
24 included studies and $I^2 > 50$ were considered to have high heterogeneity. If heterogeneity was
25 observed, we conducted a subgroup analysis to explore the possible causes.¹⁸
26
27
28
29
30

31
32 *Assessment of reporting biases*

33 If a sufficient number of included studies (at least 10 trials) were available, we used funnel
34 plots to detect reporting biases.¹⁹ However, funnel plot asymmetry was not the same as
35 publication bias; therefore, we attempted to determine the possible reasons for the asymmetry,
36 such as small-study effects, poor methodological quality and true heterogeneity in the
37 included studies.^{19 20}
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

Study selection and description

The search generated a total of 304 hits, of which only one met our inclusion criteria (Figure 1). Thirteen RCTs were among the excluded articles for the following reasons: Four RCTs, which were conducted in China, were excluded because the BVA were not made with purified, diluted bee venom but with live bee stings (Supplement 2 and 3).²¹⁻²⁴ Four RCTs employed herbal medicine as co-administrator.²⁵⁻²⁸ 2 RCTs included herbal medicine as control treatment.²⁹⁻³⁰ 1 RCT compared two different acupoints,³¹ 1 RCT was not related RA,³² and the other 1 RCT was duplicated publication.³³ The key data from the eligible RCT are summarised in Table 1. This trial was conducted in Korea.³⁴

Risk of bias in the included studies

The RCT used³⁴ has an uncertain risk of bias due to its random sequence generation, allocation concealment, outcome assessment blinding, selective reporting and other biases. This study used blinding of participants and personal employing placebo as a comparison and to address incomplete outcome data.

Outcomes

The study tested the efficacy of BVA on morning stiffness, Health Assessment Questionnaire (HAQ) scores, pain, tender joint counts, swollen joint counts, ESR, and CRP in RA patients.³⁴ Patients were randomised into two groups: one receiving BVA at ashi points and the other receiving normal saline injections at ashi points. After two months, the scores for morning stiffness, HAQ, pain on VAS, tender joint counts, swollen joint counts, ESR, and CRP were significantly better in the BVA group than in the placebo control group.

Formatted: Not Highlight

Formatted: Not Highlight

Formatted: Not Highlight

Formatted: Not Highlight

Formatted: Not Highlight

Formatted: Not Highlight

Formatted: Not Highlight

Formatted: Not Highlight

Formatted: Not Highlight

Formatted: Not Highlight

Formatted: Not Highlight

Formatted: Not Highlight

Formatted: Not Highlight

1
2
3
4
5
6
7
8 *Adverse events*

9 This trial did not assess adverse events related to BVA used for RA.³⁴
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

Only one trial testing the effects of BVA for RA is currently available.³⁴ There is low-quality evidence based on this one trial that BVA significantly reduces pain, morning stiffness, tender joint counts, swollen joint counts and improves the quality of life of RA patients compared to placebo (normal saline injection) control subjects (Table 2). To date, however, the effects of BVA for RA have not been confirmed because of small sample sizes and high risks of bias.

This systematic review has several limitations. First, although extensive efforts were made to retrieve all of the RCTs with no language and publication status limitations, only one study of BVA for RA qualified for our review. Second, the included RCT was conducted in East Asian countries, and studies from East Asian countries do not apply globally because of their lack of external validity. Third, Korean researchers tend to have positive results,³⁵ but we could not minimise the results because of the lack of methodology. Fourth, despite the possibility of delayed-type hypersensitivity occurring, there was no prolonged follow-up.

The included RCT used saline injections at the same acupoints used in the BVA group for the placebo control treatment.³⁴ The use of placebo is essential for differentiating nonspecific from specific treatment effects. If we consider that the effects of BVA could come from stimulating acupoints with the immune-modulative effect of bee venom, it is necessary to implement further RCTs that use the appropriate placebo. This study has some potential caveats. One is that a normal saline injection at the same acupoints used in the experimental group could be an inappropriate placebo. BVA combines biochemical effects of the bee venom and mechanical effects from the needles. As a result, this placebo could invoke mechanical effects from the acupoint injection. The other is that there was no reporting of previous experiences with BVA. BVA has uncomfortable sensations such as swelling and

Formatted: Not Highlight

burning during the treatment. Some participants who have previously experienced BVA treatment could know what they were treated with, thereby interrupting patient blinding. To use normal saline injections as a placebo, it is important to recruit patients who have not experienced BVA.

~~BVA can cause diverse clinical responses depending on the amount of venom used and the frequency and duration of the treatment. The acute or delayed adverse reaction is an inflammatory reaction, such as anaphylaxis or urticarial.³⁶ Although trials are conducted safely, some problems remain in using BVA in clinical practice.~~

In the absence of a sufficient number of RCTs, other types of evidence might be helpful. There was one observational study that showed favourable effects of BVA for several symptoms of RA (Supplement 4).^{37,36} However, this type of study, lacking in controls, was open to selection bias, which could lead to false-positive results.

~~The other type of BV therapy~~Traditional bee venom acupuncture include live bee sting acupuncture. It may be more commonly used when treating patients with RA in China. In considering ~~this type of trial~~traditional BVA, we found 4 additional RCTs that compared live bee sting acupuncture combined with conventional drugs to conventional treatments alone for the treatment of RA symptoms.^{21-23-24-38, 21-24} Three RCTs ²¹⁻²³⁻³⁸~~21-23~~ showed favourable effects of BVA on at least one of the main outcomes including total improvement, morning stiffness, pain, joint pain, or joint swelling, while one RCT failed to do so.²⁴ ~~Although these~~

~~These~~ RCTs did not report serious adverse effects.²²⁻²⁴⁻²⁵⁻²⁹

~~Both BVA (diluted or purified) and~~ live bee stings can ~~cause fatal~~ also cause diverse clinical

Formatted: Not Highlight

Formatted: Not Highlight

Formatted: Not Highlight

1
2
3
4
5
6
7
8 responses depending on the amount of venom used and the frequency and duration of the
9 treatment. ³⁷⁻³⁹ The acute or delayed adverse reaction is an inflammatory reaction, such as
10 anaphylaxis or urticarial. ³⁶⁻⁴⁰ No studies were done comparing the occurrence of adverse
11 events including anaphylaxis. ³⁹⁻⁴⁰ Adverse events should be examined in future studies
12 between traditional live bee sting acupuncture and BVA. Although trials are conducted safely,
13 some problems remain in using BVA in clinical practice.
14
15
16
17
18
19
20
21
22

Formatted: Not Highlight

23 The injection parts may be one issue for the assessment because Although it is very common
24 to inject on the painful point (Ashi point) in RA patients, we excluded studies used Ashi
25 points only because of assessing the evidence of efficacy of bee venom on acupoint. Even if
26 we expand the inclusion criteria to this points, no further studies were found. However, many
27 trials used acupoints with painful point. Further comparative studies are needed for finding
28 the difference of effects of BVA on acupoints and painful points.
29
30
31
32
33
34
35

Formatted: Not Highlight

Formatted: Not Highlight

Formatted: Font color: Black, Not Highlight

Formatted: Not Highlight

36 One could question the validity of the conclusion by pointing to the review method used
37 (reviewing a small number of trials with many limitations). However, reasons for doing a
38 systematic review would be to answer question not posted by individual studies, to settle
39 controversies arising from apparently conflicting studies, or to generate new hypotheses. ⁴¹
40
41
42
43
44
45

Formatted: English (U.S.), Not Highlight

Formatted: Not Highlight


46 The systematic review with a small number of trials can be done.
47
48
49
50
51
52
53
54
55

Formatted: Not Highlight

56
57
58
59
60
In conclusion, currently, very few trials have tested the effects of BVA in the management of RA. Collectively, the evidence is insufficient to suggest that BVA is an effective therapy for RA. Further studies should be of high quality, with a particular emphasis on designing adequate and appropriate control groups.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



Author Contributions

Conceived and designed the review: MSL and JAL. Extracted the data: JHJ, and MJS.
Analyzed the data: MJS, JC and JIK. Wrote the paper: JAL, MJS, JC, JIK, and MSL.
Searched and selected studies: JHJ, MJS, JC. Revised the paper: JAL, MSL. Monitored data collection: MSL.

Financial support

No external funding was received. Lee JA, Choi J, Jun JH, and Lee MS were supported by Korea Institute of Oriental Medicine (K14281, K14400). Son MJ was supported by same institute (K14380).

Conflict of interest

None

References

1. Han A, Robinson V, Judd M, et al. Tai chi for treating rheumatoid arthritis. *Cochrane Database Syst Rev* 2004(3):CD004849.
2. Odegard S, Finset A, Kvien TK, et al. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7 year study from the Oslo RA register. *Scand J Rheumatol* 2005;34(6):441-7.
3. Yelin E. Work disability in rheumatic diseases. *Curr Opin Rheumatol* 2007;19(2):91-6.
4. Kvien TK, Uhlig T. Quality of life in rheumatoid arthritis. *Scand J Rheumatol* 2005;34(5):333-41.
5. Lubeck DP. Patient reported outcomes and their role in the assessment of rheumatoid arthritis. *Pharmacoeconomics* 2004;22(2 Suppl 1):27-38.
6. Munstedt K, Hackethal A, Schmidt K. Bee venom therapy, bee venom acupuncture of apipuncture: What is the evidence behind the various health claims? *Am Bee J* 2005;145:665-68.
7. Lee MS, Pittler MH, Shin BC, et al. Bee venom acupuncture for musculoskeletal pain: a review. *J Pain* 2008;9(4):289-97.
8. Son DJ, Lee JW, Lee YH, et al. Therapeutic application of anti arthritis, pain releasing, and anti cancer effects of bee venom and its constituent compounds. *Pharmacol Ther* 2007;115:246-70.
9. Baek YH, Huh JE, Lee JD, et al. Antinociceptive effect and the mechanism of bee venom acupuncture (Apipuncture) on inflammatory pain in the rat model of collagen induced arthritis: mediation by alpha2 adrenoceptors. *Brain Research* 2006;1073-1074:305-10.
10. Chen HS, Qu F, He X, et al. The anti nociceptive effect and the possible mechanism of acupoint stimulation caused by chemical irritants in the bee venom pain model *Brain*

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- ~~Research 2010;1355:61-69.~~
- ~~11. Lee JD, Park HJ, Chae Y, et al. An overview of bee venom acupuncture in the treatment of arthritis. Evid Based Complement Alternat Med 2005;2(1):79-84.~~
- ~~12. Lim BS, Moon HJ, Li DX, et al. Effect of bee venom acupuncture on oxaliplatin induced cold allodynia in rats. Evid Based Complement Alternat Med 2013;2013:369324.~~
- ~~13. Moon DO, Park SY, Lee KJ, et al. Bee venom and melittin reduce proinflammatory mediators in lipopolysaccharide stimulated BV2 microglia. International immunopharmacology 2007;7(8):1092-101.~~
- ~~14. Nah SS, Ha E, Mun SH, et al. Effects of melittin on the production of matrix metalloproteinase 1 and 3 in rheumatoid arthritic fibroblast like synovioocytes. J Pharmacol Sci 2008;106(1):162-6.~~
- ~~15. Darwish SF, El Bakly WM, Arafa HM, et al. Targeting TNF alpha and NF kappaB activation by bee venom: role in suppressing adjuvant induced arthritis and methotrexate hepatotoxicity in rats. PloS one 2013;8(11):e79284.~~
- ~~16. Lee JA, Son MJ, Choi J, et al. Bee venom acupuncture for rheumatoid arthritis: a systematic review protocol. BMJ Open 2014;4(4).~~
- ~~17. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.10 (updated March 2011): The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org, 2011.~~
- ~~18. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.10 (updated March 2011): The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2011.~~
- ~~19. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins~~

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.10 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org, 2011.
20. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple graphical test. *Bmj* 1997;**315**(7109):629-34.
21. Deng M, Zhang WN. Clinical observation on 20 cases of bee needle therapy in the treatment of rheumatoid arthritis. *Guiding J Tradit Chin Med Pharm* 2011;**17**(6):71-73.
22. Liu XD, Zhang JI, Zheng HG, et al. Effect of bee sting therapy on TNF- α and IL-1 β in peripheral blood of rheumatoid arthritis patients. *Chin Arch Tradit Chin Med* 2008;**26**(5):996-97.
23. Zhang JL, Liu XD, Ye LH, et al. Clinical padomized comparison study of bee sting therapy for knee synovitis caused by rheumatoid arthritis. *Chin Arch Tradit Chin Med* 2011;**29**(8):1904-06.
24. Zhou YF, Li WY. Effect of needle on hypothalamic pituitary adrenal axis of patient with rheumatoid arthritis. *Nei Mongol J Tradit Chin Med* 2012;**26**(5):1-3.
25. Zhu HJ, Huang SG, Tan N, et al. Clinical observation of apiotherapy combined with Chinese drug fumigation for rheumatoid arthritis. *J Tradit Chin Med Univ Hunan* 2010;**30**(1):70-72.
26. Zhou XM, Xie XL. Bee needle combined with nursing and effect of external application of Chinese medicine in the treatment of rheumatoid arthritis. *Nurs Res Pract* 2013;**10**(07):11-12.
27. Kuang HT, Lan HQ, Zhou K, et al. Clinical observation on combination of yangxuetongbi decoction and bee pricking for the treatment of 32 cases of atrophic arthritis. *Hunan Guiding J Tradit Chin Med Pharmacol* 2004;**10**(10):6-8.

- 1
2
3
4
5
6
7
8 28. Ji W, Zhang MJ, Ma YZ. Clinical observation of tripterygiumforrestii and bee venom in
9 treating rheumatoid arthritis. Zhongguo Zhong Xi Yi Jie He Za Zhi [Chinese Journal
10 of Integrated Traditional and Western Medicine] 1993;13(12):743-44.
11
12 29. Cai J. Clinical observation on 42 cases of needle treatment of rheumatoid arthritis. Clin J
13 Anhui Tradit Chin Med 1997;9(1):16-17.
14
15 30. Xu J, Pan ZG, Chen LL, et al. Clinical study on apistoxin injection direct current electric
16 acupoint introduction for the treatment of Bi syndrome. J Bee 1999(02):3-5.
17
18 31. Li L, Yi R, Wang YM, et al. Clinical observation on bee sting therapy with ashi points
19 and with points of corresponding meridians in treating rheumatoid arthritis. Shanghai
20 J Acu-mox 2013;32(2):121-22.
21
22 32. Pertsulenko VA. Bee venom in the treatment of infectious non-specific (rheumatoid)
23 arthritis. Sovetskaia meditsina 1961;25:94-101.
24
25 33. Li L, Yi R, Wang YM, et al. Clinical observation on bee sting therapy with Ashi Points
26 and with Points of Corresponding Meridians in Treating Rheumatoid Arthritis.
27 Shanghai J Acupunct Mox 2013(2):121-22.
28
29 34. Lee SH, Hong SJ, Kim SY. Randomized controlled double blind study of bee venom
30 therapy on rheumatoid arthritis. J Korean Acupunct Mox Soc 2003;20:80-88.
31
32 35. Vickers A, Goyal N, Harland R, et al. Do certain countries produce only positive results?
33 A systematic review of controlled trials. Control Clin Trials 1998;19(2):159-66.
34
35 36. Yao H. Bee needle therapy. Journal of shanxi elderly 2000(09):39.
36
37 37. Hwang YJ, Lee GM, Hwang WJ, et al. Clinical research of bee venom acupuncture
38 effects on rheumatoid arthritis. J Korean Acupunct Mox Soc 2001;18(5):33-42.
39
40 38. Liu XD, Zhang JL, Zheng HG, et al. Clinical randomized study of bee sting therapy for
41 rheumatoid arthritis. Acupunct Res 2008;33(3):197-200.
42
43 39. Jung JW, Jeon EJ, Kim JW, et al. A fatal case of intravascular coagulation after bee sting
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

acupuncture. *Allergy, asthma & immunology research* 2012;4(2):107-9.

40. Kim YK, Jang YS, Jung JW, et al. Prevalence of bee venom allergy in children and adults living in rural area of Cheju Island. *Journal of Asthma, Allergy and Clinical Immunology* 1998;18(3):451-57.

41. Green S, Higgins JPT, Alderson P, et al. Chapter 1: Introduction. In: T. HJP, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.10* (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org, 2008.

References

1. Han A, Robinson V, Judd M, Taixiang W, Wells G, Tugwell P. Tai chi for treating rheumatoid arthritis. *Cochrane Database Syst Rev* 2004(3):CD004849.

2. Odegard S, Finset A, Kvien TK, Mowinckel P, Uhlig T. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register. *Scand J Rheumatol* 2005;34(6):441-7.

3. Yelin E. Work disability in rheumatic diseases. *Curr Opin Rheumatol* 2007;19(2):91-6.

4. Kvien TK, Uhlig T. Quality of life in rheumatoid arthritis. *Scand J Rheumatol* 2005;34(5):333-41.

5. Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. *Pharmacoeconomics* 2004;22(2 Suppl 1):27-38.

6. Munstedt K, Hackethal A, Schmidt K. Bee venom therapy, bee venom acupuncture of apipuncture: What is the evidence behind the various health claims? *Am Bee J* 2005;145:665-68.

7. Lee MS, Pittler MH, Shin BC, Kong JC, Ernst E. Bee venom acupuncture for musculoskeletal pain: a review. *J Pain* 2008;9(4):289-97.

8. Son DJ, Lee JW, Lee YH, Song HS, Lee CK, Hong JT. Therapeutic application of anti-

- 1
2
3
4
5
6
7
8 [arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent](#)
9 [compounds. Pharmacol Ther 2007;115:246-70.](#)
10
11 9. [Baek YH, Huh JE, Lee JD, Choi DY, Park DS. Antinociceptive effect and the mechanism](#)
12 [of bee venom acupuncture \(Apipuncture\) on inflammatory pain in the rat model of](#)
13 [collagen-induced arthritis: mediation by alpha2-adrenoceptors. Brain Research](#)
14 [2006;1073-1074:305-10.](#)
15
16 10. [Chen HS, Qu F, He X, Liao D, Kang SM, Lu SJ. The anti-nociceptive effect and the](#)
17 [possible mechanism of acupoint stimulation caused by chemical irritants in the bee](#)
18 [venom pain model Brain Research 2010;1355:61-69.](#)
19
20 11. [Lee JD, Park HJ, Chae Y, Lim S. An overview of bee venom acupuncture in the treatment](#)
21 [of arthritis. Evid Based Complement Alternat Med 2005;2\(1\):79-84.](#)
22
23 12. [Lim BS, Moon HJ, Li DX, Gil M, Min JK, Lee G, et al. Effect of bee venom acupuncture](#)
24 [on oxaliplatin-induced cold allodynia in rats. Evid Based Complement Alternat Med](#)
25 [2013;2013:369324.](#)
26
27 13. [Moon DO, Park SY, Lee KJ, Heo MS, Kim KC, Kim MO, et al. Bee venom and melittin](#)
28 [reduce proinflammatory mediators in lipopolysaccharide-stimulated BV2 microglia.](#)
29 [International immunopharmacology 2007;7\(8\):1092-101.](#)
30
31 14. [Nah SS, Ha E, Mun SH, Won HJ, Chung JH. Effects of melittin on the production of](#)
32 [matrix metalloproteinase-1 and -3 in rheumatoid arthritic fibroblast-like synoviocytes. J](#)
33 [Pharmacol Sci 2008;106\(1\):162-6.](#)
34
35 15. [Darwish SF, El-Bakly WM, Arafah HM, El-Demerdash E. Targeting TNF-alpha and NF-](#)
36 [kappaB activation by bee venom: role in suppressing adjuvant induced arthritis and](#)
37 [methotrexate hepatotoxicity in rats. PloS one 2013;8\(11\):e79284.](#)
38
39 16. [Lee JA, Son MJ, Choi J, Yun K-J, Jun JH, Lee MS. Bee venom acupuncture for](#)
40 [rheumatoid arthritis: a systematic review protocol. BMJ Open 2014;4\(4\).](#)
41
42
43
44
45
46
47
48
49
50
51
52
53
54

17. [Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 \(updated March 2011\): The Cochrane Collaboration, 2011. Available from \[www.cochrane-handbook.org\]\(http://www.cochrane-handbook.org\), 2011.](#)
18. [Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 \(updated March 2011\): The Cochrane Collaboration. Available from \[www.cochrane-handbook.org\]\(http://www.cochrane-handbook.org\), 2011.](#)
19. [Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 \(updated March 2011\): The Cochrane Collaboration, 2011. Available from \[www.cochrane-handbook.org\]\(http://www.cochrane-handbook.org\), 2011.](#)
20. [Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *Bmj* 1997;315\(7109\):629-34.](#)
21. [Deng M, Zhang WN. Clinical observation on 20 cases of bee needle therapy in the treatment of rheumatoid arthritis. *Guiding J Tradit Chin Med Pharm* 2011;17\(6\):71-73.](#)
22. [Liu XD, Zhang JL, Zheng HG, Li Z, D., Cai L, Liu FY, et al. Effect of bee-sting therapy on TNF- \$\alpha\$ and IL-1 \$\beta\$ in peripheral blood of rheumatoid arthritis patients. *Chin Arch Tradit Chin Med* 2008;26\(5\):996-97.](#)
23. [Zhang JL, Liu XD, Ye LH, Zhang P. Clinical randomized comparison study of bee-sting therapy for knee synovitis caused by rheumatoid arthritis. *Chin Arch Tradit Chin Med* 2011;29\(8\):1904-06.](#)
24. [Zhou YF, Li WY. Effect of needle on hypothalamic-pituitary-adrenal axis of patient with rheumatoid arthritis. *Nei Mongol J Tradit Chin Med* 2012;26\(5\):1-3.](#)
25. [Zhu HJ, Huang SG, Tan N, Wen WQ. Clinical observation of apiotherapy combined with](#)

- 1
2
3
4
5
6
7
8 [Chinese drug fumigation for rheumatoid arthritis. J Tradit Chin Med Univ Hunan](#)
9 [2010;30\(1\):70-72.](#)
10
11 26. [Zhou XM, Xie XL. Bee needle combined with nursing and effect of external application](#)
12 [of Chinese medicine in the treatment of rheumatoid arthritis. Nurs Res Pract](#)
13 [2013;10\(07\):11-12.](#)
14
15 27. [Kuang HT, Lan HQ, Zhou K, Li ZQ. Clinical observation on combination of](#)
16 [yangxuetongbi decoction and bee pricking for the treatment of 32 cases of atrophic](#)
17 [arthritis. Hunan Guiding J Tradit Chin Med Pharmacol 2004;10\(10\):6-8.](#)
18
19 28. [Ji W, Zhang MJ, Ma YZ. Clinical observation of tripterygiumforrestii and bee venom in](#)
20 [treating rheumatoid arthritis. Zhongguo Zhong Xi Yi Jie He Za Zhi \[Chinese Journal of](#)
21 [Integrated Traditional and Western Medicine\] 1993;13\(12\):743-44.](#)
22
23 29. [Cai J. Clinical observation on 42 cases of needle treatment of rheumatoid arthritis. Clin J](#)
24 [Anhui Tradit Chin Med 1997;9\(1\):16-17.](#)
25
26 30. [Xu J, Pan ZG, Chen LL, Guan ZH. Clinical study on apistoxin injection direct current](#)
27 [electric acupoint introduction for the treatment of Bi syndrome. J Bee 1999\(02\):3-5.](#)
28
29 31. [Li L, Yi R, Wang YM, Tan BH. Clinical observation on bee-sting therapy with ashi points](#)
30 [and with points of corresponding meridians in treating rheumatoid arthritis. Shanghai J](#)
31 [Acu-mox 2013;32\(2\):121-22.](#)
32
33 32. [Pertsulenko VA. Bee venom in the treatment of infectious non-specific \(rheumatoid\)](#)
34 [arthritis. Sovetskaia meditsina 1961;25:94-101.](#)
35
36 33. [Li L, Yi R, Wang YM, Tan BH. Clinical observation on bee-sting therapy with Ashi](#)
37 [Points and with Points of Corresponding Meridians in Treating Rheumatoid Arthritis.](#)
38 [Shanghai J Acupunct Mox 2013\(2\):121-22.](#)
39
40 34. [Lee SH, Hong SJ, Kim SY. Randomized controlled double blind study of bee venom](#)
41 [therapy on rheumatoid arthritis. J Korean Acupunct Mox Soc 2003;20:80-88.](#)
42
43
44
45
46
47
48
49
50
51
52
53
54

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
35. [Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. Control Clin Trials 1998;19\(2\):159-66.](#)
36. [Hwang YJ, Lee GM, Hwang WJ, Seo EM, Jang JD, Yang GB, et al. Clinical research of bee-venom acupuncture effects on rheumatoid arthritis. J Korean Acupunct Mox Soc 2001;18\(5\):33-42.](#)
37. [Hwang YJ, Lee BC. Clinical study of anaphylaxis on bee-venom acupuncture. J Korean Acupunct Mox Soc 2000;17\(4\):149-59.](#)
38. [Jung JW, Jeon EJ, Kim JW, Choi JC, Shin JW, Kim JY, et al. A fatal case of intravascular coagulation after bee sting acupuncture. Allergy, asthma & immunology research 2012;4\(2\):107-9.](#)
39. [Kim YK, Jang YS, Jung JW, Lee BJ, Kim HY, Son JW, et al. Prevalence of bee venom allergy in children and adults living in rural area of Cheju Island. Journal of Asthma, Allergy and Clinical Immunology 1998;18\(3\):451-57.](#)
40. [Yao H. Bee needle therapy. J Shanxi Elderly 2000\(9\):39.](#)
41. [Green S, Higgins JPT, Alderson P, Clarke M, Mulrow CD, Oxman AD. Chapter 1: Introduction. . In: T. HJP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 \(updated March 2011\). The Cochrane Collaboration, 2011. Available from \[www.cochrane-handbook.org\]\(http://www.cochrane-handbook.org\).](#)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legend

Figure 1. Flow chart of trial selection process. CCT: case series trials; RCT: randomised controlled trials.

Formatted: Not Highlight

For peer review only

Table 1. Characteristics of included randomized controlled trials of bee venom acupuncture for rheumatoid arthritis

<i>Lee 2003</i>	
Methods	Design: prospective randomized controlled trial
Participants	Country: South Korea Number of patients included(completed / randomized): (A) 37/40 (B) 32/40 Mean age (years): (A) 49.2±9.6 (B) 47.3±8.9 Duration of disease (years): (A) 9.2±7.0 (B) 7.3±4.6 Follow-up: 1 and 2 months
Intervention	(A) BVA (Ashi points, acupoints near the inflammation point, two times a week for 2 months)
Control	(B) Placebo (normal saline injection on ashi points, acupoints near the inflammation point, two times a week for 2 months)
Outcomes	<i>Primary outcomes:</i> 1) Morning stiffness, MD, -0.70[-2.00, 0.60], P<0.05 2) HAQ, MD, 0.00[-0.08, 0.08], P<0.05 3) VAS-pain, MD, -18.10[-23.71, -12.49], P<0.05 <i>Secondary outcomes:</i> 1) Tender joint count, MD, -1.30[-1.91, -0.69], P<0.0001 2) Swollen joint count, MD, -1.10[-1.72, -0.48], P=0.005 3) ESR, MD,20.10[-22.80,-17.40], P<0.00001 4) CRP, MD, -1.90[-2.86, -0.94], P=0.0001
Note	Treatment Rationale: CM theory, Clinical experience Adverse effect: n.r. Funding: Korea Research Foundation Grant and Kyung Hee University Language: Korean Publication: full paper Withdrawal/dropouts:yes Intention-to-treat: No Author comment: These results suggests that bee venom therapy could be an effective method in the treatment of patients with RA

Formatted Table

Risk of bias

Item	Authors' judgement	Description
Random sequence generation (selection bias)	Unclear risk	Described as randomized but information not available
Allocation concealment (selection bias)	Unclear risk	Not stated.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Described as double blinding
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated.
Incomplete outcome data (attrition bias) All outcomes	High risk	Data from 11 participants were not included in the analysis.
Selective reporting (reporting bias)	Low risk	Protocol not available, but all expected outcomes reported
Other bias	Unclear risk	Small sample size

BVA: Bee Venom Acupuncture; CRP: C - reactive protein; CM: Chinese medicine; ESR: erythrocyte sedimentation rate; HAQ: health assessment questionnaire; n.r.: not reported; RA: rheumatoid arthritis VAS: visual analogue scale

Table 2. Summary of findings

Bee venom acupuncture for patients with rheumatoid arthritis					
Patient or population: patients with rheumatoid arthritis					
Settings: Korea					
Intervention: Bee venom acupuncture vs. normal saline injection as placebo					
Outcomes	Illustrative comparative risks* (95% CI)		No of Participants (studies)	Quality of the evidence (Grade)	Comments
	Assumed risk Control (Normal Saline injection)	Corresponding risk Bee venom acupuncture			
Pain (VAS)		16.9 WMD lower ¹ (26.57 to 7.23 lower)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month -10.40 (-16.47 to -4.33)
Morning stiffness		12.1 WMD higher ¹ (11.61 to 12.59 higher)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month -0.30 (-1.01 to 0.41)
Swollen joint count		0.9 WMD lower ¹ (1.97 lower to 0.17 higher)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month 0.50 (-0.70 to -1.70)
Tender joint count		0.9 WMD lower ¹ (1.97 lower to 0.17 higher)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month 0.50 (-0.73 to -1.73)
Quality of Life (HAQ)		0.3 WMD higher ¹ (0.08 to 0.52 higher)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month 0.20 (-0.06 to 0.46)
ESR		19.4 WMD lower ¹ (28.51 to 10.29 lower)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month -2.30 (-10.17 to 5.57)
CRP		1.7 WMD lower ¹ (2.6 to 0.8 lower)	69 (1 study)	⊕⊕⊕⊖ low ^{2,3}	After 1 month 1.40 (-8.27 to 5.47)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
 CI: Confidence interval; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; HAQ: Health Assessment Questionnaire; VAS: Visual analogue scale; WMD: weight mean difference


GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

¹ After 2 months treatment
² Poorly reported paper (See 'Risk of bias' table)
³ Small sample size

Formatted Table

Formatted Table

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



188x196mm (300 x 300 DPI)



Supplement 1. Search Strategy

MEDLINE

1. exp arthritis, rheumatoid/
2. ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat\$ or reumat\$ or revmarthrit\$) adj3 (arthrit\$ or artrit\$ or diseas\$ or condition\$ or nodule\$)).tw.
3. (felty\$ adj2 syndrome).tw.
4. (caplan\$ adj2 syndrome).tw.
5. (sjogren\$ adj2 syndrome).tw.
6. (sicca adj2 syndrome).tw.
7. still\$ disease.tw.
8. bechterew\$ disease.tw.
9. or/1-8
10. bee venom\$.tw.
11. bee sting.tw.
12. wasp venom\$.tw.
13. bee venom acupuncture.tw.
14. bee venom therapy.tw.
15. bee sting therapy.tw.
16. apitoxin.tw.
17. apitherapy.tw.
18. or/10-17
19. 9 and 18

EMBASE

1. exp arthritis, rheumatoid/
2. ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat\$ or reumat\$ or revmarthrit\$) adj3 (arthrit\$ or artrit\$ or diseas\$ or condition\$ or nodule\$)).tw.

3. (felty\$ adj2 syndrome).tw.
4. (caplan\$ adj2 syndrome).tw.
5. (sjogren\$ adj2 syndrome).tw.
6. (sicca adj2 syndrome).tw.
7. still\$ disease.tw.
8. bechterew\$ disease.tw.
9. or/1-8
10. bee venom\$.tw.
11. bee sting\$.tw.
12. wasp venom\$.tw.
13. bee venom acupuncture.tw.
14. bee venom therapy.tw.
15. bee sting therapy.tw.
16. apitoxin.tw.
17. apitherapy.tw.
18. or/10-17
19. 9 and 18

The Cochrane Library (Wiley InterScience)

#1 MeSH descriptor Arthritis, Rheumatoid explode all trees

#2 ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat* or reumat* or revmarthrit*) near/3(arthrit* or artrit* or diseas* or condition* or nodule*)):ti,ab

#3 felty* NEAR/2 syndrome:ti,ab

#4 caplan* NEAR/2 syndrome:ti,ab

#6 sjogren* near/2 syndrome:ti,ab

#7 sicca near/2 syndrome:ti,ab

#8 still* next disease:ti,ab

#9 bechterew\$ disease.tw.

#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)

#11 bee venom* :ti,ab

#12 bee sting :ti,ab

#13 wasp venom* :ti,ab

1
2
3
4 #14 bee venom acupuncture :ti,ab
5

6 #15 bee venom therapy:ti,ab
7

8 #16 bee sting therapy:ti,ab
9

10 #17 apitoxin:ti,ab
11

12 #18 apitherapy:ti,ab
13

14 #19 (#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18)
15

16 #20 #10 AND #19
17

18 **CINAHL (EBSCOhost)**

19
20 S7 S3 and S6
21

22 S6 S4 or S5
23

24 S5 TI “apitoxin” or AB “apitoxin” or TI “apitherapy” or AB “apitherapy”
25

26 S4 TI “bee venom*” or AB “bee venom*” or TI “bee sting” or AB “bee sting” or TI “wasp
27 venom*” or AB “wasp venom*” or TI “bee venom acupuncture” or AB “bee venom
28 acupuncture” or TI “bee venom therapy” or AB “bee venom therapy”
29

30 #17 apitoxin:ti,ab
31

32 #18 apitherapy:ti,ab
33

34 S3 S1 or S2
35

36 S2 TI “bechterew* disease” or AB “bechterew* disease” or TI (arthritis N2 rheumat*) or AB
37 (arthritis N2 rheumat*)
38

39 S1 (MH “Arthritis, Rheumatoid+”) or TI (felty* N2 syndrome) or AB (felty* N2 syndrome)
40 or TI (caplan* N2 syndrome) or AB(caplan* N2 syndrome) or TI (rheumatoid nodule) or AB
41 (rheumatoid nodule) or TI (sjogren* N2 syndrome) or AB (sjogren* N2 syndrome) or TI (sicca
42 N2 syndrome) or AB (sicca N2 syndrome)
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplement 2. Summary of randomised controlled trials of bee sting therapy on acupoints for rheumatoid arthritis

First author (Year)	Mean age (yr); Duration of disease (yrs)	Experimental intervention (Regimen)	Control intervention (Regimen)	Primary outcome		Secondary outcome	
				measurement	result	measurement	result
Liu (2008)	(A) 47.4; 5.0 (B) 48.3; 4.9	(A) Bee sting therapy (Ashi points, dialectical acupoints, 8-15bees, n.r., once every other day for 3 months, n=50), plus (B)	(B) WM (Oral: MTX: 7.5mg, once a week for 3 months; SASP:0.5g, third daily for 3 months; Meloxicam:7.5mg, twice daily for 3 months, n=50)	(1) Total improvement score (2) Joint swelling score (3) Joint pain score	(1) RR, 1.22[1.01, 1.47], P=0.04 (2) MD, -0.24[-0.42,-0.06],P=0.010 (3) MD, -0.34[-0.37, -0.31], P<0.00001	(1) Number of Joint-swelling (2) RF (3) ESR	(1) MD, -0.46[-0.62, -0.30], P<0.00001 (2) MD, -7.74[-14.10, -1.38], P=0.02 (3) MD, -4.38[-6.28, -2.48], P<0.00001
Zhang (2011) China	(A) 33.8; 3.6 (B) 32.2; 3.4	(A) Bee sting therapy (Ashi points near the knee, 5-15bees, n.r., two or three times a week for 3months, n=23), plus (B)	(B) WM (Oral: MTX: 7.5mg, once a week for 3 months; SASP:0.5g, third daily for 3 months; Meloxicam:7.5mg, once daily for 3 months, n=23)	(1) Total improvement score (2) VAS (3) HSS	(1) RR, 1.17[0.91, 1.50] (2) MD, -1.00[-1.20, -0.80], P<0.00001 (3) MD, 3.37[3.24, 3.50], P<0.00001	(1) ESR (2) CRP	(1) MD, -4.20[-7.35, -1.05], P=0.009 (2) MD, -2.50[-5.56, 0.56], P=0.11
Deng (2011) China	n.r.	(A) Bee sting therapy (Ashi points, dialectical acupoints, before 15-25d: 2-3bees; after 15-25d: 1-3bees increase every time, n.r., three times a week for 2 months, n=20), plus (B)	(B) WM (Oral: MTX: 10mg, once a week for 2 months, n=20) (C) WM (Oral: Prednisone Acetate:7.5mg, once daily for 2 months, n=20) plus (B)	(1) Total improvement score (2) Morning stiffness (3) Joint pain score (4) Joint swelling score	(1) A vs. B: RR, 1.46[1.04, 2.05], P=0.03; A vs. C: RR, 1.36[1.00, 1.84], P=0.05 (2) A vs. B: MD, -0.29 [-0.42, -0.17], P<0.00001; A vs. C: MD, -0.11[-0.25, 0.02], P=0.05 (3) A vs. B: MD, -0.50 [-0.64, -0.36], P<0.00001; A vs. C: MD, -0.13[-0.26, 0.00], P=0.05 (4) A vs. B: MD, -0.33[-0.47, -0.19], P<0.00001; A vs. C: MD, 0.05[-0.12, 0.21], P=0.56	(1) RF (2) ESR (3) CRP	(1) A vs. B: MD, -28.00[-37.21, -18.79], P<0.00001; A vs. C: MD, -14.30[-17.60, -11.00], P<0.00001 (2) A vs. B: MD, -18.60 [-27.04,-10.16], P<0.00001; A vs. C: MD, -8.10[-15.41, -0.79], P=0.03 (3) A vs. B: MD, -10.30 [-12.46,-8.14], P<0.00001; A vs. C: MD, -3.70[-5.99,-1.41], P=0.002
Zhou (2012) China	(A) 37.9; 15.6 (B) 36.4; 14.0 (C) 40.7; 16.6	(A) Bee sting therapy (Ashi points, acupoints near the pain point, 5-10bees, n.r., three times a week for 3 months, n=40) plus NSAIDS	(B) EA (30min, three times a week y for 3 months, n=30) plus NSAIDS (C) WM (Oral:MTX:5-10mg, once a week for 3 months; Folic acid: 10mg, once a week for 3 months, n=30) plus NSAIDS	Total improvement score	A vs. B: RR, 1.23[0.97, 1.56], P=0.09; A vs. C: RR, 1.04 [0.87, 1.24], P=0.67	(1) ESR (2) CRP	(1) A vs. B: MD, -13.70[-15.08, -12.32], P<0.00001; A vs. C: MD, -2.72[-6.54, 1.10] P=0.16 (2) A vs. B: MD, -9.18[-11.47, -6.89], P<0.00001; A vs. C: MD, 3.93[-0.07, 7.93], P= 0.05

CRP: C - reactive protein; EA: electro acupuncture; ESR: erythrocyte sedimentation rate; HSS: hss knee score; HAQ: health assessment questionnaire; MTX: methotrexate; n.r.: not reported; NSAIDS: nonsteroidal anti-inflammatory drugs; RF: rheumatoid factor; SASP: sulfasalazine; VAS: visual analogue scale; TNF-α: tumor necrosis factor-alpha; WM: Western medicine

References

Deng M, Zhang WN. Clinical observation on 20 cases of bee needle therapy in the treatment of rheumatoid arthritis. Guiding J Tradit Chin Med Pharm 2011;17(6):71-73.
 Liu XD, Zhang jl, Zheng HG, Li Z, D., Cai L, Liu FY, et al. Effect of bee-sting therapy on TNF-α and IL-1β in peripheral blood of rheumatoid arthritis patients. Chin Arch Tradit Chin Med 2008;26(5):996-97.
 Zhang JL, Liu XD, Ye LH, Zhang P. Clinical randomized comparison study of bee-sting therapy for knee synovitis caused by rheumatoid arthritis. Chin Arch Tradit Chin Med 2011;29(8):1904-06.
 Zhou YF, Li WY. Effect of needle on hypothalamic-pituitary-adrenal axis of patient with rheumatoid arthritis. Nei Mongol J Tradit Chin Med 2012;26(5):1-3.

Supplement 3. Summary of treatment bee sting therapy on acupoints for rheumatoid arthritis

First author (Year)	Type of acupuncture	Total treatment (sessions)	Main acupoints	Dialectical acupoints	Treatment Rationale	Adverse events
Liu (2008)	Bee sting therapy (Live bee, 8-15bees)	3 months	Ashi points	Cold dampness invasion, joint pain: CV6, RN4; Hot and humid embodiment, joint swelling pain: LI11, GV14; Phlegm and blood stasis in the resistance, Joint deformities pain:ST40,GB39	CM theory, Clinical experience	Dizziness (B:4), fever(A:1), hypersensitivity(A:4), leukopenia(B:3), loss of appetite and nausea(B:6)
Zhang (2011)	Bee sting therapy (Live bee, 5-15bees)	3 months	Ashis points near knee	n.r.	CM theory, Clinical experience	Dizziness(A:1), epigastric discomfort(A:4), fever(A:2), hypersensitivity(A:1), leukopenia(B:3), rash(A:3)
Deng (2011)	Bee sting therapy (Live bee, before 15-25days: 2-3bees; after 15-25days: 1-3bees increase every time)	2 months	Ashi points	Ankle:BL62, KI6, BL60, GB40; back: GV26, V12, GV3; elbow: LI11, L4, SJ10, SJ5, LU5; knee:ST35, ST34, GB34, GB33; Shoulders:LI16, SJ14, SI10; wrist:SJ4, SJ5 LI5, SI4	CM theory, Clinical experience	Epigastric discomfort (C:6),hypersensitivity (A:3), insomnia(C:3), leukopenia(B:1), nausea(A:2,B:3)
Zhou (2012)	Bee sting therapy (Live bee, 5-10bees)	3 months	Ashi points, acupoints in near in the pain point	n.r.	CM theory, Clinical experience	n.r.

CM: Chinese medicine; n.r.: not reported

References

- Deng M, Zhang WN. Clinical observation on 20 cases of bee needle therapy in the treatment of rheumatoid arthritis. *Guiding J Tradit Chin Med Pharm* 2011;17(6):71-73.
- Liu XD, Zhang JI, Zheng HG, Li Z, D., Cai L, Liu FY, et al. Effect of bee-sting therapy on TNF- α and IL-1 β in peripheral blood of rheumatoid arthritis patients. *Chin Arch Tradit Chin Med* 2008;26(5):996-97.
- Zhang JL, Liu XD, Ye LH, Zhang P. Clinical randomized comparison study of bee-sting therapy for knee synovitis caused by rheumatoid arthritis. *Chin Arch Tradit Chin Med* 2011;29(8):1904-06.
- Zhou YF, Li WY. Effect of needle on hypothalamic-pituitary-adrenal axis of patient with rheumatoid arthritis. *Nei Mongol J Tradit Chin Med* 2012;26(5):1-3.

Supplement 4. Summary of non-randomized controlled trials of Bee Venom acupuncture for rheumatoid arthritis

<i>Hwang 2001</i>	
Methods	Design: case series trial
Participants	Country: South Korea Number of patients included(male / female): 15(4/11) Duration of disease (weeks): (A) < 4 (n=4), (B) 8-20 (n=2), (C) >24 (n=9) Follow-up: n.r
Intervention	BVA (Ashi points, acupoints near the inflammation point, two times a week)
Outcomes	1) Pain (VAS), improvement index (score of after treatment-score of before treatment/ score of after treatment). (A) 0.80; (B)0.68; (C) 0.51 2) Improvement of symptom (patient' assessment), Excellent (n=6); Good (n=7); Moderate (n=2)
Note	Treatment Rationale: CM theory, Clinical experience Adverse effect: n.r. Funding: none Language: Korean Publication: full paper Withdrawal/dropouts: no

n.r: not reported; VAS: visual analogue scale

Reference

Hwang YJ, Lee BC. Clinical study of anaphylaxis on bee-venom acupuncture. J Korean Acupunct Mox Soc 2000;17(4):149-59.



PRISMA 2009 Checklist: Bee venom acupuncture for rheumatoid arthritis: A systematic review of randomised clinical trials

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	4
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	7
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	8
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	8
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	8
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	10
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	10
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	9
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	10
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	Table 1,2



PRISMA 2009 Checklist: Bee venom acupuncture for rheumatoid arthritis: A systematic review of randomised clinical trials

Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	na
----------------------	----	---	----

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	12
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	na
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	12, Figure 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	13
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	13
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	na
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	13
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	na
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	14
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	16
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	17